KR101324788B1 - Organic light device and organic light compound for the same - Google Patents

Organic light device and organic light compound for the same Download PDF

Info

Publication number
KR101324788B1
KR101324788B1 KR1020100002432A KR20100002432A KR101324788B1 KR 101324788 B1 KR101324788 B1 KR 101324788B1 KR 1020100002432 A KR1020100002432 A KR 1020100002432A KR 20100002432 A KR20100002432 A KR 20100002432A KR 101324788 B1 KR101324788 B1 KR 101324788B1
Authority
KR
South Korea
Prior art keywords
compound
synthesis example
synthesis
phenyl
cdcl
Prior art date
Application number
KR1020100002432A
Other languages
Korean (ko)
Other versions
KR20110079402A (en
Inventor
김복영
안중복
이재성
진성민
강지승
안도환
박노길
한근희
시상만
이대균
Original Assignee
(주)씨에스엘쏠라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)씨에스엘쏠라 filed Critical (주)씨에스엘쏠라
Publication of KR20110079402A publication Critical patent/KR20110079402A/en
Application granted granted Critical
Publication of KR101324788B1 publication Critical patent/KR101324788B1/en

Links

Classifications

    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/60Organic compounds having low molecular weight
    • H10K85/649Aromatic compounds comprising a hetero atom
    • H10K85/657Polycyclic condensed heteroaromatic hydrocarbons
    • H10K85/6572Polycyclic condensed heteroaromatic hydrocarbons comprising only nitrogen in the heteroaromatic polycondensed ring system, e.g. phenanthroline or carbazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/14Carrier transporting layers
    • H10K50/15Hole transporting layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/17Carrier injection layers

Landscapes

  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

본 발명은 하기 화학식 a로 표시되는 화합물을 구비한 유기 광소자 및 이에 사용되는 유기 광화합물에 관한 것이다:
제1전극; 제2전극; 및 상기 제1전극과 상기 제2전극 사이에 적어도 한 층의 유기막을 포함하는 유기 광소자로서, 상기 유기막이 하기 화학식 a의 유기 광화합물을 포함하는 것을 특징으로 하는 유기 광소자:
<화학식 a>

Figure 112011102835342-pat00222

상기 식에서 A1, A2, A2', A3, A4 및 A4'는 서로 독립적 또는 유관하게, 수소, 치환 또는 비치환된 C6-C50아릴기, 치환 또는 비치환된 C2-C50헤테로아릴기, 치환 또는 비치환된 C3-C50사이클로알킬기, 치환 또는 비치환된 C2-C50헤테로사이클로알킬기, 또는 치환 또는 비치환된 포화 또는 불포화 탄화수소이고,
Ar은 수소, 치환 또는 비치환된 C6-C50아릴기, 치환 또는 비치환된 C2-C50헤테로아릴기, 치환 또는 비치환된 C3-C50사이클로알킬기, 또는 치환 또는 비치환된 C2-C50헤테로사이클로알킬기이고,
X는 0이거나, N, O 또는 S 이고,
m은 1 내지 10 사이의 정수이다. 상기 화합물을 이용하면 우수한 발광 효율, 발광 휘도, 색순도 및 발광 수명를 갖는 유기 광소자를 얻을 수 있다.The present invention relates to an organic optical device having a compound represented by the following Chemical Formula a and an organic optical compound used therein:
A first electrode; A second electrode; And an organic optical device comprising at least one organic film between the first electrode and the second electrode, wherein the organic film comprises an organic optical compound represented by Chemical Formula a:
<Formula a>
Figure 112011102835342-pat00222

Wherein A1, A2, A2 ', A3, A4 and A4' are each independently or related to hydrogen, a substituted or unsubstituted C6-C50 aryl group, a substituted or unsubstituted C2-C50 heteroaryl group, a substituted or unsubstituted A substituted C3-C50 cycloalkyl group, a substituted or unsubstituted C2-C50 heterocycloalkyl group, or a substituted or unsubstituted saturated or unsaturated hydrocarbon,
Ar is hydrogen, a substituted or unsubstituted C6-C50 aryl group, a substituted or unsubstituted C2-C50 heteroaryl group, a substituted or unsubstituted C3-C50 cycloalkyl group, or a substituted or unsubstituted C2-C50 heterocycloalkyl group ego,
X is 0 or N, O or S,
m is an integer from 1 to 10. By using the compound, an organic optical device having excellent luminous efficiency, luminous brightness, color purity and luminous lifetime can be obtained.

Description

유기 광소자 및 이를 위한 유기 광합물{ORGANIC LIGHT DEVICE AND ORGANIC LIGHT COMPOUND FOR THE SAME}ORGANIC LIGHT DEVICE AND ORGANIC LIGHT COMPOUND FOR THE SAME}

본 발명은 유기 광소자 및 이에 사용되는 유기 광화합물에 관한 것으로서, 보다 상세하게는 우수한 발광효율, 발광 휘도, 색순도 및 발광 수명을 구현할 수 있는 유기 발광 소자와 이에 사용되는 유기 발광 화합물 또는 태양광 발전용 광소자 및 이에 사용되는 광화합물에 관한 것이다.
The present invention relates to an organic optical device and an organic optical compound used therein, and more particularly, to an organic light emitting device capable of realizing excellent luminous efficiency, emission brightness, color purity, and emission lifetime, and an organic light emitting compound or solar power generation used therefor. It relates to an optical device for use and an optical compound used therefor.

정보화시대로 급속히 진입하면서 전자 정보 기기와 인간의 인터페이스 역할을 하는 디스플레이(Display)의 중요성이 더욱 커지고 있다. 특히 언제 어디서나 편리하게 사용할 수 있고, 현장감 있게 생생한 화면을 보여 줄 수 있는 디스플레이를 개발하기 위한 노력이 절실히 필요하게 되었다. 더 나아가서 디스플레이를 유리 기판 대신에 플라스틱과 같은 유연한 기판 위에 제작하여 더 얇고, 더 가볍고, 깨지지 않는 플렉서블 디스플레이(flexible display)를 개발하는 연구가 활발하게 진행되고 있다. 유기발광다이오드(OLED) 디스플레이는 이와 같은 응용에 가장 적합한 차세대 평판디스플레이 기술로 큰 주목을 받고 있다.As the information age rapidly enters, the importance of a display, which serves as an interface between the electronic information device and the human being, is increasing. In particular, there is an urgent need to develop a display that can be conveniently used anytime and anywhere, and provides a vivid screen with a sense of reality. Further research is being conducted to develop thinner, lighter, unbreakable flexible displays by fabricating displays on flexible substrates such as plastic instead of glass substrates. Organic light emitting diode (OLED) displays are attracting great attention as next generation flat panel display technologies that are best suited for such applications.

유기반도체에서의 전기발광 현상은 1963년 Pope, Kallmann, Magnate에 의해 안트라센 결정에서 처음으로 발견되었고[M. Pope, H. P. Kallmamm and P. Magnae, J. Chem. Phys. 38, 2042 (1963)], 이어서 1965년에 W. Helfrich [W. Helfrich and W. G. Schneider, Phys. Rev. Lett. 14, 229(1965)] 등의 연구가 이어졌다. 그런데 고순도의 안트라센 결정은 전기전도도가 10-20 s/cm 이하의 절연체이므로 수백볼트 이상의 높은 전압을 가해야 전자와 정공이 주입되고 발광효율이 아주 낮았다. 그리고 반응성이 높은 알칼리 금속을 전극으로 사용한 실용적인 측면에서는 큰 문제가 있었다. 이후 1982년에 Vincett 등은 진공 증착 방법으로 비결정질의 안트라센 박막을 형성하고 유기 발광다이오드를 제작하는데 성공하였다. 이 소자의 발광효율은 약 0.05% 수준으로 아주 낮았으나, 이 방법은 현재까지 대표적인 OLED 제작 방법으로 사용되고 있다.
Electroluminescence in organic semiconductors was first discovered in anthracene crystals in 1963 by Pope, Kallmann and Magnate [M. Pope, HP Kallmamm and P. Magnae, J. Chem. Phys. 38 , 2042 (1963), followed by W. Helfrich [W. Helfrich and WG Schneider, Phys. Rev. Lett. 14 , 229 (1965)]. However, the high purity anthracene crystal is an insulator with an electric conductivity of 10 -20 s / cm or less. Therefore, electrons and holes are injected and light emission efficiency is very low when a high voltage of several hundred volts is applied. In addition, there was a big problem in terms of practical use of highly reactive alkali metals as electrodes. Since 1982, Vincett et al. Succeeded in forming an amorphous anthracene thin film and fabricating an organic light emitting diode by vacuum deposition. The luminous efficiency of this device was very low at about 0.05%, but this method has been used as a typical OLED manufacturing method to date.

1987년 Kodak사의 Tang등이 발광층과 전하 수송층으로 각각 Alq3 와 TPD라는 이중 층 저분자 유기물 박막을 형성하여 효율과 안정성이 개선된 녹색의 발광 현상을 발견한 이후로 저분자 OLED 디스플레이의 개발이 급속도로 빠르게 이루어졌다. 이러한 소자 구조에서는 정공 수송 물질과 전자 수송 물질의 전자 에너지 준위의 차이에 의해 전자와 정공이 diamine/Alq3 계면에 축척되어 전자-정공의 재결함 확률이 높아진다. 그 결과 이 소자는 10V 이하의 구동 전압에서 1000 cd/m2 이상의 휘도와 1.5 lm/W 수준의 높은 발광 효율을 나타냈다. 이 결과는 유기박막 발광다이오드를 이용하여 고휘도, 고효율 디스플레이를 개발할 수 있는 가능성을 제시하기 때문에 큰 주목을 끌어서 전 세계적으로 OLED 연구를 활성화하는데 큰 역할을 했다.
In 1987 the light-emitting layer and a charge transport layer, such as Kodak's Tang each Alq 3 The development of low molecular OLED displays has been rapid since the formation of green light emitting phenomena with improved efficiency and stability by forming a double-layer low molecular organic thin film called and TPD. In this device structure, electrons and holes accumulate at the diamine / Alq 3 interface due to the difference in the electron energy levels of the hole transporting material and the electron transporting material, thereby increasing the probability of electron-hole recombination. As a result, the device showed a luminance of 1000 cd / m 2 or higher and a high luminous efficiency of 1.5 lm / W at a driving voltage of 10V or lower. This result shows the possibility of developing a high-brightness, high-efficiency display using an organic thin-film light emitting diode, so it played a big role in activating OLED research worldwide.

1980년대 후반 저분자 OLED 소자의 구조는 양극(ITO), 정공수송층 (Hole Transfer Layer, HTL) 발광층 (Emission Layer, EML), 음극(Mg:Ag)의 간단한 구조에서 출발하였다. 이후 형광소자의 경우는 CuPc같은 정공주입층(Hole Injedtion Layer, HIL)이 도입되었고, Cathode와 전자주입층 재료로 Al:Li이 개발되고 LiF 같은 재료가 개발되면서 구조가 복잡해지게 되었다. 이에 따라서 전기광학적인 특성도 효율과 구동전압이 혁신적으로 개선이 이루어지게 되었다.
In the late 1980s, the structure of a low-molecular OLED device started from a simple structure of an anode (ITO), a hole transport layer (HTL), an emission layer (EML), and a cathode (Mg: Ag). In the case of fluorescent devices, Hole Injection Layer (HIL) such as CuPc was introduced, Al: Li was developed as cathode and electron injection layer material, and materials such as LiF were developed and the structure became complicated. As a result, the efficiency and the driving voltage of the electro-optical characteristic have been improved.

발광 소자(light emitting device)는 자발광형 소자로 시야각이 넓으며 콘트라스트가 우수할 뿐만 아니라 응답시간이 빠르다는 장점을 가진다. 상기 발광 소자는 발광층(emitting layer)에 무기 화합물을 사용하는 무기 발광 소자와 유기 화합물을 사용하는 유기 광소자(Organic Light Emitting Deveice : OLED)로 구분된다. 유기 광소자는 무기 발광 소자에 비하여 높은 휘도, 낮은 구동전압, 짧은 응답속도 등의 물성이 우수하고 다색화가 가능하다는 점에서 많은 연구의 대상이 된다.상기 유기 광소자는 일반적으로 애노드/유기 발광층/캐소드의 적층구조를 가지며, 애노드/정공주입층/정공수송층/발광층/전자수송층/전자주입층/캐소드 또는 애노드/정공주입층/정공수송층/발광층/정공저지층/전자수송층/전자주입층/캐소드 등과 같은 다양한 구조를 가질 수 있다.
The light emitting device is a self-luminous device, and has a wide viewing angle, excellent contrast, and fast response time. The light emitting device is classified into an inorganic light emitting device using an inorganic compound as an emitting layer and an organic light emitting device using an organic compound. Compared with inorganic light emitting devices, organic photoelectric devices have been studied in many ways in that they have excellent physical properties such as high luminance, low driving voltage, and short response speed, and are capable of multicoloring. The organic optical devices are generally used as anodes, organic light emitting layers, and cathodes. It has a laminated structure, such as anode / hole injection layer / hole transport layer / light emitting layer / electron transport layer / electron injection layer / cathode or anode / hole injection layer / hole transport layer / light emitting layer / hole blocking layer / electron transport layer / electron injection layer / cathode It can have various structures.

한편, 발광 효율이 높고 작동 수명이 긴 유기 광소자가 구현되기 위해서 고성능의 유기 광화합물이 중요시된다.On the other hand, high-performance organic optical compounds are important in order to implement organic optical devices having high luminous efficiency and long operating life.

대형화되고 저소비전력이 요구되는 패널을 제조하기 위하여, 상기 유기 광화합물들은 발광 효율, 발광 휘도 등이 추가적으로 개선되어야 하며 특히 수명 특성이 개선되어야 한다. In order to manufacture a panel having a large size and low power consumption, the organic photochemical compounds must further improve luminous efficiency, luminous luminance, and the like, and especially life characteristics.

아울러 화석연료의 대체 에너지 개발이 절실한 현실에서 이러한 유기 발광 소자 및 유기 발광 화합물은 발상의 전환을 통하여 태양광 발전을 위한 유기 광소자 및 광화합물에 적용될 수 있다.
In addition, the development of alternative energy of fossil fuel is urgently needed, such organic light emitting devices and organic light emitting compounds can be applied to organic photoelectric devices and photo compounds for photovoltaic power generation through the conversion of ideas.

본 발명이 이루고자 하는 첫 번째 기술적 과제는 발광 효율, 발광 휘도, 색순도 및 발광 수명이 향상된 유기 광소자를 제공하는 것이다.The first technical problem to be achieved by the present invention is to provide an organic optical device having improved luminous efficiency, luminous brightness, color purity and luminous lifetime.

본 발명이 이루고자 하는 두 번째 기술적 과제는 새로운 유기 광화합물을 제공하는 것이다.The second technical problem to be achieved by the present invention is to provide a new organic photochemical compound.

아울러 본 발명은 이를 유기 발광 소자 및 유기 발광 화합물, 또는 태양광 발전을 위한 유기 광소자 및 광화합물을 제공하는 것을 목적으로 한다.
In addition, an object of the present invention is to provide an organic light emitting device and an organic light emitting compound, or an organic optical device and a photo compound for photovoltaic power generation.

본 발명의 제 1태양에 따른 유기 광소자는, 제1전극; 제2전극; 및 상기 제1전극과 상기 제2전극 사이에 적어도 한 층의 유기막을 포함하는 유기 광소자로서, 상기 유기막이 하기 화학식 a의 유기 광화합물을 포함한다:An organic optical device according to the first aspect of the present invention, the first electrode; A second electrode; And at least one organic film between the first electrode and the second electrode, the organic film comprising an organic photo compound of formula a:

<화학식 a><Formula a>

Figure 112011102835342-pat00214

Figure 112011102835342-pat00214

상기 식에서 A1, A2, A2', A3, A4 및 A4'는 서로 독립적 또는 유관하게, 수소, 치환 또는 비치환된 C6-C50아릴기, 치환 또는 비치환된 C2-C50헤테로아릴기, 치환 또는 비치환된 C3-C50사이클로알킬기, 치환 또는 비치환된 C2-C50헤테로사이클로알킬기, 또는 치환 또는 비치환된 포화 또는 불포화 탄화수소이고,Wherein A1, A2, A2 ', A3, A4 and A4' are each independently or related to hydrogen, a substituted or unsubstituted C6-C50 aryl group, a substituted or unsubstituted C2-C50 heteroaryl group, a substituted or unsubstituted A substituted C3-C50 cycloalkyl group, a substituted or unsubstituted C2-C50 heterocycloalkyl group, or a substituted or unsubstituted saturated or unsaturated hydrocarbon,

Ar은 수소, 치환 또는 비치환된 C6-C50아릴기, 치환 또는 비치환된 C2-C50헤테로아릴기, 치환 또는 비치환된 C3-C50사이클로알킬기, 치환 또는 비치환된 C2-C50헤테로사이클로알킬기이나, 하나 이상의 아릴기 또는 헤테로아릴기를 포함하며, Ar is hydrogen, a substituted or unsubstituted C6-C50 aryl group, a substituted or unsubstituted C2-C50 heteroaryl group, a substituted or unsubstituted C3-C50 cycloalkyl group, a substituted or unsubstituted C2-C50 heterocycloalkyl group, At least one aryl group or heteroaryl group,

X는 0이거나, N, O 또는 S 이고,X is 0 or N, O or S,

m은 1 내지 10 사이의 정수이다.m is an integer from 1 to 10.

상기 본 발명의 또 다른 과제를 이루기 위하여, 상기 화학식 a로 표시되는 유기 광화합물을 제공한다.
In order to achieve another object of the present invention, an organic optical compound represented by Chemical Formula a is provided.

본 발명에 따른 유기 광소자는 높은 발광 효율, 높은 발광 휘도, 높은 색순도 및 현저히 향상된 발광 수명을 제공하며,The organic optical device according to the present invention provides high luminous efficiency, high luminance, high color purity and remarkably improved luminous lifetime,

아울러 본 발명은 이를 유기 발광 소자 및 유기 발광 화합물, 또는 태양광 발전을 위한 유기 광소자 및 광화합물을 제공한다.
In addition, the present invention provides an organic light emitting device and an organic light emitting compound, or an organic optical device and a photo compound for photovoltaic power generation.

이하 실시예 등을 참고하여 본 발명을 상세히 설명하도록 한다.
Hereinafter, the present invention will be described in detail with reference to Examples.

본 발명은 다양한 변경을 가할 수 있고 여러 가지 형태를 가질 수 있는 바, 구현예(態樣, aspect)(또는 실시예)들을 본문에 상세하게 설명하고자 한다. 그러나 이는 본 발명을 특정한 개시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. The present invention may be modified in various ways and may have various forms, and thus embodiments (or embodiments) will be described in detail in the text. However, this is not intended to limit the present invention to the specific form disclosed, it should be understood to include all modifications, equivalents, and substitutes included in the spirit and scope of the present invention.

본 명세서에서 사용한 용어는 단지 특정한 구현예(태양, 態樣, aspect)(또는 실시예)를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 출원에서, ~포함하다~ 또는 ~이루어진다~ 등의 용어는 명세서 상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Singular expressions include plural expressions unless the context clearly indicates otherwise. In the present application, the term &quot; comprising &quot; or &quot; consisting of &quot;, or the like, refers to the presence of a feature, a number, a step, an operation, an element, a component, But do not preclude the presence or addition of one or more other features, integers, steps, operations, components, parts, or combinations thereof.

다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.
Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms such as those defined in commonly used dictionaries are to be interpreted as having a meaning consistent with the contextual meaning of the related art and are to be interpreted as either ideal or overly formal in the sense of the present application Do not.

본 명세서에서 유기 광화합물은 유기 광소자에 사용되는 화합물이라는 의미로서 반드시 발광이 가능한 화합물로 그 범위가 한정되지 않으며, 그 적용 범위도 유기 발광층에 한정되지 않고, 전하 주입층 및 전하 수송층 등 유기 광소자를 구성하는 어느 층에나 모두 사용될 수 있다.In the present specification, the term "organic photocompound" means a compound used in an organic photonic device. The scope of the present invention is not limited to the organic luminescent layer. The scope of the present invention is not limited to the organic luminescent layer. Can be used for any layer constituting the substrate.

또 본 명세서에서 '광화합물' 및 '광소자'라는 용어는 사전적인 또는 관습적인 정의와 무관하게 본 발명이 유기 발광 소자 및 태양광 발전을 위한 소자에 모두 적용되는 경우를 고려하여, 이를 포괄하고자 선정한 용어이다.
In this specification, the terms 'optical compound' and 'optical device' are used to cover the case where the present invention is applied to both an organic light emitting device and a device for solar power generation regardless of a dictionary or conventional definition It is a selected term.

본 발명의 제 1태양에 따르는 유기 광소자는, 제1전극; 제2전극; 및 상기 제1전극과 상기 제2전극 사이에 적어도 한 층의 유기막을 포함하는 유기 광소자로서, 상기 유기막이 하기 화학식 a의 유기 광화합물을 포함한다:
An organic photonic device according to a first aspect of the present invention includes: a first electrode; A second electrode; And at least one organic film between the first electrode and the second electrode, the organic film comprising an organic photo compound of formula a:

<화학식 a><Formula a>

Figure 112011102835342-pat00215

Figure 112011102835342-pat00215

상기 카바졸로 카바졸계 유도체에 대한 화학식에서에서 A1, A2, A2', A3, A4 및 A4'는 서로 독립적 또는 유관하게, 수소, 치환 또는 비치환된 C6-C50아릴기, 치환 또는 비치환된 C2-C50헤테로아릴기, 치환 또는 비치환된 C3-C50사이클로알킬기, 치환 또는 비치환된 C2-C50헤테로사이클로알킬기, 또는 치환 또는 비치환된 포화 또는 불포화 탄화수소이고,In the formula for the carbazole carbazole derivatives, A1, A2, A2 ', A3, A4 and A4' are independently or related to each other, hydrogen, a substituted or unsubstituted C6-C50 aryl group, a substituted or unsubstituted C2 -C50 heteroaryl group, substituted or unsubstituted C3-C50 cycloalkyl group, substituted or unsubstituted C2-C50 heterocycloalkyl group, or substituted or unsubstituted saturated or unsaturated hydrocarbon,

Ar은 수소, 치환 또는 비치환된 C6-C50아릴기, 치환 또는 비치환된 C2-C50헤테로아릴기, 치환 또는 비치환된 C3-C50사이클로알킬기, 또는 치환 또는 비치환된 C2-C50헤테로사이클로알킬기이고,Ar is hydrogen, a substituted or unsubstituted C6-C50 aryl group, a substituted or unsubstituted C2-C50 heteroaryl group, a substituted or unsubstituted C3-C50 cycloalkyl group, or a substituted or unsubstituted C2-C50 heterocycloalkyl group ego,

X는 0이거나, N, O 또는 S 이고,X is 0 or N, O or S,

m은 1 내지 10 사이의 정수이다.m is an integer from 1 to 10.

나아가 상기 Ar은 하나 이상의 아릴기 또는 헤테로아릴기를 포함하는 것이 바람직하다.
Furthermore, Ar preferably includes one or more aryl groups or heteroaryl groups.

본 발명의 발명자는 상기 화학식 a로 표시되는 화합물의 치환기에서 A1, A2, A2', A3, A4 및 A4'를 선택 특정한, 다양한 카바졸로 카바졸계 유도체를 개발하여 정공수송층(HTL), 정공주입층(HIL) 또는 발광층(EML) 등, 제1전극과 상기 제2전극 사이의 각종 유기막으로 사용될 수 있는 유기 광화합물 및 이를 이용한 유기 광소자를 개발하고, The inventor of the present invention selects A1, A2, A2 ', A3, A4 and A4' from the substituents of the compound represented by the above formula (A), and develops a variety of carbazole carbazole derivatives to form a hole transport layer (HTL), a hole injection layer To develop an organic optical compound that can be used as various organic films between the first electrode and the second electrode, such as (HIL) or light emitting layer (EML), and an organic optical device using the same,

유기발광소자로 활용될 경우 효율 증가와 구동 전압의 감소와 같은 성능의 개선 및 OLED 재료로서의 능력을 극대화시킬 수 있고, 특히 발광 수명이 현저히 향상됨을 발견하였으며,It has been found that when the organic electroluminescent device is used as an organic light emitting device, it is possible to improve the performance such as the efficiency increase and the driving voltage decrease, maximize the ability as the OLED material,

이를 태양광 발전을 위한 광소자 및 광화합물 분야에 응용 적용할 경우 우수한 발전 효율을 얻을 수 있을 것으로 기대된다.It is expected that excellent application efficiency will be obtained when applied to optical devices and optical compound fields for solar power generation.

이하에서는 화학식 a로 표시되는 화합물을 유기 발광 소자와 관련하여 설명할 것이나, 이에 의하여 본 발명이 제한 해석 되어서는 안 된다.
Hereinafter, the compound represented by Chemical Formula a will be described with reference to the organic light emitting device, but the present invention should not be construed as a limitation.

상기 화학식 a로 표시되는 화합물은 유기 광소자 중 제1전극과 제2전극 사이에 개재된 유기막을 이루는 물질로 적합하다. 상기 화학식 a로 표시되는 화합물은 유기 발광 소자의 유기막, 특히 정공수송층, 정공주입층 또는 발광층에 사용되기 적합하며 호스트 재료뿐만 아니라 도판트 재료로서도 사용된다. 상기 화학식 a로 표시되는 화합물은 청색 내지 녹색인 색상을 제공하며 백색 발광 소자에 사용하기에 적합하다.The compound represented by Chemical Formula a is suitable as a material forming an organic film interposed between the first electrode and the second electrode of the organic optical device. The compound represented by Chemical Formula a is suitable for use in an organic film of an organic light emitting device, in particular, a hole transport layer, a hole injection layer, or a light emitting layer, and is used as a dopant material as well as a host material. The compound represented by Chemical Formula a provides a color of blue to green and is suitable for use in a white light emitting device.

상기 A1, A2, A3 및 A4는 상호 독립적이며, A1, A2, A3 and A4 are independent of each other,

상기 A2 및 A2'와 A4 및 A4'는 유관하게 작용기를 구성하며, A2 and A2 'and A4 and A4' are related to constitute a functional group,

이 작용기 중 하나 또는 둘 모두는 치환 또는 비치환된 C3-C50사이클로알킬기, 치환 또는 비치환된 C2-C50헤테로사이클로알킬기, 치환 또는 비치환된 C6-C50아릴기, 또는 치환 또는 비치환된 C2-C50헤테로아릴기이고, One or both of these functional groups may be substituted or unsubstituted C3-C50 cycloalkyl group, substituted or unsubstituted C2-C50 heterocycloalkyl group, substituted or unsubstituted C6-C50 aryl group, or substituted or unsubstituted C2- C50 heteroaryl group,

또 상기 A1, A2, A2', A3, A4 및 A4' 중 하나 이상이 페닐기인 것이 바람직하다.Moreover, it is preferable that at least one of said A1, A2, A2 ', A3, A4, and A4' is a phenyl group.

상기 아릴기는 방향족 고리 시스템을 갖는 1가 그룹으로서, 2 이상의 고리 시스템을 포함할 수 있으며, 상기 2이상의 고리 시스템은 서로 결합 또는 융합된 형태로 존재할 수 있다. 상기 헤테로아릴기는 상기 아릴기 중 하나 이상의 탄소가 N, O, S, P 및 Si로 이루어진 군으로부터 선택된 하나 이상으로 치환된 그룹을 가리킨다. The aryl group is a monovalent group having an aromatic ring system, and may include two or more ring systems, and the two or more ring systems may exist in a bonded or fused form with each other. The heteroaryl group refers to a group in which at least one carbon of the aryl group is substituted with at least one selected from the group consisting of N, O, S, P, and Si.

한편, 사이클로알킬기는 고리 시스템을 갖는 알킬기를 가리키며, 상기 헤테로사이클로알킬기는 상기 사이클로알킬기 중 하나 이상의 탄소가 N, O, S, P 및 Si로 이루어진 군으로부터 선택된 하나 이상으로 치환된 그룹을 가리킨다. Meanwhile, a cycloalkyl group refers to an alkyl group having a ring system, and the heterocycloalkyl group refers to a group in which at least one carbon of the cycloalkyl group is substituted with at least one selected from the group consisting of N, O, S, P and Si.

상기 아릴기 및 헤테로아릴기의 하나 이상의 수소가 치환될 경우, 이들의 치환기는 C1-C50알킬기; C1-C50알콕시기; 비치환 또는 C1-C50알킬기 또는 C1-C50알콕시기로 치환된 C6-C50아릴기; 비치환 또는 C1-C50알킬기 또는 C1-C50알콕시기로 치환된 C2-C50헤테로아릴기; 비치환 또는 C1-C50알킬기 또는 C1-C50알콕시기로 치환된 C5-C50사이클로알킬기및 비치환 또는 C1-C20알킬기 또는 C1-C20알콕시기로 치환된 C5-C50헤테로사이클로알킬기, 또는 실레인기로 표시되는 그룹으로 이루어진 군으로부터 선택된 하나 이상일 수 있다.
When at least one hydrogen of the aryl group and the heteroaryl group is substituted, the substituent is a C1-C50 alkyl group; A C1-C50 alkoxy group; A C6-C50 aryl group unsubstituted or substituted with a C1-C50 alkyl group or a C1-C50 alkoxy group; A C2-C50 heteroaryl group unsubstituted or substituted with a C1-C50 alkyl group or a C1-C50 alkoxy group; A C5-C50 cycloalkyl group which is unsubstituted or substituted by a C1-C50 alkyl group or a C1-C50 alkoxy group and a C5-C50 heterocycloalkyl group which is unsubstituted or substituted by a C1-C20 alkyl group or a C1-C20 alkoxy group, &Lt; / RTI &gt;

보다 구체적으로, A1, A2, A2', A3, A4 및 A4'는 서로 독립적 또는 유관하게, 수소, 페닐기, 톨일기, 비페닐기, 펜타레닐기, 인데닐기, 나프틸기, 비페닐레닐기, 안트라세닐기, 벤조안트라세닐기, 아즈레닐기, 헵타레닐기, 아세나프틸레닐기, 페나레닐기, 메틸안트릴기, 페난트레닐기, 트리페닐레닐기, 피레닐기, 크리세닐기, 피세닐기, 페릴레닐기, 클로로페릴레닐기, 펜타페닐기, 펜타세닐기, 테트라페닐레닐기, 헥사페닐기, 헥사세닐기, 루비세닐기, 코로네닐기, 트리나프틸레닐기, 헵타페닐기, 헵타세닐기, 플루오레닐기, 피란트레닐기, 오바레닐기, 카르바졸릴기, 디벤조퓨라닐기, 디벤조티오페닐기, 티오페닐기, 인돌일기, 푸리닐기, 벤즈이미다졸일기, 퀴놀리닐기, 벤조티오페닐기, 파라티아지닐기, 피롤일기, 피라졸릴기, 이미다졸릴기, 이미다졸리닐기, 옥사졸릴기, 티아졸릴기, 트리아졸릴기, 테트라졸일기, 옥사디아졸릴기, 피리디닐기, 피리다지닐기, 피리미디닐기, 피라지닐기, 티안트레닐기(thianthrenyl), 사이클로펜틸기, 사이클로헥실기, 옥시라닐기, 피롤리디닐기, 피라졸리디닐기, 이미다졸리디닐기, 피페리디닐기, 피페라지닐기, 모르폴리닐기, 디(C6-C50아릴)아미노기, 실레인기 및 이들의 유도체로 이루어진 군으로부터 선택될 수 있다.
More specifically, A1, A2, A2 ', A3, A4 and A4' are independently or related to each other, hydrogen, phenyl group, tolyl group, biphenyl group, pentarenyl group, indenyl group, naphthyl group, biphenylenyl group, anthra Senyl group, benzoanthracenyl group, azurenyl group, heptarenyl group, acenaphthylenyl group, phenenalenyl group, methyl anthryl group, phenanthrenyl group, triphenylenyl group, pyrenyl group, chrysenyl group, picenyl group, Perylyl group, chloroperylenyl group, pentaphenyl group, pentaxenyl group, tetraphenylenyl group, hexaphenyl group, hexasenyl group, rubisenyl group, coronyl group, trinaphthyleneyl group, heptaphenyl group, heptasenyl group, fluorene Nilyl group, pyrantrenyl group, ovarenyl group, carbazolyl group, dibenzofuranyl group, dibenzothiophenyl group, thiophenyl group, indolyl group, furinyl group, benzimidazolyl group, quinolinyl group, benzothiophenyl group, parathiazinyl Groups, pyrrolyl groups, pyrazolyl groups, imidazolyl groups, imidazolinyl groups, Sazolyl group, thiazolyl group, triazolyl group, tetrazolyl group, oxadiazolyl group, pyridinyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, thianthrenyl group, thianthrenyl group, cyclopentyl group, cyclo Hexyl group, oxiranyl group, pyrrolidinyl group, pyrazolidinyl group, imidazolidinyl group, piperidinyl group, piperazinyl group, morpholinyl group, di (C6-C50 aryl) amino group, silane group and these It may be selected from the group consisting of derivatives.

본 명세서에 있어서, 상기 "유도체"란 용어는 상기 나열한 그룹들 중 하나 이상의 수소가 전술한 바와 같은 치환기로 치환된 그룹을 가리키는 것이다.In the present specification, the term "derivative" refers to a group in which at least one hydrogen of the groups listed above is substituted with a substituent as described above.

바람직하게는, 상기 A1, A2, A2', A3, A4 및 A4'는 서로 독립적 또는 유관하게, 수소, 페닐기, 비페닐기, 톨일기, 나프틸기, 나프탈레닐페닐기, 디메틸벤질기, 피레닐기, 페난트레닐기, 벤조[de]안트라세닐기, 벤조[a]안트라세닐기, 벤조[b]안트라세닐기, 벤조[c]안트라세닐기, 11,11 -디메틸벤조[de]안트라세닐기, 11,11 -디에틸벤조[de]안트라세닐기, 11,11 -디메틸벤조[a]안트라세닐기, 11,11 -디메틸벤조[b]안트라세닐기, 11,11 -디메틸벤조[c]안트라세닐기, 바이플루오레닐기, 6,6 ,12,12 -테트라메틸-인데노[1,2-b]플루오레닐기, N-페닐카르바졸릴기, N-에틸카르바졸릴기, 카르바졸릴기, 디벤조퓨라닐기, 디벤조티오페닐기, 이미다졸리닐기, 인돌일기, 퀴놀리닐기, 디페닐아미노기, 디비페닐아미노기, 디(tert-부틸벤질)아미노기, (톨일)(페닐)아미노기, (페닐)(비페닐)아미노기, (페닐)(나프틸)아미노기, 디(비페틸)아미노기, 디플루오레닐아미노기, 디-p-톨일아미노기, 실레인기 및 이들의 유도체로 이루어진 군으로부터 선택될 수 있다.Preferably, A1, A2, A2 ', A3, A4 and A4' are independently or related to each other, hydrogen, phenyl group, biphenyl group, tolyl group, naphthyl group, naphthalenylphenyl group, dimethylbenzyl group, pyrenyl group, Phenanthrenyl group, benzo [de] anthracenyl group, benzo [a] anthracenyl group, benzo [b] anthracenyl group, benzo [c] anthracenyl group, 11, 11-dimethylbenzo [de] anthracenyl group, 11 , 11-diethylbenzo [de] anthracenyl group, 11,11-dimethylbenzo [a] anthracenyl group, 11,11-dimethylbenzo [b] anthracenyl group, 11,11-dimethylbenzo [c] anthracenyl Group, bifluorenyl group, 6,6,12,12-tetramethyl-indeno [1,2-b] fluorenyl group, N-phenylcarbazolyl group, N-ethylcarbazolyl group, carbazolyl Group, dibenzofuranyl group, dibenzothiophenyl group, imidazolinyl group, indolyl group, quinolinyl group, diphenylamino group, dibiphenylamino group, di (tert-butylbenzyl) amino group, (tolyl) (phenyl) amino group, ( Phenyl) (biphenyl) amino group, (pe ) (Naphthyl) may be selected from amino group, a di (non petil) amino group, di-fluorenyl group, a di -p- tolyl group, a popular silane, and derivatives thereof.

보다 상세하게 본 발명의 일 구현예에 따르면, 본 발명의 유기 광소자에 사용되는 유기 광화합물은 하기 화학식 1 내지 161의 구조(본 명세서에서 '화학식'은 생략하고 숫자만 기재함)를 가질 수 있으나 이에 한정되는 것은 아니다:In more detail, according to one embodiment of the present invention, the organic photochemical compound used in the organic photoelectric device of the present invention may have a structure of Formula 1 to 161 (in the present specification, the formula is omitted, not described). But not limited to:

Figure 112010001724795-pat00003

Figure 112010001724795-pat00003

Figure 112010001724795-pat00004

Figure 112010001724795-pat00004

Figure 112010001724795-pat00005

Figure 112010001724795-pat00005

Figure 112010001724795-pat00006

Figure 112010001724795-pat00006

Figure 112010001724795-pat00007

Figure 112010001724795-pat00007

Figure 112010001724795-pat00008

Figure 112010001724795-pat00008

Figure 112010001724795-pat00009
Figure 112010001724795-pat00009

Figure 112010001724795-pat00010

Figure 112010001724795-pat00010

Figure 112010001724795-pat00011

Figure 112010001724795-pat00011

Figure 112010001724795-pat00012

Figure 112010001724795-pat00012

Figure 112010001724795-pat00013
Figure 112010001724795-pat00013

Figure 112010001724795-pat00014

Figure 112010001724795-pat00014

Figure 112010001724795-pat00015

Figure 112010001724795-pat00015

상기 화학식 a로 표시되는 본 발명에 따른 유기 광화합물은 통상의 합성 방법을 이용하여 합성될 수 있으며, 상기 화합물의 보다 상세한 합성 경로는 하기 합성예의 반응식 1 내지 161을 참조한다. 상기 화학식 a의 화합물은 유기 광소자의 유기막, 특히 정공수송층, 정공주입층 또는 발광층에 사용되기 적합하다. 본 발명을 따르는 유기 발광 소자의 구조는 매우 다양하다. 상기 제1전극과 제2전극 사이에 정공주입층, 정공수송층, 정공저지층, 전자저지층, 전자수송층 및 전자주입층으로 이루어진 군으로부터 선택된 하나 이상의 층을 더 포함할 수 있다.The organic photochemical compound according to the present invention represented by Chemical Formula a may be synthesized using a conventional synthesis method, and for more detailed synthesis route of the compound, see Schemes 1 to 161 of Synthesis Examples below. The compound of formula (a) is suitable for use in organic membranes of organic optical devices, in particular hole transport layers, hole injection layers or light emitting layers. The structure of the organic light emitting device according to the present invention is very diverse. The organic EL device may further include at least one layer selected from the group consisting of a hole injecting layer, a hole transporting layer, a hole blocking layer, an electron blocking layer, an electron transporting layer, and an electron injecting layer between the first electrode and the second electrode.

보다 구체적으로, 본 발명을 따르는 유기 발광 소자의 구현예는 More specifically, an embodiment of an organic light emitting device according to the present invention

먼저, 유기 발광 소자는 제1전극/정공주입층/발광층/전자수송층/전자주입층/제2전극으로 이루어진 구조를 가질 수 있고, First, the organic light emitting device may have a structure including a first electrode / a hole injection layer / a light emitting layer / an electron transport layer / an electron injection layer / a second electrode,

또 유기 발광 소자는 제1전극/정공주입층/정공수송층/발광층/전자수송층/전자주입층/제2전극으로 이루어진 구조를 가질 수 있으며,The organic light emitting device may have a structure including a first electrode / a hole injection layer / a hole transport layer / a light emitting layer / an electron transport layer / an electron injection layer / a second electrode,

나아가 유기 발광 소자는 제1전극/정공주입층/정공수송층/발광층/정공저지층/전자수송층/전자주입층/제2전극의 구조를 가질 수 있다.Further, the organic light emitting device may have a structure of a first electrode / a hole injection layer / a hole transport layer / a light emitting layer / a hole blocking layer / an electron transport layer / an electron injection layer / a second electrode.

이때, 상기 정공수송층, 정공주입층 및 발광층 중 하나 이상은 본 발명을 따르는 화합물을 포함할 수 있다.At this time, one or more of the hole transporting layer, the hole injecting layer, and the light emitting layer may include a compound according to the present invention.

본 발명을 따르는 유기 광소자의 발광층은 적색, 녹색, 청색 또는 백색을 포함하는 인광 또는 형광 도펀트를 포함할 수 있다. 이 중, 상기 인광 도펀트는 Ir, Pt, Os, Ti, Zr, Hf, Eu, Tb 및 Tm으로 이루어진 군으로부터 선택된 하나 이상의 원소를 포함하는 유기금속화합물일 수 있다. 또한, 본 발명에 따르는 화합물은 발광층에서 형광 도펀트로도 사용될 수 있다.The light-emitting layer of the organic optical device according to the present invention may include a phosphorescent or fluorescent dopant including red, green, blue or white. The phosphorescent dopant may be an organometallic compound containing at least one element selected from the group consisting of Ir, Pt, Os, Ti, Zr, Hf, Eu, Tb and Tm. In addition, the compound according to the present invention can also be used as a fluorescent dopant in the light emitting layer.

이하, 본 발명을 따르는 유기 광소자의 제조 방법을 유기 광소자를 참조하여, 살펴보기로 한다. 먼저 기판 상부에 높은 일함수를 갖는 제1전극용 물질을 증착법 또는 스퍼터링법 등에 의해 형성하여 제1전극을 형성한다. 상기 제1전극은 애노드(Anode)일 수 있다. 여기에서 기판으로는 통상적인 유기 광소자에서 사용되는 기판을 사용하는데 기계적 강도, 열적 안정성, 투명성, 표면 평활성, 취급용이성 및 방수성이 우수한 유리 기판 또는 투명 플라스틱 기판이 바람직하다. 제1전극용 물질로는 투명하고 전도성이 우수한 산화인듐주석(ITO), 산화인듐아연(IZO), 산화주석(SnO2), 산화아연(ZnO) 등을 사용한다.Hereinafter, a method of manufacturing an organic optical device according to the present invention will be described with reference to an organic optical device. First, a first electrode material having a high work function on the substrate is formed by a deposition method or a sputtering method to form a first electrode. The first electrode may be an anode. Here, the substrate used in a typical organic optical device is preferably a glass substrate or a transparent plastic substrate having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and waterproofness. As the material for the first electrode, indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO2), zinc oxide (ZnO) or the like is used which is transparent and excellent in conductivity.

다음으로, 상기 제1전극 상부에 진공증착법, 스핀코팅법, 캐스트법, LB법 등과 같은 다양한 방법을 이용하여 정공주입층(HIL)을 형성할 수 있다.Next, a hole injection layer (HIL) may be formed on the first electrode by various methods such as a vacuum deposition method, a spin coating method, a casting method, and an LB method.

진공증착법에 의하여 정공주입층을 형성하는 경우, 그 증착 조건은 정공주입층의 재료로서 사용하는 화합물, 목적으로 하는 정공주입층의 구조 및 열적 특성 등에 따라 다르지만, 일반적으로 증착온도 100 내지 500℃, 진공도 10-5 내지 10-3 torr, 증착속도 0.01 내지 100Å/sec, 막 두께는 통상 100Å 내지 1㎛ 범위에서 적절히 선택하는 것이 바람직하다.When the hole injection layer is formed by the vacuum deposition method, the deposition conditions vary depending on the compound used as the material of the hole injection layer, the structure and the thermal characteristics of the desired hole injection layer, and the like. In general, A degree of vacuum of 10 &lt; -5 &gt; to 10 &lt; -3 &gt; torr, a deposition rate of 0.01 to 100 A / sec and a film thickness of 100 to 1 mu m.

스핀코팅법에 의하여 정공주입층을 형성하는 경우, 그 코팅 조건은 정공주입층의 재료로서 사용하는 화합물, 목적하는 하는 정공주입층의 구조 및 열적 특성에 따라 상이하지만, 약 2000rpm 내지 5000rpm의 코팅 속도, 코팅 후 용매 제거를 위한 열처리 온도는 약 80℃ 내지 200℃의 온도 범위 에서 적절히 선택하는 것이 바람직하다.When the hole injection layer is formed by the spin coating method, the coating conditions vary depending on the compound used as the material of the hole injection layer, the structure and the thermal properties of the desired hole injection layer, but the coating speed is preferably from about 2000 rpm to 5000 rpm , And the heat treatment temperature for removing the solvent after coating is suitably selected within a temperature range of about 80 캜 to 200 캜.

상기 정공주입층 물질은 전술한 바와 같은 화학식 a를 갖는 화합물일 수 있다. The hole injection layer material may be a compound having the formula a as described above.

또는, 예를 들어, 미국특허 제4,356,429호에 개시된 구리프탈로시아닌 등의 프탈로시아닌 화합물 또는 Advanced Material, 6, p.677(1994)에 기재되어 있는 스타버스트형 아민 유도체류인 TCTA, m-MTDATA, m-MTDAPB, 2-TNATA(4,4 ,4 -tris(N-(2-naphtyl)-N-phenylamino)triphenylamine:4,4 ,4 -트리스(N-(나프틸)-N-페닐아미노)트리페닐아민), 용해성이 있는 전도성 고분자인 Pani/DBSA (Polyaniline/Dodecylbenzenesulfonic acid:폴리아닐린/도데실벤젠술폰산) 또는 PEDOT/PSS (Poly(3,4-ethylenedioxythiophene)/Poly(4-styrenesulfonate):폴리(3,4-에틸렌디옥시티오펜)/폴리(4-스티렌술포네이트)), PANI/CSA (Polyaniline/Camphor sulfonicacid:폴리아닐린/캠퍼술폰산) 또는 PANI/PSSOr phthalocyanine compounds such as copper phthalocyanine disclosed in US Pat. No. 4,356,429 or the starburst type amine derivatives described in Advanced Material, 6, p.677 (1994), for example, TCTA, m-MTDATA, m-. MTDAPB, 2-TNATA (4,4,4-tris (N- (2-naphtyl) -N-phenylamino) triphenylamine: 4,4,4-tris (N- (naphthyl) -N-phenylamino) triphenyl Amines), Pani / DBSA (Polyaniline / Dodecylbenzenesulfonic acid: polyaniline / dodecylbenzenesulfonic acid) or PEDOT / PSS (Poly (3,4-ethylenedioxythiophene) / Poly (4-styrenesulfonate): poly (3, 4-ethylenedioxythiophene) / poly (4-styrenesulfonate)), PANI / CSA (Polyaniline / Camphor sulfonicacid: polyaniline / camphorsulfonic acid) or PANI / PSS

(Polyaniline)/Poly(4-styrenesulfonate):폴리아닐린)/폴리(4-스티렌술포네이트)) 등과 같은 공지된 정공주입 물질을 사용할 수 있다.
(Polyaniline) / poly (4-styrenesulfonate): polyaniline) / poly (4-styrenesulfonate)) and the like can be used.

상기 정공주입층의 두께는 약 100Å 내지 10000Å, 바람직하게는 100Å 내지 1000Å일 수 있다. 상기 정공주입층의 두께가 100Å 미만인 경우, 정공주입 특성이 저하될 수 있으며, 상기 정공주입층의 두께가 10000Å를 초과하는 경우, 구동전압이 상승할 수 있기 때문이다.The thickness of the hole injection layer may be about 100 Å to 10000 Å, preferably 100 Å to 1000 Å. If the thickness of the hole injection layer is less than 100 angstroms, the hole injection characteristics may be degraded. If the thickness of the hole injection layer exceeds 10000 angstroms, the driving voltage may increase.

다르게는, 상기 정공주입층은 진공기상증착법에 의해 형성할 수 있다. 구체적인 증착조건은 사용하는 화합물에 따라 다르지만, 일반적인 정공주입층의 형성과 거의 동일한 조건범위 중에서 선택된다. 예를 들어 DNTPD(N,N-bis-[4-(di-m-tolylamino)phenyl]-N,N -diphenylbiphenyl-4,4 -diamine) 등이 사용될 수 있다.Alternatively, the hole injection layer may be formed by a vacuum vapor deposition method. The specific deposition conditions vary depending on the compound used, but are selected from substantially the same range of conditions as the formation of a general hole injection layer. For example, DNTPD (N, N-bis- [4- (di-m-tolylamino) phenyl] -N, N-diphenylbiphenyl-4,4-diamine) may be used.

다음으로 상기 정공주입층 상부에 진공증착법, 스핀코팅법, 캐스트법, LB법 등과 같은 다양한 방법을 이용하여 정공수송층(HTL)을 형성할 수 있다. 진공증착법 및 스핀팅법에 의하여 정공수송층을 형성하는 경우, 그 증착조건 및 코팅조건은 사용하는 화합물에 따라 다르지만, 일반적으로 정공주입층의 형성과 거의 동일한 조건범위 중에서 선택된다.Next, a hole transport layer (HTL) may be formed on the hole injection layer by various methods such as a vacuum deposition method, a spin coating method, a casting method, and an LB method. In the case of forming the hole transporting layer by the vacuum deposition method and the sputtering method, the deposition conditions and the coating conditions vary depending on the compound used, but are generally selected from substantially the same range of conditions as the formation of the hole injection layer.

상기 정공수송층 물질은 전술한 바와 같은 화학식 a의 화합물을 포함할 수 있다. 또는, 예를 들어, N-페닐카르바졸, 폴리비닐카르바졸 등의 카르바졸 유도체, N,N'-비스(3-메틸페닐)-N,N'-디페닐-[1,1-비페닐]-4,4'-디아민(TPD), N,N'-디(나프탈렌-1-일)-N,N'-디페닐 벤지딘(α-NPD) 등의 방향족 축합환을 가지는 통상적인 아민 유도체 등과 같은 공지된 정공수송 물질을 사용할 수 있다.상기 정공수송층의 두께는 약 50Å 내지 1000Å, 바람직하게는 100Å 내지 600Å일 수 있다. 상기 정공수송층의 두께가 50Å 미만인 경우, 정공수송 특성이 저하될 수 있으며, 상기 정공수송층의 두께가 1000Å를 초과하는 경우, 구동전압이 상승할 수 있기 때문이다.The hole transport layer material may comprise a compound of formula (a) as described above. Or carbazole derivatives such as N-phenylcarbazole, polyvinylcarbazole and the like, N, N'-bis (3-methylphenyl) -N, N'- diphenyl- [ Amine having an aromatic condensed ring such as N, N'-tetramethyldisiloxane, -4,4'-diamine (TPD) and N, N'-di (naphthalen- The hole transporting layer may have a thickness of about 50 Å to 1000 Å, preferably 100 Å to 600 Å. When the thickness of the hole transporting layer is less than 50 Å, the hole transporting property may be degraded. When the thickness of the hole transporting layer is more than 1000 Å, the driving voltage may increase.

다음으로 상기 정공수송층 상부에 진공증착법, 스핀코팅법, 캐스트법, LB법 등과 같은 방법을 이용하여 발광층(EML)을 형성할 수 있다. 진공증착법 및 스핀코팅법에 의해 발광층을 형성하는 경우, 그 증착조건은 사용하는 화합물에 따라 다르지만, 일반적으로 정공주입층의 형성과 거의 동일한 조건범위 중에서 선택된다.Next, a light emitting layer (EML) may be formed on the hole transporting layer by a method such as a vacuum evaporation method, a spin coating method, a casting method, or an LB method. When a light emitting layer is formed by a vacuum deposition method and a spin coating method, the deposition conditions vary depending on the compound used, but generally, the conditions are substantially the same as those for forming the hole injection layer.

상기 발광층은 전술한 바와 같이 본 발명을 따르는 화학식 a의 화합물을 포함할 수 있다. 이 때, 화학식 a의 화합물은 적합한 공지의 호스트 재료와 함께 사용될 수 있거나, 공지의 도펀트 재료와 함께 사용될 수 있다.The luminescent layer may comprise a compound of formula (a) according to the invention as described above. At this time, the compound of the formula (a) can be used together with a suitable known host material or can be used together with a known dopant material.

상기 화학식 a의 화합물을 단독으로 사용하는 것도 가능하다. 호스트 재료의 경우, 예를 들면, Alq3(tris(8-hydroxy-quinolatealuminium) 또는 CBP(4,4'-N,N'-디카바졸-비페닐), 또는 PVK(폴리(n-비닐카바졸)) 등을 사용할 수 있다.
It is also possible to use the compound of formula (a) alone. In the case of the host material, for example, Alq3 (tris (8-hydroxy-quinolatealuminium) or CBP (4,4'-N, N'-dicarbazole- ) Can be used.

도펀트 재료의 경우, 형광 도펀트로서는 이데미츠사(Idemitsu사)에서 구입 가능한 IDE102, IDE105 및 하야시바라사에서 구입 가능한 C545T 등을 사용할 수 있으며, 인광 도펀트로서는 적색 인광 도펀트 PtOEP, UDC사의 RD61, 녹색 인광 도판트 Ir(PPy)3(PPy=2-phenylpyridine), 청색 인광 도펀트인 F2Irpic, UDC사의 적색 인광 도펀트 RD 61 등을 사용할 수 있다. MQD(N-methylquinacridone), 쿠마린(Coumarine)유도체 등도 사용할 수 있다.In the case of the dopant material, IDE102, IDE105 and IDE55 available from Idemitsu Co., Ltd. and C545T available from Hayashibara Co., Ltd. can be used. As the phosphorescent dopant, red phosphorescent dopant PtOEP, UDC RD61, green phosphorescent dopant Ir (PPy) 3 (PPy = 2-phenylpyridine), a blue phosphorescent dopant F2Irpic, and a red phosphorescent dopant RD 61 manufactured by UDC. MQD (N-methylquinacridone), coumarine derivatives and the like can also be used.

도핑 농도는 특별히 제한 되지 않으나 통상적으로 호스트100 중량부를 기준으로 하여 상기 도펀트의 함량은 0.01 ~ 15 중량부이다.상기 발광층의 두께는 약 100Å 내지 1000Å, 바람직하게는 200Å 내지 600Å일 수 있다.The doping concentration is not particularly limited, but the content of the dopant is usually 0.01 to 15 parts by weight based on 100 parts by weight of the host. The thickness of the light emitting layer may be about 100 Å to 1000 Å, preferably 200 Å to 600 Å.

상기 발광층의 두께가 100Å 미만인 경우, 발광 특성이 저하될 수 있으며, 상기 발광층의 두께가 1000Å를 초과하는 경우, 구동전압이 상승할 수 있기 때문이다.When the thickness of the light emitting layer is less than 100 Å, the light emitting characteristics may be degraded. If the thickness of the light emitting layer is more than 1000 Å, the driving voltage may increase.

발광층에 발광 화합물이 인광 도펀트와 함께 사용할 경우에는 삼중항 여기자 또는 정공이 전자수송층으로 확산되는 현상을 방지하기 위하여, 상기 발광층 상부에 진공증착법, 스핀코팅법, 캐스트법, LB법 등과 같은 방법을 이용하여 정공저지층(HBL)을 형성할 수 있다. 진공증착법 및 스핀코팅법에 의해 정공저지층을 형성하는 경우, 그 조건은 사용하는 화합물에 따라 다르지만, 일반적으로 정공주입층의 형성과 거의 동일한 조건범위 중에서 선택된다. 사용가능한 공지의 정공저지재료, 예를 들면 옥사디아졸 유도체나 트리아졸 유도체, 페난트롤린 유도체, BCP 등을 들 수 있다.When a luminescent compound is used together with a phosphorescent dopant in the luminescent layer, a method such as vacuum deposition, spin coating, casting, LB or the like is performed on the luminescent layer to prevent the triplet excitons or holes from diffusing into the electron transporting layer The hole blocking layer HBL can be formed. In the case of forming the hole blocking layer by the vacuum deposition method and the spin coating method, the conditions vary depending on the compound used, but are generally selected from substantially the same range of conditions as the formation of the hole injection layer. Known hole blocking materials which can be used, for example, oxadiazole derivatives, triazole derivatives, phenanthroline derivatives, BCP, and the like.

상기 정공저지층의 두께는 약 50Å 내지 1000Å, 바람직하게는 100Å 내지 300Å일 수 있다. 상기 정공저지층의 두께가 50Å 미만인 경우, 정공저지 특성이 저하될 수 있으며, 상기 정공저지층의 두께가 1000Å를 초과하는 경우, 구동전압이 상승할 수 있기 때문이다.상기 정공저지층이 생략될 경우 도 1b에 도시된 구조를 가지는 유기발광 소자가 얻어진다.The thickness of the hole blocking layer may be about 50 Å to 1000 Å, preferably 100 Å to 300 Å. If the thickness of the hole blocking layer is less than 50 angstroms, the hole blocking characteristics may be deteriorated. If the thickness of the hole blocking layer exceeds 1000 angstroms, the driving voltage may be increased. An organic light emitting element having the structure shown in FIG. 1B is obtained.

다음으로 전자수송층(ETL)을 진공증착법, 또는 스핀코팅법, 캐스트법 등의 다양한 방법을 이용하여 형성한다.Next, an electron transport layer (ETL) is formed by various methods such as a vacuum evaporation method, a spin coating method, and a casting method.

진공증착법 및 스핀코팅법에 의해 전자수송층을 형성하는 경우, 그 조건은 사용하는 화합물에 따라 다르지만, 일반적으로 정공주입층의 형성과 거의 동일한 조건범위 중에서 선택된다. 상기 전자수송층 재료는 전자주입전극(Cathode)로부터 주입된 전자를 안정하게 수송하는 기능을 하는 것으로서 퀴놀린 유도체, 특히 트리스(8-퀴놀리노레이트)알루미늄(Alq3), TAZ, Balq, PBD등과 같은 공지의 재료를 사용할 수도 있다.
In the case of forming the electron transporting layer by the vacuum deposition method and the spin coating method, the conditions vary depending on the compound used, but generally, the conditions are substantially the same as those for forming the hole injection layer. The electron transport layer material serves to stably transport electrons injected from an electron injection electrode, and is a quinoline derivative, particularly a known material such as tris (8-quinolinolate) aluminum (Alq3), TAZ, Balq, Materials may also be used.

상기 전자수송층의 두께는 약 100Å 내지 1000Å, 바람직하게는 200Å 내지 500Å일 수 있다. 상기 전자수송층의 두께가 100Å 미만인 경우, 전자수송 특성이 저하될 수 있으며, 상기 전자수송층의 두께가 1000Å를 초과하는 경우, 구동전압이 상승할 수 있기 때문이다.The thickness of the electron transporting layer may be about 100 ANGSTROM to 1000 ANGSTROM, preferably 200 ANGSTROM to 500 ANGSTROM. When the thickness of the electron transporting layer is less than 100 angstroms, the electron transporting characteristics may be deteriorated. When the thickness of the electron transporting layer exceeds 1000 angstroms, the driving voltage may increase.

또한 전자수송층 상부에 음극으로부터 전자의 주입을 용이하게 하는 기능을 가지는 물질인 전자주입층(EIL)이 적층될 수 있으며 이는 특별히 재료를 제한하지 않는다.Further, an electron injection layer (EIL), which is a material having a function of facilitating the injection of electrons from the cathode, may be laminated on the electron transporting layer, which is not particularly limited.

전자 주입층으로서는 LiF, NaCl, CsF, Li2O, BaO 등과 같은 전자주입층 형성 재료로서 공지된 임의의 물질을 이용할 수 있다. 상기 전자주입층의 증착조건은 사용하는 화합물에 따라 다르지만, 일반적으로 정공주입층의 형성과 거의 동일한 조건범위 중에서 선택된다.As the electron injection layer, any material known as an electron injection layer forming material such as LiF, NaCl, CsF, Li2O, BaO, or the like can be used. The deposition conditions of the electron injection layer vary depending on the compound used, but are generally selected from substantially the same range of conditions as the formation of the hole injection layer.

상기 전자주입층의 두께는 약 1Å 내지 100Å, 바람직하게는 5Å 내지 50Å일 수 있다. 상기 전자주입층의 두께가 1Å 미만인 경우, 전자주입 특성이 저하될 수 있으며, 상기 전자주입층의 두께가 100Å를 초과하는 경우, 구동전압이 상승할 수 있기 때문이다.The thickness of the electron injection layer may be about 1 A to 100 A, preferably 5 A to 50 A. If the thickness of the electron injection layer is less than 1 angstrom, the electron injection characteristics may be deteriorated. If the thickness of the electron injection layer exceeds 100 angstroms, the driving voltage may increase.

마지막으로 전자주입층 상부에 진공증착법이나 스퍼터링법 등의 방법을 이용하여 제2전극을 형성할 수 있다.Finally, the second electrode can be formed on the electron injection layer by a vacuum evaporation method, a sputtering method, or the like.

상기 제2전극은 캐소드(Cathode)로 사용될 수 있다. 상기 제2전극 형성용 금속으로는 낮은 일함수를 가지는 금속, 합금, 전기전도성 화합물 및 이들의 혼합물을 사용할 수 있다. 구체적인 예로서는 리튬(Li), 마그네슘(Mg), 알루미늄(Al), 알루미늄-리튬(Al-Li), 칼슘(Ca), 마그네슘-인듐(Mg-In), 마그네슘-은(Mg-Ag)등을 들 수 있다. 또한 전면 발광소자를 얻기 위하여 ITO, IZO를 사용한 투과형 캐소드를 사용할 수도 있다.The second electrode may be used as a cathode. As the metal for forming the second electrode, a metal, an alloy, an electrically conductive compound having a low work function, or a mixture thereof may be used. Specific examples thereof include lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al-Li), calcium (Ca), magnesium-indium (Mg-In), magnesium- . Also, a transmissive cathode using ITO or IZO may be used to obtain a front light emitting element.

본 발명의 다른 구현예에 따르는 유기 전계 발광 화합물은 상기 화학식 a로 표현될 수 있으며, 보다 구체적으로는 상기 화학식 1 내지 161로 표현될 수 있다. 상기 화합물들에 대한 구체적인 내용은 상술한 유기 발과 소자에 대하여 설명한 부분과 동일하다.
The organic electroluminescent compound according to another embodiment of the present invention may be represented by Chemical Formula a, and more specifically, may be represented by Chemical Formulas 1 to 161. The details of the compounds are the same as those described for the organic foot and the device described above.

이하에서, 본 발명의 합성예 및 실시예를 구체적으로 예시하지만, 본 발명이 하기의 합성예 및 실시예로 한정되는 것은 아니다. 이하의 합성예에서 중간체 화합물은 최종 생성물의 번호에 일련번호를 추가하는 방식으로 표기한다. 예를 들어, 화합물 1은 화합물 [1] 로 상기 화합물의 중간체 화합물은 [1-1] 등으로 표기한다. 본 명세서에서 화학물의 번호는 화학식의 번호로서 표기한다. 예를 들어, 화학식 1로 표시되는 화합물은 화합물 1로 표기한다.
Hereinafter, the synthesis examples and examples of the present invention will be specifically illustrated, but the present invention is not limited to the following synthesis examples and examples. In the following synthesis, the intermediate compound is indicated by adding the serial number to the number of the final product. For example, Compound 1 is represented by the compound [1], and the intermediate compound of the above compound is represented by [1-1] or the like. In the present specification, the chemical number is represented by the chemical number. For example, the compound represented by the formula (1) is represented by the compound (1).

[합성 예 1] 화합물 [1]의 합성Synthesis Example 1 Synthesis of Compound [1]

Figure 112010001724795-pat00016
Figure 112010001724795-pat00016

둥근 바닥 플라스크에 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-에틸-9H-카바졸-3-일 보론산 4.65g(19.44mmol), 테트라키스(트리페닐포스핀)팔라듐 408mg(0.353mmol), 2몰-탄산나트륨수용액 5mL, 톨루엔 50mL를 가한 후 질소 분위기에서 10시간 동안 환류 교반한다. 상온에서 메탄올을 가하여 결정화 시킨다. 고체를 디클로로메탄과 헥산을 전개 용매로 사용하여 컬럼 크로마토그라프로 분리 정제하여 중간체 화합물 [1-1] 5.5g(89%)을 흰색로 수득하였다.5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 4.65 g (19.44 mmol) of 9-ethyl-9H-carbazol-3-yl boronic acid, tetrakis (triphenylphosphine) in a round bottom flask 408 mg (0.353 mmol) of palladium, 5 mL of 2 mol-sodium carbonate solution and 50 mL of toluene were added thereto, followed by stirring under reflux for 10 hours in a nitrogen atmosphere. Methanol is added at room temperature to crystallize. The solid was separated and purified through column chromatography using dichloromethane and hexane as a developing solvent, to obtain 5.5 g (89%) of the intermediate compound [1-1] in white.

중간체 화합물 [1-1] 5.5g(15.7mmol), 카바졸 2.63g(15.7mmol), 톨루엔 50mL 를 100mL 둥근바닥 플라스크에 투입하고 질소분위기에서 팔라듐 아세테이트(II) 70mg (0.314mmol), 소디움 터트부톡시드 2.26g (23.55mmol), 터트부틸포스핀(50% 톨루엔 용액) 0.30mL (0.628mmol)을 첨가하여 10시간 동안 환류교반 시킨다. 반응액을 상온으로 냉각시켜 메탄올 50mL를 적가한다. 생성된 고체를 여과하여 미색고체의 목적화합물 [1] 3.5g(51%)을 수득하였다.5.5 g (15.7 mmol) of intermediate compound [1-1] , 2.63 g (15.7 mmol) of carbazole, and 50 mL of toluene were added to a 100 mL round bottom flask, and 70 mg (0.314 mmol) of palladium acetate (II) and sodium tert-butoxide in a nitrogen atmosphere. 2.26 g (23.55 mmol) of the seed and 0.30 mL (0.628 mmol) of tertbutylphosphine (50% toluene solution) were added thereto, and the mixture was stirred under reflux for 10 hours. The reaction solution was cooled to room temperature and 50 mL of methanol was added dropwise. The resulting solid was filtered to yield 3.5 g (51%) of the title compound [1] as an off-white solid.

1H NMR (300 MHz, CDCl3):δ 1.35(t, 3H), 4.45(q, 2H), 7.20~7.50(m, 7H), 7.61~7.95(m, 8H), 8.15(m, 2H), 8.27~8.40(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.35 (t, 3H), 4.45 (q, 2H), 7.20 ~ 7.50 (m, 7H), 7.61 ~ 7.95 (m, 8H), 8.15 (m, 2H) , 8.27-8.40 (m, 2H)

MS/FAB : 436(M+)MS / FAB: 436 (M + )

[합성 예 2] 화합물 [2]의 합성Synthesis Example 2 Synthesis of Compound [2]

Figure 112010001724795-pat00017
Figure 112010001724795-pat00017

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-옥틸-9H-카바졸-3-일 보론산, 카바졸을 사용하여 노란색 고체의 목적화합물 [2] 4.5g(49%)을 수득하였다. Synthesis Example 1 In the same manner, the title compound as a yellow solid using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-octyl-9H-carbazol-3-yl boronic acid, and carbazole [2] 4.5 g (49%) was obtained.

1H NMR (300 MHz, CDCl3):δ 0.85(t, 3H), 1.30(m, 10H), 1.75(m, 2H), 4.15(m, 2H), 7.20~7.40(m, 5H), 7.51(m, 2H), 7.60~7.91(m, 8H), 8.13(m, 2H), 8.25~8.30(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 0.85 (t, 3H), 1.30 (m, 10H), 1.75 (m, 2H), 4.15 (m, 2H), 7.20 ~ 7.40 (m, 5H), 7.51 (m, 2H), 7.60-7.91 (m, 8H), 8.13 (m, 2H), 8.25-8.30 (m, 2H)

MS/FAB : 520(M+)MS / FAB: 520 (M + )

[합성 예 3] 화합물 [3]의 합성Synthesis Example 3 Synthesis of Compound [3]

Figure 112010001724795-pat00018
Figure 112010001724795-pat00018

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [3] 3.7g(43%)을 수득하였다. Synthesis Example 1 In the same manner, the title compound as a white solid using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole [3] 3.7 g (43%) was obtained.

1H NMR (300 MHz, CDCl3):δ 7.21~7.35(m, 4H), 7.51~7,81(m, 14H), 7.95~8.15(m, 5H), 8.45(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.21-7.35 (m, 4H), 7.51-7,81 (m, 14H), 7.95-8.15 (m, 5H), 8.45 (m, 1H)

MS/FAB : 484(M+)MS / FAB: 484 (M + )

[합성 예 4] 화합물 [4]의 합성Synthesis Example 4 Synthesis of Compound [4]

Figure 112010001724795-pat00019
Figure 112010001724795-pat00019

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(비페닐-4-일)-9H-카바졸-3-일 보론산, 카바졸을 사용하여 목적화합물 [4] 3.9g(39%)을 수득하였다. Synthesis Example 1 In the same manner, using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9- (biphenyl-4-yl) -9H-carbazol-3-yl boronic acid, carbazole 3.9 g (39%) of compound [4] was obtained.

1H NMR (300 MHz, CDCl3):δ 7.25~7.55(m, 11H), 7.61~7.80(m, 11H), 7.95~8.20(m, 5H), 8.50(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.55 (m, 11H), 7.61-7.80 (m, 11H), 7.95-8.20 (m, 5H), 8.50 (m, 1H)

MS/FAB : 560(M+)MS / FAB: 560 (M + )

[합성 예 5] 화합물 [5]의 합성Synthesis Example 5 Synthesis of Compound [5]

Figure 112010001724795-pat00020
Figure 112010001724795-pat00020

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(9,9-디메틸-9H-플로렌-2-일)-9H-카바졸-3-일보론산, 카바졸을 사용하여 목적화합물 [5] 4.6g(43%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9- (9,9-dimethyl-9H-floren-2-yl) -9H-carbazol-3-ylboronic acid , Carbazole was used to obtain 4.6 g (43%) of the target compound [5] .

1H NMR (300 MHz, CDCl3):δ 1.65(s, 6H), 7.25~7.45(m, 7H), 7.55(m, 4H), 7.60~7.70(m, 4H), 7.80~7.95(m, 7H), 8.13(m, 3H), 8.45(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.65 (s, 6H), 7.25-7.45 (m, 7H), 7.55 (m, 4H), 7.60-7.70 (m, 4H), 7.80-7.95 (m, 7H), 8.13 (m, 3H), 8.45 (m, 1H)

MS/FAB : 600(M+)MS / FAB: 600 (M + )

[합성 예 6] 화합물 [6]의 합성Synthesis Example 6 Synthesis of Compound [6]

Figure 112010001724795-pat00021
Figure 112010001724795-pat00021

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(나프탈렌-2-일)-9H-카바졸-3-일 보론산, 카바졸을 사용하여 목적화합물 [6] 4.9g(52%)을 수득하였다. Synthesis Example 1 In the same manner, the target compound is prepared by using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9- (naphthalen-2-yl) -9H-carbazol-3-yl boronic acid, and carbazole. [6] 4.9 g (52%) was obtained.

1H NMR (300 MHz, CDCl3):δ 7.23~7.61(m, 18H), 7.75~7.80(m, 4H), 7.85~8.00(m, 3H), 8.15(m, 2H), 8.45(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.23-7.61 (m, 18H), 7.75-7.80 (m, 4H), 7.85-8.00 (m, 3H), 8.15 (m, 2H), 8.45 (m, 2H)

MS/FAB : 534(M+)MS / FAB: 534 (M + )

[합성 예 7] 화합물 [7]의 합성Synthesis Example 7 Synthesis of Compound [7]

Figure 112010001724795-pat00022
Figure 112010001724795-pat00022

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6,9-디페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 목적화합물 [7] 3.8g(38%)을 수득하였다. Synthesis Example 1 Using the same method, the desired compound was prepared using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 6,9-diphenyl-9H-carbazol-3-yl boronic acid and carbazole [7] 3.8 g (38%) were obtained.

1H NMR (300 MHz, CDCl3):δ 7.23~7.61(m, 18H), 7.75~7.80(m, 4H), 7.85~8.00(m, 3H), 8.15(m, 2H), 8.45(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.23-7.61 (m, 18H), 7.75-7.80 (m, 4H), 7.85-8.00 (m, 3H), 8.15 (m, 2H), 8.45 (m, 1H)

MS/FAB : 560(M+)MS / FAB: 560 (M + )

[합성 예 8] 화합물 [8]의 합성Synthesis Example 8 Synthesis of Compound [8]

Figure 112010001724795-pat00023
Figure 112010001724795-pat00023

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(비페닐-4-일)-6-페닐-9H-카바졸-3-일보론산, 카바졸을 사용하여 목적화합물 [8] 5.8g(51%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9- (biphenyl-4-yl) -6-phenyl-9H-carbazole-3-ylboronic acid, and carbazole 5.8 g (51%) of the title compound [8] were obtained.

1H NMR (300 MHz, CDCl3):δ 7.20~7.50(m, 14H), 7.61~7.70(m, 6H), 7.80(m, 6H), 7.85~8.10(m, 5H), 8.46(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.20 to 7.50 (m, 14H), 7.61 to 7.70 (m, 6H), 7.80 (m, 6H), 7.85 to 8.10 (m, 5H), 8.46 (m, 1H)

MS/FAB : 636(M+)MS / FAB: 636 (M + )

[합성 예 9] 화합물 [9]의 합성Synthesis Example 9 Synthesis of Compound [9]

Figure 112010001724795-pat00024
Figure 112010001724795-pat00024

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3-페닐-9H-카바졸을 사용하여 목적화합물 [9] 4.8g(48%)을 수득하였다. Synthesis Example 1 In the same manner, the target compound was prepared using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-phenyl-9H-carbazol-3-yl boronic acid, and 3-phenyl-9H-carbazole. [9] 4.8 g (48%) were obtained.

1H NMR (300 MHz, CDCl3):δ 7.21~7.60(m, 18H), 7.71~7.79(m, 4H), 7.95~8.15(m, 5H), 8.49(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.21-7.70 (m, 18H), 7.71-7.79 (m, 4H), 7.95-8.15 (m, 5H), 8.49 (m, 1H)

MS/FAB : 560(M+)MS / FAB: 560 (M + )

[합성 예 10] 화합물 [10]의 합성Synthesis Example 10 Synthesis of Compound [10]

Figure 112010001724795-pat00025
Figure 112010001724795-pat00025

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(비페닐-4-일)-9H-카바졸-3-일 보론산, 3-페닐-9H-카바졸을 사용하여 목적화합물 [10] 5.0g(44%)을 수득하였다. Synthesis Example 1 In the same manner, 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9- (biphenyl-4-yl) -9H-carbazol-3-yl boronic acid, 3-phenyl-9H- Carbazole was used to obtain 5.0 g (44%) of the target compound [10] .

1H NMR (300 MHz, CDCl3):δ 7.25~7.55(m, 14H), 7.60~7.81(m, 12H), 7.90~8.13(m, 5H), 8.50(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25 to 7.55 (m, 14H), 7.60 to 7.81 (m, 12H), 7.90 to 8.13 (m, 5H), 8.50 (m, 1H)

MS/FAB : 636(M+)MS / FAB: 636 (M + )

[합성 예 11] 화합물 [11]의 합성Synthesis Example 11 Synthesis of Compound [11]

Figure 112010001724795-pat00026
Figure 112010001724795-pat00026

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6,9-디페닐-9H-카바졸-3-일 보론산, 3-페닐-9H-카바졸을 사용하여 목적화합물 [11] 5.3g(47%)을 수득하였다. Synthesis Example 1 In the same manner, 1-bromo-4-iodobenzene 5.0g (17.67mmol), 6,9-diphenyl-9H-carbazol-3-yl boronic acid, 3-phenyl-9H-carbazole This gave 5.3 g (47%) of the title compound [11] .

1H NMR (300 MHz, CDCl3):δ 7.21~7.56(m, 17H), 7.70(m, 4H), 7.75~7.80(m, 5H), 7.95~8.15(m, 5H), 8.51(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.21-7.56 (m, 17H), 7.70 (m, 4H), 7.75-7.80 (m, 5H), 7.95-8.15 (m, 5H), 8.51 (m, 1H)

MS/FAB : 636(M+)MS / FAB: 636 (M + )

[합성 예 12] 화합물 [12]의 합성Synthesis Example 12 Synthesis of Compound [12]

Figure 112010001724795-pat00027
Figure 112010001724795-pat00027

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(비페닐-4-일)-6-페닐-9H-카바졸-3-일 보론산, 3-페닐-9H-카바졸을 사용하여 목적화합물 [12] 5.5g(43%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9- (biphenyl-4-yl) -6-phenyl-9H-carbazol-3-yl boronic acid, 3- Phenyl-9H-carbazole was used to obtain 5.5 g (43%) of the title compound [12] .

1H NMR (300 MHz, CDCl3):δ 7.24~7.55(m, 17H), 7.65~7.70(m, 6H), 7.75~7.85(m, 7H), 7.85~8.00(m, 4H), 8.15(m, 1H), 8.48(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.55 (m, 17H), 7.65 to 7.70 (m, 6H), 7.75 to 7.85 (m, 7H), 7.85 to 8.00 (m, 4H), 8.15 ( m, 1H), 8.48 (m, 1H)

MS/FAB : 712(M+)MS / FAB: 712 (M + )

[합성 예 13] 화합물 [13]의 합성Synthesis Example 13 Synthesis of Compound [13]

Figure 112010001724795-pat00028
Figure 112010001724795-pat00028

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-디페날-9H-카바졸을 사용하여 목적화합물 [13] 5.1g(45%)을 수득하였다. Synthesis Example 1 In the same manner, using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-diphenal-9H-carbazole This gave 5.1 g (45%) of the title compound [13] .

1H NMR (300 MHz, CDCl3):δ 7.25~7.65(m, 21H), 7.75~7.80(m, 5H), 8.01~8.15(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.75 (m, 21H), 7.75-7.80 (m, 5H), 8.01-8.15 (m, 5H)

MS/FAB : 636(M+)MS / FAB: 636 (M + )

[합성 예 14] 화합물 [14]의 합성Synthesis Example 14 Synthesis of Compound [14]

Figure 112010001724795-pat00029
Figure 112010001724795-pat00029

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-디(나프탈렌-1-일)-9H-카바졸을 사용하여 목적화합물 [14] 5.5g(42%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-di (naphthalen-1-yl)- 9H-carbazole was used to obtain 5.5 g (42%) of the target compound [14] .

1H NMR (300 MHz, CDCl3):δ 7.28~7.85(m, 23H), 8.00~8.20(m, 9H), 8.40~8.45(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.28-7.85 (m, 23H), 8.00-8.20 (m, 9H), 8.40-8.45 (m, 4H)

MS/FAB : 736(M+)MS / FAB: 736 (M + )

[합성 예 15] 화합물 [15]의 합성Synthesis Example 15 Synthesis of Compound [15]

Figure 112010001724795-pat00030
Figure 112010001724795-pat00030

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-디(나프탈렌-2-일)-9H-카바졸을 사용하여 목적화합물 [15] 5.8g(44%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-di (naphthalen-2-yl)- 9H-carbazole was used to obtain 5.8 g (44%) of the target compound [15] .

1H NMR (300 MHz, CDCl3):δ 7.25~7.80(m, 24H), 7.90~8.00(m, 9H), 8.10~8.20(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.80 (m, 24H), 7.90-8.00 (m, 9H), 8.10-8.20 (m, 3H)

MS/FAB : 736(M+)MS / FAB: 736 (M + )

[합성 예 16] 화합물 [16]의 합성Synthesis Example 16 Synthesis of Compound [16]

Figure 112010001724795-pat00031
Figure 112010001724795-pat00031

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-디(비페닐-4-일)-9H-카바졸을 사용하여 목적화합물 [16] 6.8g(49%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-di (biphenyl-4-yl) -9H-carbazole was used to obtain 6.8 g (49%) of the target compound [16] .

1H NMR (300 MHz, CDCl3):δ 7.20~7.30(m, 9H), 7.41~7.61(m, 20H), 7.75~7.85(m, 6H), 8.00~8.20(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.20 to 7.30 (m, 9H), 7.41 to 7.61 (m, 20H), 7.75 to 7.85 (m, 6H), 8.00 to 8.20 (m, 5H)

MS/FAB : 788(M+)MS / FAB: 788 (M + )

[합성 예 17] 화합물 [17]의 합성Synthesis Example 17 Synthesis of Compound [17]

Figure 112010001724795-pat00032
Figure 112010001724795-pat00032

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-비스(9,9-디메틸-9H-플로렌-2-일)-9H-카바졸을 사용하여 목적화합물 [17] 7.2g(47%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-bis (9,9-dimethyl-9H 7.2 g (47%) of the title compound [17] was obtained using -floren-2-yl) -9H-carbazole.

1H NMR (300 MHz, CDCl3):δ 1.65(s, 12H), 7.25~7.65(m, 19H), 7.72~7.80(m, 7H), 7.85~8.05(m, 7H), 8.15(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.65 (s, 12H), 7.25 ~ 7.65 (m, 19H), 7.72 ~ 7.80 (m, 7H), 7.85 ~ 8.05 (m, 7H), 8.15 (m, 3H)

MS/FAB : 869(M+)MS / FAB: 869 (M + )

[합성 예 18] 화합물 [18]의 합성Synthesis Example 18 Synthesis of Compound [18]

Figure 112010001724795-pat00033
Figure 112010001724795-pat00033

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(비페닐-4-일)-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 목적화합물 [18] 6.1g(48%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9- (biphenyl-4-yl) -9H-carbazol-3-yl boronic acid, 3,6-diphenyl -9H-carbazole was used to obtain 6.1 g (48%) of the target compound [18] .

1H NMR (300 MHz, CDCl3):δ 7.26~7.54(m, 17H), 7.65~7.90(m, 14H), 8.01~8.15(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.26 to 7.54 (m, 17H), 7.65 to 7.90 (m, 14H), 8.01 to 8.15 (m, 5H)

MS/FAB : 712(M+)MS / FAB: 712 (M + )

[합성 예 19] 화합물 [19]의 합성Synthesis Example 19 Synthesis of Compound [19]

Figure 112010001724795-pat00034
Figure 112010001724795-pat00034

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(9,9-디메틸-9H-플로렌-2-일)-9H-카바졸-3-일 보론산, 3,6-비스(9,9-디메틸-9H-플로렌-2-일l)-9H-카바졸을 사용하여 목적화합물 [19] 7.5g(43%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9- (9,9-dimethyl-9H-floren-2-yl) -9H-carbazol-3-yl boron 7.5 g (43%) of the title compound [19] was obtained using acid, 3,6-bis (9,9-dimethyl-9H-floren-2-yll) -9H-carbazole.

1H NMR (300 MHz, CDCl3):δ 1.67(s, 18H), 7.21~7.31(m, 4H), 7.48~7.65(m, 11H), 7.70~7.79(m, 7H), 7.85~8.20(m, 12H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.67 (s, 18H), 7.21 ~ 7.31 (m, 4H), 7.48 ~ 7.65 (m, 11H), 7.70 ~ 7.79 (m, 7H), 7.85 ~ 8.20 ( m, 12H)

MS/FAB : 985(M+)MS / FAB: 985 (M + )

[합성 예 20] 화합물 [20]의 합성Synthesis Example 20 Synthesis of Compound [20]

Figure 112010001724795-pat00035
Figure 112010001724795-pat00035

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-비스(트리메틸실릴)-9H-카바졸을 사용하여 목적화합물 [20] 4.5g(40%)을 수득하였다. Synthesis Example 1 in the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-bis (trimethylsilyl) -9H-carba The sol was used to obtain 4.5 g (40%) of the title compound [20] .

1H NMR (300 MHz, CDCl3):δ 0.31(s, 18H), 7.26(m, 3H), 7.48~7.65(m, 10H), 7.75~7.80(m, 5H), 7.90~8.15(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 0.31 (s, 18H), 7.26 (m, 3H), 7.48-7.75 (m, 10H), 7.75-7.80 (m, 5H), 7.90-7.81 (m, 4H)

MS/FAB : 628(M+)MS / FAB: 628 (M + )

[합성 예 21] 화합물 [21]의 합성Synthesis Example 21 Synthesis of Compound [21]

Figure 112010001724795-pat00036
Figure 112010001724795-pat00036

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-비스(트리페닐실릴)-9H-카바졸을 사용하여 목적화합물 [21] 5.5g(31%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-bis (triphenylsilyl) -9H- Carbazole was used to obtain 5.5 g (31%) of the title compound [21] .

1H NMR (300 MHz, CDCl3):δ 7.27~7.81(m, 48H), 8.01~8.19(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.27 to 7.81 (m, 48H), 8.01 to 8.19 (m, 4H)

MS/FAB : 1001(M+)MS / FAB: 1001 (M + )

[합성 예 22] 화합물 [22]의 합성Synthesis Example 22 Synthesis of Compound [22]

Figure 112010001724795-pat00037
Figure 112010001724795-pat00037

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-비스(4-(트리메틸실릴)페닐)-9H-카바졸을 사용하여 목적화합물 [22] 5.0g(36%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-bis (4- (trimethylsilyl) phenyl ) -9H-carbazole was used to obtain 5.0 g (36%) of the target compound [22] .

1H NMR (300 MHz, CDCl3):δ 0.30(s, 18H), 7.25(m, 1H), 7.39~7.65(m, 14H), 7.75~7.81(m, 9H), 8.05~8.19(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 0.30 (s, 18H), 7.25 (m, 1H), 7.39-7.75 (m, 14H), 7.75-7.81 (m, 9H), 8.05-8.19 (m, 5H)

MS/FAB : 781(M+)MS / FAB: 781 (M + )

[합성 예 23] 화합물 [23]의 합성Synthesis Example 23 Synthesis of Compound [23]

Figure 112010001724795-pat00038
Figure 112010001724795-pat00038

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일 보론산, 9H-카바졸을 사용하여 목적화합물 [23] 5.9g(51%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 6- (diphenylamino) -9-phenyl-9H-carbazol-3-yl boronic acid, 9H-carbazole 5.9 g (51%) of the title compound [23] was obtained.

1H NMR (300 MHz, CDCl3):δ 6.95~7.15(m, 8H), 7.21~7.60(m, 17H), 7.80~7.95(m, 5H), 8.20~8.40(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.95 to 7.15 (m, 8H), 7.21 to 7.60 (m, 17H), 7.80 to 7.95 (m, 5H), 8.20 to 8.40 (m, 3H)

MS/FAB : 651(M+)MS / FAB: 651 (M &lt; + & gt ; ).

[합성 예 24] 화합물 [24]의 합성Synthesis Example 24 Synthesis of Compound [24]

Figure 112010001724795-pat00039
Figure 112010001724795-pat00039

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 목적화합물 [24] 4.9g(43%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, N, N-diphenyl-9H-carbazole-3 -Amine was used to obtain 4.9 g (43%) of the title compound [24] .

1H NMR (300 MHz, CDCl3):δ 7.00~7.20(m, 8H), 7.25~7.81(m, 20H), 8.05~8.45(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.00-7.20 (m, 8H), 7.25-7.81 (m, 20H), 8.05-8.45 (m, 5H)

MS/FAB : 651(M+)MS / FAB: 651 (M &lt; + & gt ; ).

[합성 예 25] 화합물 [25]의 합성Synthesis Example 25 Synthesis of Compound [25]

Figure 112010001724795-pat00040
Figure 112010001724795-pat00040

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 9H-카바졸을 사용하여 목적화합물 [25] 5.0g(43%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9- (4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, 9H-carbazole Was obtained to give 5.0 g (43%) of the title compound [25] .

1H NMR (300 MHz, CDCl3):δ 7.01~7.18(m, 8H), 7.23~7.53(m, 12H), 7.61~7.69(m, 4H), 7.80(m, 3H), 7.95~8.15(m, 5H), 8.45(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.01-7.18 (m, 8H), 7.23-7.73 (m, 12H), 7.61-7.69 (m, 4H), 7.80 (m, 3H), 7.95-8.15 ( m, 5H), 8.45 (m, 1H)

MS/FAB : 651(M+)MS / FAB: 651 (M &lt; + & gt ; ).

[합성 예 26] 화합물 [26]의 합성Synthesis Example 26 Synthesis of Compound [26]

Figure 112010001724795-pat00041
Figure 112010001724795-pat00041

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐-9H-카바졸-3-일 보론산, 9H-카바졸을 사용하여 목적화합물 [26] 5.8g(40%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 6- (diphenylamino) -9- (4- (diphenylamino) phenyl-9H-carbazol-3-yl Boronic acid, 9H-carbazole, was used to obtain 5.8 g (40%) of the target compound [26] .

1H NMR (300 MHz, CDCl3):δ 6.99~7.20(m, 16H), 7.23~7.50(m, 15H), 7.65~7.80(m, 6H), 7.99~8.40(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.99 to 7.20 (m, 16H), 7.23 to 7.50 (m, 15H), 7.65 to 7.80 (m, 6H), 7.99 to 8.40 (m, 5H)

MS/FAB : 819(M+)MS / FAB: 819 (M + )

[합성 예 27] 화합물 [27]의 합성Synthesis Example 27 Synthesis of Compound [27]

Figure 112010001724795-pat00042
Figure 112010001724795-pat00042

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 목적화합물 [27] 6.8g(47%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9- (4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, N, N- Diphenyl-9H-carbazole-3-amine was used to give 6.8 g (47%) of the title compound [27] .

1H NMR (300 MHz, CDCl3):δ 7.00~7.18(m, 16H), 7.21~7.55(m, 15H), 7.60~7.80(m, 6H), 8.01~8.15(m, 4H), 8.50(m, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.00 to 7.18 (m, 16H), 7.21 to 7.75 (m, 15H), 7.60 to 7.80 (m, 6H), 8.01 to 8.15 (m, 4H), 8.50 ( m, 1H)

MS/FAB : 819(M+)MS / FAB: 819 (M + )

[합성 예 28] 화합물 [28]의 합성Synthesis Example 28 Synthesis of Compound [28]

Figure 112010001724795-pat00043
Figure 112010001724795-pat00043

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 노란색 고체의 목적화합물 [28] 6.9g(48%)을 수득하였다. Synthesis Example 1 In the same manner, 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 6- (diphenylamino) -9-phenyl-9H-carbazol-3-ylboronic acid, N, N-diphenyl -9H-carbazole-3-amine was used to give 6.9 g (48%) of the title compound [28] as a yellow solid.

1H NMR (300 MHz, CDCl3):δ 6.19~6.23(m, 8H), 6.75~6.84(m, 8H), 7.19~7.26(m, 6H), 7.32~7.40(m, 6H), 7.47~7.53(m, 5H), 7.68~7.74(m, 5H), 7.96~8.02(m, 2H), 8.19~8.20(d, 1H), 8.55~8.56(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.19-6.23 (m, 8H), 6.75-6.84 (m, 8H), 7.19-7.26 (m, 6H), 7.32-7.40 (m, 6H), 7.47- 7.53 (m, 5H), 7.68-7.74 (m, 5H), 7.96-8.02 (m, 2H), 8.19-8.20 (d, 1H), 8.55-8.56 (d, 1H)

MS/FAB : 818(M+)MS / FAB: 818 (M + )

[합성 예 29] 화합물 [29]의 합성Synthesis Example 29 Synthesis of Compound [29]

Figure 112010001724795-pat00044
Figure 112010001724795-pat00044

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 흰색 고체의 목적화합물 [29] 7.6g(44%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 6- (diphenylamino) -9- (4- (diphenylamino) phenyl) -9H-carbazole-3- Ilboronic acid, N, N-diphenyl-9H-carbazol-3-amine, was used to obtain 7.6 g (44%) of the title compound [29] as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.62~6.70(m, 14H), 6.76~6.83(m, 10H), 7.19~7.24(m, 12H), 7.29~7.38(m, 6H), 7.69~7.76(m, 5H), 7.95~7.99(m, 2H), 8.20~8.21(d, 1H), 8.54~8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.62 ~ 6.70 (m, 14H), 6.76 ~ 6.83 (m, 10H), 7.19 ~ 7.24 (m, 12H), 7.29 ~ 7.38 (m, 6H), 7.69 ~ 7.76 (m, 5H), 7.95-7.99 (m, 2H), 8.20-8.21 (d, 1H), 8.54-8.55 (d, 1H)

MS/FAB : 985(M+)MS / FAB: 985 (M + )

[합성 예 30] 화합물 [30]의 합성Synthesis Example 30 Synthesis of Compound [30]

Figure 112010001724795-pat00045
Figure 112010001724795-pat00045

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-디아민을 사용하여 흰색 고체의 목적화합물 [30] 6.9g(40%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 6- (diphenylamino) -9-phenyl-9H-carbazol-3-ylboronic acid, N3, N3, N6, 6.9 g (40%) of the target compound [30] as a white solid was obtained using N 6 -tetraphenyl-9H-carbazole-3,6-diamine.

1H NMR (300 MHz, CDCl3):δ 6.63~6.69(m, 13H), 6.75~6.82(m, 10H), 7.19~7.25(m, 12H), 7.38~7.47(m, 5H), 7.56~7.67(m, 6H), 7.78~7.82(m, 3H), 8.01~8.03(d, 1H), 8.18~8.20(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.63 ~ 6.69 (m, 13H), 6.75 ~ 6.82 (m, 10H), 7.19 ~ 7.25 (m, 12H), 7.38 ~ 7.47 (m, 5H), 7.56 ~ 7.67 (m, 6H), 7.78-7.82 (m, 3H), 8.01-8.03 (d, 1H), 8.18-8.20 (d, 1H)

MS/FAB : 985(M+)MS / FAB: 985 (M + )

[합성 예 31] 화합물 [31]의 합성Synthesis Example 31 Synthesis of Compound [31]

Figure 112010001724795-pat00046
Figure 112010001724795-pat00046

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-디아민을 사용하여 흰색 고체의 목적화합물 [31] 9.1g(45%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 6- (diphenylamino) -9- (4- (diphenylamino) phenyl) -9H-carbazole-3- 9.1 g (45%) of the title compound [31] as a white solid was obtained using ilboronic acid, N 3, N 3, N 6, N 6 -tetraphenyl-9H-carbazole-3,6-diamine.

1H NMR (300 MHz, CDCl3):δ 6.61~6.70(m, 19H), 6.75~6.83(m, 12H), 7.18~7.29(m, 16H), 7.35~7.39(m, 4H), 7.65~7.71(m, 4H), 7.78~7.82(m, 3H), 8.01~8.03(d, 1H), 8.18~8.19(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.61-6.70 (m, 19H), 6.75-6.63 (m, 12H), 7.18-7.29 (m, 16H), 7.35-7.39 (m, 4H), 7.65- 7.71 (m, 4H), 7.78-7.82 (m, 3H), 8.01-8.03 (d, 1H), 8.18-8.19 (d, 1H)

MS/FAB : 1152(M+)MS / FAB: 1152 (M + )

[합성 예 32] 화합물 [32]의 합성Synthesis Example 32 Synthesis of Compound [32]

Figure 112010001724795-pat00047
Figure 112010001724795-pat00047

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-3,9'-비카바졸-3'-일보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [32] 5.5g(48%)을 수득하였다. Synthesis Example 1 In the same manner, a white solid using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-phenyl-9H-3,9'-bicarbazole-3'-ylboronic acid, carbazole 5.5 g (48%) of the title compound [32] was obtained.

1H NMR (300 MHz, CDCl3):δ 7.25~7.35(m, 7H), 7.52~7.69(m, 13H), 7.79~7.84(m, 3H), 7.93~7.99(m, 3H), 8.16~8.22(m, 3H), 8.53~8.56(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25 to 7.35 (m, 7H), 7.52 to 7.69 (m, 13H), 7.79 to 7.84 (m, 3H), 7.93 to 7.99 (m, 3H), 8.16 to 8.22 (m, 3H), 8.53 ~ 8.56 (m, 2H)

MS/FAB : 649(M+)MS / FAB: 649 (M + )

[합성 예 33] 화합물 [33]의 합성Synthesis Example 33 Synthesis of Compound [33]

Figure 112010001724795-pat00048
Figure 112010001724795-pat00048

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-3,9'-비카바졸-3'-일보론산, 9H-3,9'-비카바졸을 사용하여 흰색 고체의 목적화합물 [33] 7.3g(51%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-phenyl-9H-3,9'-bicarbazole-3'-ylboronic acid, 9H-3,9'- Bicarbazole was used to obtain 7.3 g (51%) of the title compound [33] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.24~7.36(m, 10H), 7.49~7.66(m, 15H), 7.78~7.82(m, 3H), 7.93~8.01(m, 4H), 8.12~8.19(m, 3H), 8.55~8.58(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.36 (m, 10H), 7.49 to 7.62 (m, 15H), 7.78 to 7.82 (m, 3H), 7.93 to 8.01 (m, 4H), 8.12 to 8.19 (m, 3H), 8.55 to 8.58 (m, 3H)

MS/FAB : 814(M+)MS / FAB: 814 (M + )

[합성 예 34] 화합물 [34]의 합성Synthesis Example 34 Synthesis of Compound [34]

Figure 112010001724795-pat00049
Figure 112010001724795-pat00049

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-3,9'-비카바졸-3'-일보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [34] 6.2g(54%)을 수득하였다. Synthesis Example 1 In the same manner, a white solid using 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-phenyl-9H-3,9'-bicarbazole-3'-ylboronic acid, carbazole 6.2 g (54%) of the desired compound [34] were obtained.

1H NMR (300 MHz, CDCl3):δ 7.25~7.33(m, 5H), 7.53~7.69(m, 15H), 7.77~7.82(m, 3H), 7.95~8.01(m, 3H), 8.11~8.19(m, 4H), 8.56~8.57(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25 to 7.33 (m, 5H), 7.53 to 7.69 (m, 15H), 7.77 to 7.82 (m, 3H), 7.95 to 8.01 (m, 3H), 8.11 to 8.19 (m, 4H), 8.56-8.57 (d, 1H)

MS/FAB : 649(M+)MS / FAB: 649 (M + )

[합성 예 35] 화합물 [35]의 합성Synthesis Example 35 Synthesis of Compound [35]

Figure 112010001724795-pat00050
Figure 112010001724795-pat00050

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6'-(9H-카바졸-9-일)-9-페닐-9H-3,9'-비카바졸-3'-일보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [35] 7.2g(50%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 6 '-(9H-carbazol-9-yl) -9-phenyl-9H-3,9'-bicarbazole 7.2 g (50%) of the title compound [35] as a white solid was obtained using -3'-ylboronic acid and carbazole.

1H NMR (300 MHz, CDCl3):δ 7.23~7.34(m, 8H), 7.52~7.71(m, 17H), 7.80~7.84(m, 3H), 7.95~8.02(m, 4H), 8.12~8.17(m, 4H), 8.55~8.57(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.23 to 7.74 (m, 8H), 7.52 to 7.71 (m, 17H), 7.80 to 7.84 (m, 3H), 7.95 to 8.02 (m, 4H), 8.12 to 8.17 (m, 4H), 8.55-8.57 (m, 2H)

MS/FAB : 814(M+)MS / FAB: 814 (M + )

[합성 예 36] 화합물 [36]의 합성Synthesis Example 36 Synthesis of Compound [36]

Figure 112010001724795-pat00051
Figure 112010001724795-pat00051

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-3,9'-비카바졸-3'-일보론산, 9H-3,9'-비카바졸을 사용하여 흰색 고체의 목적화합물 [36] 6.7g(47%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9-phenyl-9H-3,9'-bicarbazole-3'-ylboronic acid, 9H-3,9'- using non-carbazole, to give the desired compound [36] 6.7g (47%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 7.25~7.35(m, 8H), 7.49~7.69(m, 17H), 7.79~7.84(m, 3H), 7.95~8.02(m, 4H), 8.11~8.19(m, 4H), 8.53~8.55(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25 to 7.35 (m, 8H), 7.49 to 7.69 (m, 17H), 7.79 to 7.84 (m, 3H), 7.95 to 8.02 (m, 4H), 8.11 to 8.19 (m, 4H), 8.53-8.55 (m, 2H)

MS/FAB : 814(M+)MS / FAB: 814 (M + )

[합성 예 37] 화합물 [37]의 합성Synthesis Example 37 Synthesis of Compound [37]

Figure 112010001724795-pat00052
Figure 112010001724795-pat00052

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 5,11-디페닐-5,11-디하이드로인돌로[3,2-b]카바졸-2-일보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [37] 4.4g(39%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 5,11-diphenyl-5,11-dihydroindolo [3,2-b] carbazole-2-ylbo Lonic acid, carbazole was used to obtain 4.4 g (39%) of the title compound [37] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.24~7.31(m, 5H), 7.44~7.68(m, 17H), 7.76~7.80(m, 3H), 7.96~8.01(m, 2H), 8.11~8.16(m, 3H), 8.55~8.56(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.31 (m, 5H), 7.44 to 7.68 (m, 17H), 7.76 to 7.80 (m, 3H), 7.96 to 8.01 (m, 2H), 8.11 to 8.16 (m, 3H), 8.55 to 8.56 (d, 1H)

MS/FAB : 649(M+)MS / FAB: 649 (M + )

[합성 예 38] 화합물 [38]의 합성Synthesis Example 38 Synthesis of Compound [38]

Figure 112010001724795-pat00053
Figure 112010001724795-pat00053

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일보론산, 5-페닐-5,11-디하이드로인돌로[3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [38] 4.6g(40%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-ylboronic acid, 5-phenyl-5,11-dihydroindolo [3 , 2-b] carbazole was used to obtain 4.6 g (40%) of the title compound [38] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.26~7.34(m, 5H), 7.42~7.67(m, 17H), 7.77~7.81(m, 3H), 7.95~7.99(m, 2H), 8.13~8.18(m, 3H), 8.54~8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.26-7.74 (m, 5H), 7.42-7.67 (m, 17H), 7.77-7.81 (m, 3H), 7.95-7.99 (m, 2H), 8.13- 8.18 (m, 3H), 8.54-8.55 (d, 1H)

MS/FAB : 649(M+)MS / FAB: 649 (M + )

[합성 예 39] 화합물 [39]의 합성Synthesis Example 39 Synthesis of Compound [39]

Figure 112010001724795-pat00054
Figure 112010001724795-pat00054

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(4-(9H-카바졸-9-일)페닐)-9H-카바졸-3-일보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [39] 4.8g(42%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9- (4- (9H-carbazol-9-yl) phenyl) -9H-carbazol-3-ylboronic acid, Carbazole was used to obtain 4.8 g (42%) of the title compound (39 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.24~7.34(m, 7H), 7.49~7.53(m, 3H), 7.62~7.70(m, 9H), 7.77~7.82(m, 3H), 7.95~8.02(m, 3H), 8.11~8.20(m, 4H), 8.55~8.57(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.74 (m, 7H), 7.49 to 7.73 (m, 3H), 7.62 to 7.70 (m, 9H), 7.77 to 7.82 (m, 3H), 7.95 to 8.02 (m, 3H), 8.11-8.20 (m, 4H), 8.55-8.57 (m, 2H)

MS/FAB : 649(M+)MS / FAB: 649 (M + )

[합성 예 40] 화합물 [40]의 합성Synthesis Example 40 Synthesis of Compound [40]

Figure 112010001724795-pat00055
Figure 112010001724795-pat00055

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 5-(4-(디페닐아미노)페닐)-11-페닐-5,11-디하이드로인돌로[3,2-b]카바졸-2-일보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [40] 6.6g(46%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 5- (4- (diphenylamino) phenyl) -11-phenyl-5,11-dihydroindolo [3, 2-b] carbazol-2-ylboronic acid, carbazole, gave 6.6 g (46%) of the title compound [40] as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.62~6.68(m, 6H), 6.81~6.84(m, 2H), 7.25~7.38(m, 11H), 7.44~7.68(m, 12H), 7.78~7.84(m, 3H), 7.95~8.00(m, 2H), 8.11~8.16(m, 3H), 8.54~8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.62-6.68 (m, 6H), 6.81-6.84 (m, 2H), 7.25-7.38 (m, 11H), 7.44-7.68 (m, 12H), 7.78- 7.84 (m, 3H), 7.95-8.00 (m, 2H), 8.11-8.16 (m, 3H), 8.54-8.55 (d, 1H)

MS/FAB : 816(M+)MS / FAB: 816 (M + )

[합성 예 41] 화합물 [41]의 합성Synthesis Example 41 Synthesis of Compound [41]

Figure 112010001724795-pat00056
Figure 112010001724795-pat00056

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(4-(9H-카바졸-9-일)페닐)-9H-카바졸-3-일보론산, 9H-3,9'-비카바졸을 사용하여 흰색 고체의 목적화합물 [41] 6.2g(43%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 9- (4- (9H-carbazol-9-yl) phenyl) -9H-carbazol-3-ylboronic acid, 9H-3,9'-bicarbazole was used to obtain 6.2 g (43%) of the title compound [41] as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.63~6.67(m, 4H), 6.77~6.83(m, 4H), 7.20~7.35(m, 11H), 7.49~7.52(m, 2H), 7.61~7.70(m, 8H), 7.77~7.82(m, 3H), 7.95~8.02(m, 3H), 8.13~8.20(m, 3H), 8.55~8.57(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.63-6.67 (m, 4H), 6.77-6.63 (m, 4H), 7.20-7.35 (m, 11H), 7.49-7.52 (m, 2H), 7.61- 7.70 (m, 8H), 7.77-7.82 (m, 3H), 7.95-8.02 (m, 3H), 8.13-8.20 (m, 3H), 8.55-8.57 (m, 2H)

MS/FAB : 816(M+)MS / FAB: 816 (M + )

[합성 예 42] 화합물 [42]의 합성Synthesis Example 42 Synthesis of Compound [42]

Figure 112010001724795-pat00057
Figure 112010001724795-pat00057

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-3,9'-비카바졸-6-일보론산, 9H-3,9'-비카바졸을 사용하여 흰색 고체의 목적화합물 [42] 5.9g(41%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-3,9'-bicarbazole-6-ylboronic acid, 9H-3,9'-ratio Carbazole was used to obtain 5.9 g (41%) of the title compound [42] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.22~7.35(m, 10H), 7.47~7.69(m, 15H), 7.76~7.80(m, 3H), 7.95~8.02(m, 4H), 8.14~8.21(m, 3H), 8.54~8.57(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.22 to 7.35 (m, 10H), 7.47 to 7.69 (m, 15H), 7.76 to 7.80 (m, 3H), 7.95 to 8.02 (m, 4H), 8.14 to 8.21 (m, 3H), 8.54-8.57 (m, 3H)

MS/FAB : 814(M+)MS / FAB: 814 (M + )

[합성 예 43] 화합물 [43]의 합성Synthesis Example 43 Synthesis of Compound [43]

Figure 112010001724795-pat00058
Figure 112010001724795-pat00058

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(9-페닐-9H-카바졸-3-yl)-9H-3,9'-비카바졸-6-일보론산, 9H-3,9'-비카바졸을 사용하여 흰색 고체의 목적화합물 [43] 6.5g(38%)을 수득하였다. Synthesis Example 1 In the same manner, 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9- (9-phenyl-9H-carbazole-3-yl) -9H-3,9'-bicarbazole- using 6-Daily acid, 9H-carbazol-3,9'- ratio to give the desired compound as a white solid [43] 6.5g (38%) .

1H NMR (300 MHz, CDCl3):δ 7.24~7.36(m, 11H), 7.48~7.72(m, 19H), 7.78~7.81(m, 3H), 7.93~8.01(m, 5H), 8.13~8.20(m, 4H), 8.53~8.57(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.36 (m, 11H), 7.48 to 7.72 (m, 19H), 7.78 to 7.81 (m, 3H), 7.93 to 8.01 (m, 5H), 8.13 to 8.20 (m, 4H), 8.53-8.57 (m, 3H)

MS/FAB : 979(M+)MS / FAB: 979 (M &lt; + & gt ; ) [

[합성 예 44] 화합물 [44]의 합성Synthesis Example 44 Synthesis of Compound [44]

Figure 112010001724795-pat00059
Figure 112010001724795-pat00059

합성예1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일보론산, N,N,11-트리페닐-5,11-디하이드로인돌로[3,2-b]카보졸-2-아민을 사용하여 흰색 고체의 목적화합물 [44] 6.0g(35%)을 수득하였다. Synthesis Example 1 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 6- (diphenylamino) -9-phenyl-9H-carbazol-3-ylboronic acid, N, N, 6.0 g (35%) of the title compound [44] as a white solid was obtained using 11-triphenyl-5,11-dihydroindolo [3,2-b] carbozol-2-amine.

1H NMR (300 MHz, CDCl3):δ 6.62~6.69(m, 9H), 6.76~6.83(m, 6H), 7.21~7.32(m, 9H), 7.49~7.69(m, 19H), 7.78~7.82(m, 3H), 8.07~8.15(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.62 ~ 6.69 (m, 9H), 6.76 ~ 6.83 (m, 6H), 7.21 ~ 7.32 (m, 9H), 7.49 ~ 7.69 (m, 19H), 7.78 ~ 7.82 (m, 3H), 8.07-8.15 (m, 3H)

MS/FAB : 983(M+)MS / FAB: 983 (M + )

[합성 예 45] 화합물 [45]의 합성Synthesis Example 45 Synthesis of Compound [45]

Figure 112010001724795-pat00060
Figure 112010001724795-pat00060

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 5-(4-(디페닐아미노)페닐)-11-페닐-5,11-디하이드로인돌로[3,2-b]카바졸-2-일보론산, N,N,11-트리페닐-5,11-디하이드로인돌로[3,2-b]카보졸-2-아민을 사용하여 흰색 고체의 목적화합물 [45] 6.5g(32%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 5- (4- (diphenylamino) phenyl) -11-phenyl-5,11-dihydroindolo [3, 2-b] carbazole-2-ylboronic acid, N, N, 11-triphenyl-5,11-dihydroindolo [3,2-b] carbozol-2-amine, to give a white solid [45] 6.5 g (32%) were obtained.

1H NMR (300 MHz, CDCl3):δ 6.61~6.69(m, 11H), 6.80~6.86(m, 4H), 7.19~7.42(m, 14H), 7.51~7.67(m, 20H), 7.78~7.84(m, 3H), 8.07~8.16(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.61 to 6.69 (m, 11H), 6.80 to 6.66 (m, 4H), 7.19 to 7.42 (m, 14H), 7.51 to 7.67 (m, 20H), 7.78 to 7.84 (m, 3H), 8.07-8.16 (m, 4H)

MS/FAB : 1148(M+)MS / FAB: 1148 (M + )

[합성 예 46] 화합물 [46]의 합성Synthesis Example 46 Synthesis of Compound [46]

Figure 112010001724795-pat00061
Figure 112010001724795-pat00061

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 5,11-디페닐-5,11-디하이드로인돌로[3,2-b]카바졸-2-일보론산, 5-페닐-5,11-디하이드로인돌로[3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [46] 6.0g(42%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 5,11-diphenyl-5,11-dihydroindolo [3,2-b] carbazole-2-ylbo Lonic acid, 5-phenyl-5,11-dihydroindolo [3,2-b] carbazole, was used to obtain 6.0 g (42%) of the title compound [46] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.24~7.38(m, 5H), 7.43~7.70(m, 24H), 7.76~7.82(m, 3H), 7.96~8.02(m, 2H), 8.11~8.17(m, 3H), 8.55~8.56(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.38 (m, 5H), 7.43 to 7.70 (m, 24H), 7.76 to 7.82 (m, 3H), 7.96 to 8.02 (m, 2H), 8.11 to 8.17 (m, 3H), 8.55 to 8.56 (d, 1H)

MS/FAB : 814(M+)MS / FAB: 814 (M + )

[합성 예 47] 화합물 [47]의 합성Synthesis Example 47 Synthesis of Compound [47]

Figure 112010001724795-pat00062
Figure 112010001724795-pat00062

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 5-(4-(디페닐아미노)페닐)-11-페닐-5,11-디하이드로인돌로[3,2-b]카바졸-2-일보론산, 5-페닐-5,11-디하이드로인돌로[3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [47] 6.2g(36%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 5- (4- (diphenylamino) phenyl) -11-phenyl-5,11-dihydroindolo [3, 2-b] carbazole-2-6.2g Daily acid, 5-phenyl -5,11- dihydro-indol [3,2-b] the desired compound (47) as a white solid using the carbazole (36%) Obtained.

1H NMR (300 MHz, CDCl3):δ 6.62~6.70(m, 6H), 6.80~6.83(m, 2H), 7.21~7.42(m, 12H), 7.44~7.71(m, 18H), 7.75~7.81(m, 3H), 7.96~8.00(m, 2H), 8.15~8.19(m, 3H), 8.55~8.56(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.62 ~ 6.70 (m, 6H), 6.80 ~ 6.83 (m, 2H), 7.21 ~ 7.42 (m, 12H), 7.44 ~ 7.71 (m, 18H), 7.75 ~ 7.81 (m, 3H), 7.96-8.00 (m, 2H), 8.15-8.19 (m, 3H), 8.55-8.56 (d, 1H)

MS/FAB : 981(M+)MS / FAB: 981 (M + )

[합성 예 48] 화합물 [48]의 합성Synthesis Example 48 Synthesis of Compound [48]

Figure 112010001724795-pat00063
Figure 112010001724795-pat00063

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 5,11-디페닐-5,11-디하이드로인돌로[3,2-b]카바졸-2-일보론산, N,N,11-트리페닐-5,11-디하이드로인돌로[3,2-b]카보졸-2-아민을 사용하여 흰색 고체의 목적화합물 [48] 5.9g(34%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 5,11-diphenyl-5,11-dihydroindolo [3,2-b] carbazole-2-ylbo 5.9 g (34%) of the target compound [48] as a white solid was obtained using lonic acid, N, N, 11-triphenyl-5,11-dihydroindolo [3,2-b] carbozol-2-amine. Obtained.

1H NMR (300 MHz, CDCl3):δ 6.61~6.67(m, 5H), 6.79~6.83(m, 2H), 7.21~7.30(m, 6H), 7.46~7.68(m, 27H), 7.77~7.82(m, 3H), 8.05~8.14(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.61-6.67 (m, 5H), 6.79-6.63 (m, 2H), 7.21-7.30 (m, 6H), 7.46-7.68 (m, 27H), 7.77- 7.82 (m, 3H), 8.05-8.14 (m, 4H)

MS/FAB : 981(M+)MS / FAB: 981 (M + )

[합성 예 49] 화합물 [49]의 합성Synthesis Example 49 Synthesis of Compound [49]

Figure 112010001724795-pat00064
Figure 112010001724795-pat00064

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 5-(4-(디페닐아미노)페닐)-11-페닐-5,11-디하이드로인돌로[3,2-b]카바졸-2-일보론산, N,N,11-트리페닐-5,11-디하이드로인돌로[3,2-b]카보졸-2-아민을 사용하여 흰색 고체의 목적화합물 [49] 5.6g(28%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (17.67 mmol) of 1-bromo-4-iodobenzene, 5- (4- (diphenylamino) phenyl) -11-phenyl-5,11-dihydroindolo [3, 2-b] carbazole-2-ylboronic acid, N, N, 11-triphenyl-5,11-dihydroindolo [3,2-b] carbozol-2-amine, to give a white solid [49] 5.6 g (28%) were obtained.

1H NMR (300 MHz, CDCl3):δ 6.60~6.68(m, 5H), 6.81~6.85(m, 2H), 7.20~7.29(m, 7H), 7.47~7.72(m, 31H), 7.75~7.81(m, 3H), 7.95~8.01(m, 2H), 8.11~8.20(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.60-6.68 (m, 5H), 6.81-6.85 (m, 2H), 7.20-7.29 (m, 7H), 7.47-7.72 (m, 31H), 7.75- 7.81 (m, 3H), 7.95-8.01 (m, 2H), 8.11-8.20 (m, 4H)

MS/FAB : 1146(M+)MS / FAB: 1146 (M + )

[합성 예 50] 화합물 [50]의 합성Synthesis Example 50 Synthesis of Compound [50]

Figure 112010001724795-pat00065
Figure 112010001724795-pat00065

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐5.0g (17.67mmol), 9-페닐-9H-카바졸-3-보론산, 카보졸을 사용하여 흰색 고체의 목적화합물 [50] 4.3g(56%)을 수득하였다. Synthesis Example 1 In the same manner, the title compound as a white solid using 4-bromo-4'-iodobiphenyl5.0g (17.67mmol), 9-phenyl-9H-carbazole-3-boronic acid, carbosol [50] 4.3 g (56%) was obtained.

1H NMR (300 MHz, CDCl3):δ 7.24~7.36(m, 8H), 7.47~7.70(m, 11H), 7.79~7.84(m, 3H), 7.95~7.99(m, 2H), 8.13~8.19(m, 3H), 8.56~8.57(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.36 (m, 8H), 7.47 to 7.70 (m, 11H), 7.79 to 7.84 (m, 3H), 7.95 to 7.99 (m, 2H), 8.13 to 8.19 (m, 3H), 8.56-8.57 (d, 1H)

MS/FAB : 560(M+)MS / FAB: 560 (M + )

[합성 예 51] 화합물 [51]의 합성Synthesis Example 51 Synthesis of Compound [51]

Figure 112010001724795-pat00066
Figure 112010001724795-pat00066

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐5.0g (17.67mmol), 4-(9-페닐-9H-카바졸-3-일)페닐보론산, 카보졸을 사용하여 흰색 고체의 목적화합물 [51] 4.5g(51%)을 수득하였다. Synthesis Example 1 In the same manner, a white solid using 4-bromo-4'-iodobiphenyl5.0 g (17.67 mmol), 4- (9-phenyl-9H-carbazol-3-yl) phenylboronic acid, carbosol 4.5 g (51%) of the title compound [51] was obtained.

1H NMR (300 MHz, CDCl3):δ 7.24~7.36(m, 12H), 7.49~7.70(m, 11H), 7.77~7.81(m, 3H), 7.96~8.00(m, 2H), 8.15~8.21(m, 3H), 8.54~8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.36 (m, 12H), 7.49 to 7.70 (m, 11H), 7.77 to 7.81 (m, 3H), 7.96 to 8.00 (m, 2H), 8.15 to 8.21 (m, 3H), 8.54-8.55 (d, 1H)

MS/FAB : 636(M+)MS / FAB: 636 (M + )

[합성 예 52] 화합물 [52]의 합성Synthesis Example 52 Synthesis of Compound [52]

Figure 112010001724795-pat00067
Figure 112010001724795-pat00067

합성예 1과동일한방법으로4-브로모-4'-요오도트리페닐5.0g (17.67mmol), 4-(9-페닐-9H-카바졸-3-일)페닐보론산, 카보졸을 사용하여 흰색 고체의 목적화합물 [52] 3.4g(42%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodotriphenyl5.0 g (17.67 mmol), 4- (9-phenyl-9H-carbazol-3-yl) phenylboronic acid, white with carbozol 3.4 g (42%) of the title compound (52 ) were obtained as a solid.

1H NMR (300 MHz, CDCl3):δ 7.26~7.36(m, 16H), 7.48~7.68(m, 11H), 7.76~7.81(m, 3H), 7.97~8.01(m, 2H), 8.13~8.19(m, 3H), 8.55~8.56(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.26-7.36 (m, 16H), 7.48-7.68 (m, 11H), 7.76-7.81 (m, 3H), 7.97-8.01 (m, 2H), 8.13- 8.19 (m, 3H), 8.55 to 8.56 (d, 1H)

MS/FAB : 712(M+)MS / FAB: 712 (M + )

[합성 예 53] 화합물 [53]의 합성Synthesis Example 53 Synthesis of Compound [53]

Figure 112010001724795-pat00068
Figure 112010001724795-pat00068

합성예 1과동일한방법으로4-브로모-4'-요오도트리페닐5.0g (17.67mmol), 4'-(9-페닐-9H-카바졸-3-일)바이페닐-4-일보론산, 카보졸을 사용하여 흰색 고체의 목적화합물 [53] 2.8g(31%)을 수득하였다. Synthesis Example 1 In the same manner as 4-bromo-4'-iodotriphenyl5.0g (17.67mmol), 4 '-(9-phenyl-9H-carbazol-3-yl) biphenyl-4-ylboronic acid, carbo The sol was used to obtain 2.8 g (31%) of the title compound (53 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.25~7.38(m, 20H), 7.49~7.69(m, 11H), 7.77~7.82(m, 3H), 7.98~8.03(m, 2H), 8.14~8.20(m, 3H), 8.54~8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25 to 7.38 (m, 20H), 7.49 to 7.69 (m, 11H), 7.77 to 7.82 (m, 3H), 7.98 to 8.03 (m, 2H), 8.14 to 8.20 (m, 3H), 8.54-8.55 (d, 1H)

MS/FAB : 788(M+)MS / FAB: 788 (M + )

[합성 예 54] 화합물 [54]의 합성Synthesis Example 54 Synthesis of Compound [54]

Figure 112010001724795-pat00069
Figure 112010001724795-pat00069

합성예 1과동일한방법으로 2-브로모-6-요오도나프탈렌 5.0g (15.02mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [54] 3.5g(44%)을 수득하였다. Synthesis Example 1 In the same manner, the title compound as a white solid, using 5.0 g (15.02 mmol) of 2-bromo-6-iodonaphthalene, 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole [54] 3.5 g (44%) was obtained.

1H NMR (300 MHz, CDCl3):δ 7.25~7.59(m, 15H), 7.73~7.83(m, 3H), 7.92~8.01(m, 4H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25 to 7.59 (m, 15H), 7.73 to 7.83 (m, 3H), 7.92 to 8.01 (m, 4H), 8.12 to 8.18 (m, 4H)

MS/FAB : 534(M+)MS / FAB: 534 (M + )

[합성 예 55] 화합물 [55]의 합성Synthesis Example 55 Synthesis of Compound [55]

Figure 112010001724795-pat00070
Figure 112010001724795-pat00070

합성예 1과동일한방법으로 1-브로모-4-요오도나프탈렌 5.0g (15.02mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [55] 3.9g(48%)을 수득하였다. Synthesis Example 1 In the same manner, the title compound as a white solid using 5.0 g (15.02 mmol) of 1-bromo-4-iodonaphthalene, 9-phenyl-9H-carbazol-3-yl boronic acid, and carbazole [55] 3.9 g (48%) was obtained.

1H NMR (300 MHz, CDCl3):δ 7.24~7.58(m, 16H), 7.83~8.10(m, 9H), 8.55~8.56(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.58 (m, 16H), 7.83 to 8.10 (m, 9H), 8.55 to 8.56 (d, 1H)

MS/FAB : 535(M+)MS / FAB: 535 (M + )

[합성 예 56] 화합물 [56]의 합성Synthesis Example 56 Synthesis of Compound [56]

Figure 112010001724795-pat00071
Figure 112010001724795-pat00071

합성예 1과동일한방법으로 1-브로모-4-요오도나프탈렌 5.0g (15.02mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [56] 3.8g(47%)을 수득하였다. Synthesis Example 1 In the same manner, the title compound as a white solid using 5.0 g (15.02 mmol) of 1-bromo-4-iodonaphthalene, 9-phenyl-9H-carbazol-3-yl boronic acid, and carbazole [56] 3.8 g (47%) was obtained.

1H NMR (300 MHz, CDCl3):δ 7.25~7.32(m, 5H), 7.50~7.62(m, 11H), 7.78(s, 1H), 8.00~8.19(m, 7H), 8.42(d, 1H), 8.54(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.32 (m, 5H), 7.50-7.62 (m, 11H), 7.78 (s, 1H), 8.00-8.19 (m, 7H), 8.42 (d, 1H), 8.54 (d, 1H)

MS/FAB : 534(M+)MS / FAB: 534 (M + )

[합성 예 57] 화합물 [57]의 합성Synthesis Example 57 Synthesis of Compound [57]

Figure 112010001724795-pat00072
Figure 112010001724795-pat00072

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플루오렌 5.0g (12.53mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [57] 3.5g(46%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-fluorene 5.0 g (12.53 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, and carbazole are used. This gave 3.5 g (46%) of the title compound [57] as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.64(m, 16H), 7.78~7.79(m, 2H), 7.87~8.00(m, 4H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25 to 7.74 (m, 16H), 7.78 to 7.79 (m, 2H), 7.87 to 8.00 (m, 4H), 8.12 to 8.18 ( m, 4H)

MS/FAB : 600(M+)MS / FAB: 600 (M + )

[합성 예 58] 화합물 [58]의 합성Synthesis Example 58 Synthesis of Compound [58]

Figure 112010001724795-pat00073
Figure 112010001724795-pat00073

합성예 1과동일한방법으로2-브로모-8-요오드-6,6,12,12-테트라메틸-6,12-디하이드로인데노[1,2-b]플루오렌 6.0g (11.65mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [58] 3.8g(45%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodine-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 6.0 g (11.65 mmol), 9 -phenyl -9H- carbazol-3-yl, using the boronic acid, carbazole, to give the desired compound as a white solid [58] 3.8g (45%) .

1H NMR (300 MHz, CDCl3):δ 1.73(s, 12H), 7.24~7.28(m, 4H), 7.50~7.64(m, 13H), 7.77~7.78(m, 3H), 7.93~7.99(m, 3H), 8.08~8.18(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 12H), 7.24 to 7.28 (m, 4H), 7.50 to 7.74 (m, 13H), 7.77 to 7.78 (m, 3H), 7.93 to 7.99 ( m, 3H), 8.08-8.18 (m, 5H)

MS/FAB : 716(M+)MS / FAB: &lt; / RTI & gt ; 716 (M + )

[합성 예 59] 화합물 [59]의 합성Synthesis Example 59 Synthesis of Compound [59]

Figure 112010001724795-pat00074
Figure 112010001724795-pat00074

합성예 1과동일한방법으로2-브로모-7-요오드-9,10-디하이드로펜안스렌 5.0g (12.99mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [59] 3.4g(45%)을 수득하였다. Synthesis Example 1 In the same manner, using 2-bromo-7-iodine-9,10-dihydrophenanthrene 5.0 g (12.99 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole 3.4 g (45%) of the title compound [59] was obtained as a white solid.

1H NMR (300 MHz, CDCl3):δ 2.98(s, 4H), 7.25~7.33(m, 5H),7.50~7.80(m, 14H), 7.91~8.00(m, 3H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 2.98 (s, 4H), 7.25 to 7.33 (m, 5H), 7.50 to 7.80 (m, 14H), 7.91 to 8.00 (m, 3H), 8.12 to 8.18 ( m, 4H)

MS/FAB : 586(M+)MS / FAB: 586 (M &lt; + & gt ; ).

[합성 예 60] 화합물 [60]의 합성Synthesis Example 60 Synthesis of Compound [60]

Figure 112010001724795-pat00075
Figure 112010001724795-pat00075

합성예 1과동일한방법으로2-브로모-7-요오드-4,5,9,10-테트라하이드로파이렌 5.0g (12.16mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [60] 3.5g(47%)을 수득하였다. Synthesis Example 1 In the same manner 2-bromo-7-iodine-4,5,9,10-tetrahydropyrene 5.0 g (12.16 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole To obtain 3.5g (47%) of the title compound [60] as a white solid.

1H NMR (300 MHz, CDCl3):δ 2.99(s, 8H), 7.25~7.33(m, 4H), 7.50~7.63(m, 11H), 7.74~7.77(m, 3H), 7.94~8.00(m, 2H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 2.99 (s, 8H), 7.25 ~ 7.33 (m, 4H), 7.50 ~ 7.63 (m, 11H), 7.74 ~ 7.77 (m, 3H), 7.94 ~ 8.00 ( m, 2H), 8.12-8.18 (m, 4H)

MS/FAB : 612(M+)
MS / FAB: 612 (M + )

[합성 예 61] 화합물 [61]의 합성Synthesis Example 61 Synthesis of Compound [61]

Figure 112010001724795-pat00076
Figure 112010001724795-pat00076

합성예 1과동일한방법으로1-브로모-4-(4-요오드페닐)나프탈렌 5.0g (12.22mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [61] 3.4g(46%)을 수득하였다. Synthesis Example 1 In the same manner, the purpose of a white solid using 5.0 g (12.22 mmol) of 1-bromo-4- (4-iodinephenyl) naphthalene, 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole 3.4 g (46%) of Compound [61] were obtained.

1H NMR (300 MHz, CDCl3):δ 7.24~7.59(m, 20H), 7.78(s, 1H), 7.94~8.00(m, 3H), 7.12~7.18(m, 5H), 8.54(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.59 (m, 20H), 7.78 (s, 1H), 7.94 to 8.00 (m, 3H), 7.12 to 7.18 (m, 5H), 8.54 (d, 1H)

MS/FAB : 610(M+)MS / FAB: 610 (M &lt; + & gt ; ).

[합성 예 62] 화합물 [62]의 합성Synthesis Example 62 Synthesis of Compound [62]

Figure 112010001724795-pat00077
Figure 112010001724795-pat00077

합성예 1과동일한방법으로2-브로모-6-(4-요오드페닐)나프탈렌 5.0g (12.22mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [62] 3.4g(45%)을 수득하였다. Synthesis Example 1 Purpose of white solid using 5.0 g (12.22 mmol) of 2-bromo-6- (4-iodinephenyl) naphthalene, 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole in the same manner 3.4 g (45%) of Compound [62] were obtained.

1H NMR (300 MHz, CDCl3):δ 7.24~7.36(m, 9H), 7.50~7.68(m, 10H), 7.73~7.77(m, 2H), 7.83(s, 1H), 7.92~8.00(m, 4H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.36 (m, 9H), 7.50 to 7.68 (m, 10H), 7.73 to 7.77 (m, 2H), 7.83 (s, 1H), 7.92 to 8.00 ( m, 4H), 8.12-8.18 (m, 4H)

MS/FAB : 610(M+)MS / FAB: 610 (M + )

[합성 예 63] 화합물 [63]의 합성Synthesis Example 63 Synthesis of Compound [63]

Figure 112010001724795-pat00078
Figure 112010001724795-pat00078

합성예 1과동일한방법으로2-브로모-7-(4-요오드페닐)-9,9-디메틸-9H-플루오렌 5.0g (10.52mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [63] 3.3g(46%)을 수득하였다. Synthesis Example 1 Bromo-7- (4-iodinephenyl) -9,9-dimethyl-9H-fluorene 5.0 g (10.52 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid , Carbazole was used to obtain 3.3 g (46%) of the title compound (63 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.63(m, 20H), 7.78~7.79(m, 2H), 7.87~8.01(m, 4H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25 to 7.63 (m, 20H), 7.78 to 7.79 (m, 2H), 7.87 to 8.01 (m, 4H), 8.12 to 8.18 ( m, 4H)

MS/FAB : 676(M+)MS / FAB: 676 (M &lt; + & gt ; ) [

[합성 예 64] 화합물 [64]의 합성Synthesis Example 64 Synthesis of Compound [64]

Figure 112010001724795-pat00079
Figure 112010001724795-pat00079

합성예 1과동일한방법으로7-브로모-7'-요오드-9,9,9',9'-테트라메틸-9H,9'H-2,2'-바이플루오렌 6.0g (10.15mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [64] 3.6g(45%)을 수득하였다. Synthesis Example 1 In the same manner, 7-bromo-7'-iodine-9,9,9 ', 9'-tetramethyl-9H, 9'H-2,2'-bifluorene 6.0 g (10.15 mmol), 9 3.6 g (45%) of the title compound (64 ) as a white solid was obtained using -phenyl-9H-carbazol-3-yl boronic acid, carbazole.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 12H), 7.25~7.64(m, 18H), 7.78~7.79(m, 4H), 7.87~8.00(m, 6H), 8.12~8.14(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 12H), 7.25 ~ 7.64 (m, 18H), 7.78 ~ 7.79 (m, 4H), 7.87 ~ 8.00 (m, 6H), 8.12 ~ 8.14 ( m, 4H)

MS/FAB : 792(M+)MS / FAB: 792 (M + )

[합성 예 65] 화합물 [65]의 합성Synthesis Example 65 Synthesis of Compound [65]

Figure 112010001724795-pat00080
Figure 112010001724795-pat00080

합성예 1과동일한방법으로2-브로모-8-(4-요오드페닐)-6,6,12,12-테트라메틸-6,12-디하이드로인데노[1,2-b]플루오렌 6.0g (10.15mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [65] 3.7g(46%)을 수득하였다. Synthesis Example 1 in the same manner as 2-bromo-8- (4-iodinephenyl) -6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 6.0 g ( 10.15mmol), 9- phenyl -9H- carbazol-3-yl, using the boronic acid, carbazole, to give the desired compound as a white solid [65] 3.7g (46%) .

1H NMR (300 MHz, CDCl3):δ 1.73(s, 12H), 7.25~7.33(m, 8H), 7.45~7.64(m, 13H), 7.78~7.79(m, 3H), 7.93~8.00(m, 3H), 8.09~8.17(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 12H), 7.25 ~ 7.33 (m, 8H), 7.45 ~ 7.64 (m, 13H), 7.78 ~ 7.79 (m, 3H), 7.93 ~ 8.00 ( m, 3H), 8.09-8.17 (m, 5H)

MS/FAB : 792(M+)MS / FAB: 792 (M + )

[합성 예 66] 화합물 [66]의 합성Synthesis Example 66 Synthesis of Compound [66]

Figure 112010001724795-pat00081
Figure 112010001724795-pat00081

합성예 1과동일한방법으로2,6-디브로모-9,9,10,10-테트라메틸-9,10-디하이드로안드라센 5.0g (12.69mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [66] 3.4g(42%)을 수득하였다. Synthesis Example 1 In the same manner, 2,6-dibromo-9,9,10,10-tetramethyl-9,10-dihydroandracene 5.0g (12.69mmol), 9-phenyl-9H-carbazole-3- using one acid, carbazole, to give the desired compound as a white solid [66] 3.4g (42%) .

1H NMR (300 MHz, CDCl3):δ 1.74(s, 12H), 7.23~7.60(m, 19H), 7.78(s, 1H), 7.95~7.99(m, 2H), 8.12~8.16(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.74 (s, 12 H), 7.23 to 7.60 (m, 19 H), 7.78 (s, 1 H), 7.95 to 7.99 (m, 2H), 8.12 to 8.16 (m, 4H)

MS/FAB : 642(M+)MS / FAB: 642 (M &lt; + & gt ; ).

[합성 예 67] 화합물 [67]의 합성Synthesis Example 67 Synthesis of Compound [67]

Figure 112010001724795-pat00082
Figure 112010001724795-pat00082

합성예 1과동일한방법으로2-디브로모-6-(4-요오드페닐)-9,9,10,10-테트라메틸-9,10-디하이드로안드라센 5.0g (9.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [67] 3.0g(43%)을 수득하였다. Synthesis Example 1 In the same manner as 2-dibromo-6- (4-iodinephenyl) -9,9,10,10-tetramethyl-9,10-dihydroandracene 5.0 g (9.67 mmol), 9-phenyl- 3.0 g (43%) of the title compound [67] as a white solid was obtained using 9H-carbazol-3-yl boronic acid and carbazole.

1H NMR (300 MHz, CDCl3):δ 1.74(s, 12H), 7.24~7.63(m, 23H), 7.77(s, 1H),m 7.96~7.99(m, 2H), 8.12~8.17(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.74 (s, 12H), 7.24 to 7.63 (m, 23H), 7.77 (s, 1H), m 7.96 to 7.99 (m, 2H), 8.12 to 8.17 (m , 4H)

MS/FAB : 718(M+)MS / FAB: 718 (M &lt; + & gt ; ).

[합성 예 68] 화합물 [68]의 합성Synthesis Example 68 Synthesis of Compound [68]

Figure 112010001724795-pat00083
Figure 112010001724795-pat00083

합성예 1과동일한방법으로6-브로모-6'-요오드-2,2'-바이나프틸 5.0g (10.89mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [68] 3.2g(44%)을 수득하였다. Synthesis Example 1 In the same manner, using 5.0 g (10.89 mmol) of 6-bromo-6'-iodine-2,2'-binapthyl, 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole 3.2 g (44%) of the title compound (68 ) as a white solid was obtained.

1H NMR (300 MHz, CDCl3):δ7.25~7.36(m, 5H), 7.50~7.59(m, 12H), 7.73~7.78(m, 5H), 7.92~8.00(m, 6H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ7.25-7.36 (m, 5H), 7.50-7.59 (m, 12H), 7.73-7.78 (m, 5H), 7.92-8.00 (m, 6H), 8.12 ~ 8.18 (m, 4H)

MS/FAB : 660(M+)MS / FAB: 660 (M + )

[합성 예 69] 화합물 [69]의 합성Synthesis Example 69 Synthesis of Compound [69]

Figure 112010001724795-pat00084
Figure 112010001724795-pat00084

합성예 1과동일한방법으로3-브로모-9-요오드-7,7-디메틸-7H-벤조[de]안트라센 5.0g (11.13mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [69] 3.3g(45%)을 수득하였다. Synthesis Example 1 In the same way, 3-bromo-9-iodine-7,7-dimethyl-7H-benzo [de] anthracene 5.0 g (11.13 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, carba using the sol, to give the desired compound as a white solid [69] 3.3g (45%) .

1H NMR (300 MHz, CDCl3):δ 1.86(s, 6H), 7.01~7.06(m, 2H), 7.25~7.64(m, 16H), 7.78~7.79(m, 2H), 7.92~8.00(m, 4H), 8.12~8.17(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.86 (s, 6H), 7.01 ~ 7.06 (m, 2H), 7.25 ~ 7.64 (m, 16H), 7.78 ~ 7.79 (m, 2H), 7.92 ~ 8.00 ( m, 4H), 8.12-8.17 (m, 4H)

MS/FAB : 650(M+)MS / FAB: 650 (M &lt; + & gt ; ).

[합성 예 70] 화합물 [70]의 합성Synthesis Example 70 Synthesis of Compound [70]

Figure 112010001724795-pat00085
Figure 112010001724795-pat00085

합성예 1과동일한방법으로8-브로모-2-요오드-11,11-디메틸-11H-벤조[b]플루오렌 5.0g (11.13mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [70] 3.2g(44%)을 수득하였다. Synthesis Example 1 5.0 g (11.13 mmol) of 8-bromo-2-iodine-11,11-dimethyl-11H-benzo [b] fluorene, 9-phenyl-9H-carbazol-3-yl boronic acid, Carbazole was used to obtain 3.2 g (44%) of the title compound [70] as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.77(s, 6H), 7.25~7.32(m, 5H), 7.45~7.64(m, 12H), 7.78~7.82(m, 3H), 7.94~8.02(m, 3H), 8.12~8.15(m, 4H), 8.27(s, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.77 (s, 6H), 7.25 to 7.32 (m, 5H), 7.45 to 7.74 (m, 12H), 7.78 to 7.82 (m, 3H), 7.94 to 8.02 ( m, 3H), 8.12-8.15 (m, 4H), 8.27 (s, 1H)

MS/FAB : 650(M+)MS / FAB: 650 (M &lt; + & gt ; ).

[합성 예 71] 화합물 [71]의 합성Synthesis Example 71 Synthesis of Compound [71]

Figure 112010001724795-pat00086
Figure 112010001724795-pat00086

합성예 1과동일한방법으로3-브로모-9-요오드-11,11-디메틸-11H-벤조[a]플루오렌 5.0g (11.13mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [71] 3.4g(47%)을 수득하였다. Synthesis Example 1 5.0 g (11.13 mmol) of 3-bromo-9-iodine-11,11-dimethyl-11H-benzo [a] fluorene, 9-phenyl-9H-carbazol-3-yl boronic acid, Carbazole was used to obtain 3.4 g (47%) of the title compound (71 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.86(s, 6H), 7.25~7.32(m, 5H), 7.46~7.63(m, 12H), 7.78~7.83(m, 3H), 7.96~8.00(m, 2H), 8.12~8.17(m, 6H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.86 (s, 6H), 7.25 to 7.32 (m, 5H), 7.46 to 7.63 (m, 12H), 7.78 to 7.83 (m, 3H), 7.96 to 8.00 ( m, 2H), 8.12-8.17 (m, 6H)

MS/FAB : 650(M+)MS / FAB: 650 (M &lt; + & gt ; ).

[합성 예 72] 화합물 [72]의 합성Synthesis Example 72 Synthesis of Compound [72]

Figure 112010001724795-pat00087
Figure 112010001724795-pat00087

합성예 1과동일한방법으로3-브로모-7-요오드-5,5-디페닐-5H-디벤조[b,d]실로레 6.0g (11.13mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [72] 3.8g(46%)을 수득하였다. Synthesis Example 1 Bromo-7-iodine-5,5-diphenyl-5H-dibenzo [b, d] silore 6.0 g (11.13 mmol), 9-phenyl-9H-carbazole-3- One boronic acid, carbazole, was used to obtain 3.8 g (46%) of the title compound (72 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.23~7.58(m, 25H), 7.78~7.79(m, 3H), 7.89~8.01(m, 4H), 8.12~8.17(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.23 to 7.58 (m, 25H), 7.78 to 7.79 (m, 3H), 7.89 to 8.01 (m, 4H), 8.12 to 8.17 (m, 4H)

MS/FAB : 740(M+)MS / FAB: 740 (M &lt; + & gt ; ).

[합성 예 73] 화합물 [73]의 합성Synthesis Example 73 Synthesis of Compound [73]

Figure 112010001724795-pat00088
Figure 112010001724795-pat00088

합성예 1과동일한방법으로출발물질[73-1] 6.0g (7.54mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [73] 3.4g(45%)을 수득하였다. Synthesis Example (1 ) 6.0 g (7.54 mmol) of starting material [73-1], 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole as a white solid target compound [73] 3.4 g ( 45%) was obtained.

1H NMR (300 MHz, CDCl3):δ 7.23~7.57(m, 35H), 7.78~7.79(m, 3H), 7.89~8.01(m, 6H), 8.12~8.17(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.23 to 7.57 (m, 35H), 7.78 to 7.79 (m, 3H), 7.89 to 8.01 (m, 6H), 8.12 to 8.17 (m, 4H)

MS/FAB : 996(M+)MS / FAB: 996 (M + )

[합성 예 74] 화합물 [74]의 합성Synthesis Example 74 Synthesis of Compound [74]

Figure 112010001724795-pat00089
Figure 112010001724795-pat00089

합성예 1과동일한방법으로3-브로모-9-요오드-5,11-디페닐-5,11-디하이드로인돌로[3,2-b]카바졸 6.0g (9.78mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [74] 3.4g(43%)을 수득하였다. Synthesis Example 1 Bromo-9-iodine-5,11-diphenyl-5,11-dihydroindolo [3,2-b] carbazole 6.0 g (9.78 mmol), 9-phenyl-9H -carbazol-3-yl, using the boronic acid, carbazole, to give the desired compound as a white solid [74] 3.4g (43%) .

1H NMR (300 MHz, CDCl3):δ 7.24~7.62(m, 25H), 7.78(s, 1H), 7.94~8.00(m, 2H), 8.10~8.17(m, 5H), 8.44~8.49(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.24 to 7.82 (m, 25H), 7.78 (s, 1H), 7.94 to 8.00 (m, 2H), 8.10 to 8.17 (m, 5H), 8.44 to 8.49 ( m, 2H)

MS/FAB : 814(M+)MS / FAB: 814 (M + )

[합성 예 75] 화합물 [75]의 합성Synthesis Example 75 Synthesis of Compound [75]

Figure 112010001724795-pat00090
Figure 112010001724795-pat00090

합성예 1과동일한방법으로2-브로모-7-요오드-9-페닐-9H-카바졸 5.0g (11.16mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [75] 3.2g(44%)을 수득하였다. Synthesis Example 1 In the same way, using 2-bromo-7-iodine-9-phenyl-9H-carbazole 5.0 g (11.16 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole 3.2 g (44%) of the title compound (75 ) were obtained as a solid.

1H NMR (300 MHz, CDCl3):δ 7.22~7.58(m, 21H), 7.78(s, 1H), 7.94~8.00(m, 2H), 8.10~8.17(m, 6H), 8.47(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.22-7.58 (m, 21H), 7.78 (s, 1H), 7.94-8.00 (m, 2H), 8.10-8.17 (m, 6H), 8.47 (d, 1H)

MS/FAB : 649(M+)MS / FAB: 649 (M + )

[합성 예 76] 화합물 [76]의 합성Synthesis Example 76 Synthesis of Compound [76]

Figure 112010001724795-pat00091
Figure 112010001724795-pat00091

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플루오렌 5.0g (12.53mmol), 화합물 [76-1], 카바졸을 사용하여 흰색 고체의 목적화합물 [76] 4.1g(43%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-fluorene 5.0 g (12.53 mmol), a compound [76-1] , and a target compound as a white solid using carbazole [76 ] to give the 4.1g (43%).

1H NMR (300 MHz, CDCl3):δ 1.72(s, 6H), 7.24~7.59(m, 22H), 7.79(s, 1H), 7.87~7.96(m, 5H), 8.10~8.13(m, 4H), 8.48(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 6H), 7.24 ~ 7.59 (m, 22H), 7.79 (s, 1H), 7.87 ~ 7.96 (m, 5H), 8.10 ~ 8.13 (m, 4H), 8.48 (d, 1H)

MS/FAB : 765(M+)MS / FAB: 765 (M + )

[합성 예 77] 화합물 [77]의 합성Synthesis Example 77 Synthesis of Compound [77]

Figure 112010001724795-pat00092
Figure 112010001724795-pat00092

합성예 1과동일한방법으로2-브로모-7-요오드트리페닐렌 5.0g (11.55mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [77] 3.2g(44%)을 수득하였다. Synthesis Example 1 in the same manner as 2-bromo-7-iodine triphenylene 5.0g (11.55mmol), 9- phenyl -9H- carbazol-3-yl boronic target compound as a white solid using the acid, carbazole [77 ] to give the 3.2g (44%).

1H NMR (300 MHz, CDCl3):δ 7.25~7.29(m, 4H), 7.45~7.62(m, 9H), 7.86~8.12(m, 14H), 8.91~8.93(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.29 (m, 4H), 7.45-7.82 (m, 9H), 7.86-8.12 (m, 14H), 8.91-8.83 (m, 2H)

MS/FAB : 634(M+)MS / FAB: 634 (M + )

[합성 예 78] 화합물 [78]의 합성Synthesis Example 78 Synthesis of Compound [78]

Figure 112010001724795-pat00093
Figure 112010001724795-pat00093

합성예 1과동일한방법으로2-브로모-11-요오드트리페닐렌 5.0g (11.55mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [78] 3.2g(43%)을 수득하였다. Synthesis Example 1 In the same manner, the title compound as a white solid using 2-bromo-11-iodinetriphenylene 5.0g (11.55 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole [78 ] to give the 3.2g (43%).

1H NMR (300 MHz, CDCl3):δ 7.26~7.32(m, 4H), 7.46~7.63(m, 9H), 7.87~8.13(m, 14H), 8.91~8.93(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.26 to 7.32 (m, 4H), 7.46 to 7.63 (m, 9H), 7.87 to 8.13 (m, 14H), 8.91 to 8.83 (m, 2H)

MS/FAB : 634(M+)MS / FAB: 634 (M + )

[합성 예 79] 화합물 [79]의 합성Synthesis Example 79 Synthesis of Compound [79]

Figure 112010001724795-pat00094
Figure 112010001724795-pat00094

합성예 1과동일한방법으로2-브로모-7-요오드-5,5,10,10,15,15-헥사메틸-10,15-디하이드로-5H-디인데노[1,2-a:1',2'-c]플루오렌 6.0g (9.50mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [79] 3.3g(42%)을 수득하였다. Synthesis Example 1 In the same manner as 2-bromo-7-iodine-5,5,10,10,15,15-hexamethyl-10,15-dihydro-5H-diindeno [1,2-a: 1 ' , the 2'-c] fluorene 6.0g (9.50mmol), 9- phenyl -9H- carbazol-3-yl, using the boronic acid, carbazole target compound as a white solid [79] 3.3g (42%) Obtained.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 18H), 7.29~7.62(m, 19H), 7.77(s, 1H), 7.84~7.85(m, 2H), 7.96~8.00(m, 2H), 8.10~8.17(m, 6H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 18 H), 7.29 to 7.82 (m, 19 H), 7.77 (s, 1 H), 7.84 to 7.85 (m, 2H), 7.96 to 8.00 (m, 2H), 8.10-8.17 (m, 6H)

MS/FAB : 832(M+)MS / FAB: 832 (M + )

[합성 예 80] 화합물 [80]의 합성Synthesis Example 80 Synthesis of Compound [80]

Figure 112010001724795-pat00095
Figure 112010001724795-pat00095

합성예 1과동일한방법으로2-브로모-6-요오드-4,4,8,8,12,12-헥사메틸-4,8,12,-테트라하이드로디벤조[cd,mn]파이렌 6.0g (10.54mmol), 9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [80] 3.5g(43%)을 수득하였다. Synthesis Example 1 In the same way as 2-bromo-6-iodine-4,4,8,8,12,12-hexamethyl-4,8,12, tetrahydrodibenzo [cd, mn] pyrene 6.0 g ( 10.54 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, carbazole were used to obtain 3.5 g (43%) of the title compound (80 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 18H), 7.10~7.18(m, 6H), 7.24~7.33(m, 8H), 7.50~7.63(m, 8H), 7.77(s, 1H), 7.89~7.94(m, 3H), 8.10~8.14(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 18H), 7.10 to 7.18 (m, 6H), 7.24 to 7.33 (m, 8H), 7.50 to 7.63 (m, 8H), 7.77 (s, 1H), 7.89 ~ 7.94 (m, 3H), 8.10 ~ 8.14 (m, 2H)

MS/FAB : 770(M+)MS / FAB: 770 (M + )

[합성 예 81] 화합물 [81]의 합성Synthesis Example 81 Synthesis of Compound [81]

Figure 112010001724795-pat00096
Figure 112010001724795-pat00096

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-(비페닐-4-일)-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [81] 3.7g(42%)을 수득하였다. Synthesis Example 1 In the same manner, using 5.0 g (13.93 mmol) of 4-bromo-4'-iodobiphenyl, 9- (biphenyl-4-yl) -9H-carbazol-3-yl boronic acid, carbazole 3.7 g (42%) of the title compound (81 ) as a white solid were obtained.

1H NMR (300 MHz, CDCl3):δ 7.15~7.42(m, 15H), 7.53~7.58(m, 5H), 7.67~7.69(m, 4H), 7.84~7.90(m, 2H), 8.02~8.08(m, 3H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.42 (m, 15H), 7.53-7.58 (m, 5H), 7.67-7.69 (m, 4H), 7.84-7.90 (m, 2H), 8.02- 8.08 (m, 3H), 8.25 (d, 1H)

MS/FAB : 635(M+)MS / FAB: 635 (M + )

[합성 예 82] 화합물 [82]의 합성Synthesis Example 82 Synthesis of Compound

Figure 112010001724795-pat00097
Figure 112010001724795-pat00097

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-(비페닐-4-일)-9H-카바졸-3-일 보론산, 3-페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [82] 4.3g(43%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9- (biphenyl-4-yl) -9H-carbazol-3-yl boronic acid, 3-phenyl-9H Carbazole was used to obtain 4.3 g (43%) of the title compound (82 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.42(m, 18H), 7.53~7.58(m, 6H), 7.67~7.69(m, 6H), 7.77~7.90(m, 3H), 8.02~8.08(m, 2H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.42 (m, 18H), 7.53-7.58 (m, 6H), 7.67-7.69 (m, 6H), 7.77-7.90 (m, 3H), 8.02- 8.08 (m, 2 H), 8.25 (d, 1 H)

MS/FAB : 713(M+)MS / FAB: 713 (M &lt; + & gt ; ).

[합성 예 83] 화합물 [83]의 합성Synthesis Example 83 Synthesis of Compound [83]

Figure 112010001724795-pat00098
Figure 112010001724795-pat00098

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [83] 4.5g(45%)을 수득하였다. Synthesis Example 1 In the same manner, 5.0 g (13.93 mmol) of 4-bromo-4'-iodobiphenyl, 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-diphenyl-9H-carbazole To give 4.5 g (45%) of the title compound [83] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.19(m, 5H), 7.31~7.59(m, 20H), 7.67~7.69(m, 5H), 7.77(d, 1H), 7.90(d, 2H), 8.02~8.08(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.19 (m, 5H), 7.31-7.59 (m, 20H), 7.67-7.69 (m, 5H), 7.77 (d, 1H), 7.90 (d, 2H), 8.02-8.08 (m, 3H)

MS/FAB : 713(M+)MS / FAB: 713 (M &lt; + & gt ; ).

[합성 예 84] 화합물 [84]의 합성Synthesis Example 84 Synthesis of Compound

Figure 112010001724795-pat00099
Figure 112010001724795-pat00099

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-디(비페닐-4-일)-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [84] 4.9g(41%)을 수득하였다. Synthesis Example 1 In the same manner as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 3,6-di (biphenyl-4-yl ) using -9H- carbazole, to give the desired compound [84] 4.9g (41%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.19(m, 13H), 7.31~7.59(m, 20H), 7.67~7.69(m, 5H), 7.77(d, 1H), 7.90(d, 2H), 8.02~8.08(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.19 (m, 13H), 7.31-7.59 (m, 20H), 7.67-7.69 (m, 5H), 7.77 (d, 1H), 7.90 (d, 2H), 8.02-8.08 (m, 3H)

MS/FAB : 865(M+)MS / FAB: 865 (M &lt; + & gt ; ).

[합성 예 85] 화합물 [85]의 합성Synthesis Example 85 Synthesis of Compound

Figure 112010001724795-pat00100
Figure 112010001724795-pat00100

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-(비페닐-4-일)-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [85] 4.7g(43%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9- (biphenyl-4-yl) -9H-carbazol-3-yl boronic acid, 3,6-di Phenyl-9H-carbazole was used to obtain 4.7 g (43%) of the title compound [85] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.19(m, 5H), 7.31~7.42(m, 16H), 7.53~7.59(m, 6H), 7.67~7.69(m, 7H), 7.77(d, 1H), 7.90(d, 2H), 8.02~8.08(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.19 (m, 5H), 7.31-7.42 (m, 16H), 7.53-7.59 (m, 6H), 7.67-7.69 (m, 7H), 7.77 ( d, 1H), 7.90 (d, 2H), 8.02-8.08 (m, 3H)

MS/FAB : 789(M+)MS / FAB: 789 (M + )

[합성 예 86] 화합물 [86]의 합성Synthesis Example 86 Synthesis of Compound

Figure 112010001724795-pat00101
Figure 112010001724795-pat00101

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-(비페닐-4-일)-6-페닐-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [86] 4.7g(39%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9- (biphenyl-4-yl) -6-phenyl-9H-carbazol-3-yl boronic acid, 3 , 6-diphenyl-9H-carbazole was used to obtain 4.7 g (39%) of the title compound [86] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15(m, 4H), 7.31~7.42(m, 20H), 7.58~7.59(m, 6H), 7.67~7.69(m, 8H), 7.77(d, 2H), 7.90(d, 2H), 8.08(d, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 (m, 4H), 7.31-7.42 (m, 20H), 7.58-7.59 (m, 6H), 7.67-7.69 (m, 8H), 7.77 (d, 2H), 7.90 (d, 2H), 8.08 (d, 2H)

MS/FAB : 865(M+)MS / FAB: 865 (M &lt; + & gt ; ).

[합성 예 87] 화합물 [87]의 합성Synthesis Example 87 Synthesis of Compound [87]

Figure 112010001724795-pat00102
Figure 112010001724795-pat00102

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-페닐-9H-카바졸-3-일 보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 흰색 고체의 목적화합물 [87] 4.1g(40%)을 수득하였다. Synthesis Example 1 In the same manner as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, N, N-diphenyl-9H-carbazole- using 3-amine, to give the desired compound as a white solid [87] 4.1g (40%) .

1H NMR (300 MHz, CDCl3):δ 6.91(m, 4H), 7.05~7.17(m, 4H), 7.20~7.58(m, 21H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.02~8.08(m, 2H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.91 (m, 4H), 7.05 to 7.17 (m, 4H), 7.20 to 7.58 (m, 21H), 7.67 to 7.69 (m, 3H), 7.84 to 7.90 ( m, 2H), 8.02 to 8.08 (m, 2H), 8.25 (d, 1H)

MS/FAB : 728(M+)MS / FAB: 728 (M &lt; + & gt ; ).

[합성 예 88] 화합물 [88]의 합성Synthesis Example 88 Synthesis of Compound [88]

Figure 112010001724795-pat00103
Figure 112010001724795-pat00103

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [88] 4.3g(42%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9- (4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, carbazole To give 4.3 g (42%) of the title compound (88 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.93(m, 6H), 7.11(t, 2H), 7.20~7.27(m, 14H), 7.40(t, 2H), 7.53~7.68(m, 4H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.02~8.08(m, 3H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.93 (m, 6H), 7.11 (t, 2H), 7.20 ~ 7.27 (m, 14H), 7.40 (t, 2H), 7.53 ~ 7.68 (m, 4H) , 7.67-7.69 (m, 3H), 7.84-7.90 (m, 2H), 8.02-8.08 (m, 3H), 8.25 (d, 1H)

MS/FAB : 728(M+)MS / FAB: 728 (M &lt; + & gt ; ).

[합성 예 89] 화합물 [89]의 합성Synthesis Example 89 Synthesis of Compound [89]

Figure 112010001724795-pat00104
Figure 112010001724795-pat00104

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [89] 4.2g(41%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 6- (diphenylamino) -9-phenyl-9H-carbazol-3-yl boronic acid and carbazole are used. This gave 4.2 g (41%) of the title compound [89] as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.93(m, 4H), 7.05~7.11(m, 4H), 7.20~7.58(m, 21H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.02~8.08(m, 2H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.93 (m, 4H), 7.05 to 7.71 (m, 4H), 7.20 to 7.58 (m, 21H), 7.67 to 7.69 (m, 3H), 7.84 to 7.90 ( m, 2H), 8.02 to 8.08 (m, 2H), 8.25 (d, 1H)

MS/FAB : 728(M+)MS / FAB: 728 (M &lt; + & gt ; ).

[합성 예 90] 화합물 [90]의 합성Synthesis Example 90 Synthesis of Compound

Figure 112010001724795-pat00105
Figure 112010001724795-pat00105

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일 보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 흰색 고체의 목적화합물 [90] 4.7g(38%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 6- (diphenylamino) -9-phenyl-9H-carbazol-3-yl boronic acid, N, N- Diphenyl-9H-carbazole-3-amine was used to obtain 4.7 g (38%) of the title compound [90] as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.93(m, 8H), 7.05~7.11(m, 8H), 7.20~7.48(m, 21H), 7.58(d, 2H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.08(d, 1H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.93 (m, 8H), 7.05 ~ 7.11 (m, 8H), 7.20 ~ 7.48 (m, 21H), 7.58 (d, 2H), 7.67 ~ 7.69 (m, 3H), 7.84 ~ 7.90 (m, 2H), 8.08 (d, 1H), 8.25 (d, 1H)

MS/FAB : 895(M+)MS / FAB: 895 (M + )

[합성 예 91] 화합물 [91]의 합성Synthesis Example 91 Synthesis of Compound [91]

Figure 112010001724795-pat00106
Figure 112010001724795-pat00106

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 흰색 고체의 목적화합물 [91] 4.4g(35%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9- (4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, N, N 4.4 g (35%) of the title compound [91] as a white solid was obtained using diphenyl-9H-carbazole-3-amine.

1H NMR (300 MHz, CDCl3):δ 6.93(m, 10H), 7.05~7.11(m, 6H), 7.20~7.28(m, 18H), 7.40(t, 1H), 7.53~7.58(m, 3H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.02~8.08(m, 2H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.93 (m, 10H), 7.05 ~ 7.11 (m, 6H), 7.20 ~ 7.28 (m, 18H), 7.40 (t, 1H), 7.53 ~ 7.58 (m, 3H), 7.67-7.69 (m, 3H), 7.84-7.90 (m, 2H), 8.02-8.08 (m, 2H), 8.25 (d, 1H)

MS/FAB : 895(M+)MS / FAB: 895 (M + )

[합성 예 92] 화합물 [92]의 합성Synthesis Example 92 Synthesis of Compound

Figure 112010001724795-pat00107
Figure 112010001724795-pat00107

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-페닐-9H-카바졸-3-일 보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-디아민을 사용하여 흰색 고체의 목적화합물 [92] 4.7g(38%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, N3, N3, N6, N6-tetraphenyl-9H -Carbazole-3,6-diamine was used to obtain 4.7 g (38%) of the title compound (92 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.86(d, 1H), 6.93(m, 8H), 7.05~7.11(m, 6H), 7.20~7.59(m, 25H), 7.67~7.69(m, 3H), 7.90(d, 1H), 8.02~8.08(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.86 (d, 1H), 6.93 (m, 8H), 7.05-7.11 (m, 6H), 7.20-7.75 (m, 25H), 7.67-7.69 (m, 3H), 7.90 (d, 1H), 8.02-8.08 (m, 2H)

MS/FAB : 895(M+)MS / FAB: 895 (M + )

[합성 예 93] 화합물 [93]의 합성Synthesis Example 93 Synthesis of Compound [93]

Figure 112010001724795-pat00108
Figure 112010001724795-pat00108

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일 보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-디아민을 사용하여 흰색 고체의 목적화합물 [93] 4.6g(31%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 6- (diphenylamino) -9-phenyl-9H-carbazol-3-yl boronic acid, N3, N3, N6, N6- using tetraphenyl -9H- carbazol-3,6-diamine to give the desired compound [93] 4.6g (31%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 6.86(d, 1H), 6.93(m, 12H), 7.05~7.11(m, 10H), 7.20~7.59(m, 27H), 7.67~7.69(m, 3H), 7.90(d, 1H), 8.08(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.86 (d, 1H), 6.93 (m, 12H), 7.05 ~ 7.11 (m, 10H), 7.20 ~ 7.59 (m, 27H), 7.67 ~ 7.69 (m, 3H), 7.90 (d, 1H), 8.08 (d, 1H)

MS/FAB : 1062(M+)MS / FAB: 1062 (M + )

[합성 예 94] 화합물 [94]의 합성Synthesis Example 94 Synthesis of Compound [94]

Figure 112010001724795-pat00109
Figure 112010001724795-pat00109

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N,N-디페닐-9H-카바졸-3-아민 을 사용하여 흰색 고체의 목적화합물 [94] 4.9g(33%)을 수득하였다. Synthesis Example 1 In the same way as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 6- (diphenylamino) -9- (4- (diphenylamino) phenyl) -9H-carbazole-3 - to give the one-boronic acid, N, N- diphenyl -9H- carbazol -3- 4.9g amine target compound as a white solid [94] (33%).

1H NMR (300 MHz, CDCl3):δ 6.93(m, 14H), 7.05~7.11(m, 10H), 7.20~7.28(m, 22H), 7.58(d, 2H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.08(d, 1H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.93 (m, 14H), 7.05 ~ 7.11 (m, 10H), 7.20 ~ 7.28 (m, 22H), 7.58 (d, 2H), 7.67 ~ 7.69 (m, 3H), 7.84 ~ 7.90 (m, 2H), 8.08 (d, 1H), 8.25 (d, 1H)

MS/FAB : 1062(M+)MS / FAB: 1062 (M + )

[합성 예 95] 화합물 [95]의 합성Synthesis Example 95 Synthesis of Compound

Figure 112010001724795-pat00110
Figure 112010001724795-pat00110

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-디아민을 사용하여 흰색 고체의 목적화합물 [95] 5.0g(29%)을 수득하였다. Synthesis Example 1 In the same way as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 6- (diphenylamino) -9- (4- (diphenylamino) phenyl) -9H-carbazole-3 -yl boronic acid, N3, N3, N6, N6- using tetraphenyl -9H- carbazol-3,6-diamine to give the desired compound [95] 5.0g (29%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 6.86(d, 1H), 6.93(m, 18H), 7.05~7.11(m, 12H), 7.20~7.25(m, 20H), 7.27~7.28(m, 4H), 7.58~7.59(m, 4H), 7.67~7.69(m, 3H), 7.90(d, 1H), 8.08(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.86 (d, 1H), 6.93 (m, 18H), 7.05 ~ 7.11 (m, 12H), 7.20 ~ 7.25 (m, 20H), 7.27 ~ 7.28 (m, 4H), 7.58-7.59 (m, 4H), 7.67-7.69 (m, 3H), 7.90 (d, 1H), 8.08 (d, 1H)

MS/FAB : 1230(M+)MS / FAB: 1230 (M + )

[합성 예 96] 화합물 [96]의 합성Synthesis Example 96 Synthesis of Compound

Figure 112010001724795-pat00111
Figure 112010001724795-pat00111

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-(4-(트리페닐실릴)페닐)-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [96] 4.7g(35%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9- (4- (triphenylsilyl) phenyl) -9H-carbazol-3-yl boronic acid, 3,6 - diphenyl using -9H- carbazole, to give the desired compound [96] 4.7g (35%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.69(m, 44H), 7.77(d, 1H), 7.90(d, 2H), 8.02~8.08(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.69 (m, 44H), 7.77 (d, 1H), 7.90 (d, 2H), 8.02-8.08 (m, 3H)

MS/FAB : 971(M+)MS / FAB: 971 (M + )

[합성 예 97] 화합물 [97]의 합성Synthesis Example 97 Synthesis of Compound [97]

Figure 112010001724795-pat00112
Figure 112010001724795-pat00112

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 5,11-디페닐-5,11-디하이드로인돌[3,2-b]카바졸-2-일 보론산, 5-페닐-5,11-디하이드로인돌[3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [97] 3.6g(29%)을 수득하였다. Synthesis Example 1 In the same manner as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 5,11-diphenyl-5,11-dihydroindol [3,2-b] carbazol-2-yl the desired compound of boric acid, 5-phenyl-using -5,11- dihydro-indole [3,2-b] carbazole-white solid [97] to give the 3.6g (29%).

1H NMR (300 MHz, CDCl3):δ 7.15~7.58(m, 33H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.02~8.08(m, 3H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 to 7.58 (m, 33H), 7.67 to 7.69 (m, 3H), 7.84 to 7.90 (m, 2H), 8.02 to 8.08 (m, 3H), 8.25 ( d, 1H)

MS/FAB : 891(M+)MS / FAB: 891 (M &lt; + & gt ; ).

[합성 예 98] 화합물 [98]의 합성Synthesis Example 98 Synthesis of Compound [98]

Figure 112010001724795-pat00113
Figure 112010001724795-pat00113

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-페닐-9H-카바졸-3-일 보론산, 5-페닐-5,11-디하이드로인돌[3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [98] 3.1g(31%)을 수득하였다. Synthesis Example 1 In the same manner as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 5-phenyl-5,11-dihydroindole [ 3,2-b] carbazole was used to obtain 3.1 g (31%) of the title compound (98 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.58(m, 26H), 7.67~7.69(m, 3H), 7.84~7.90(m, 2H), 8.02~8.08(m, 3H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 to 7.58 (m, 26H), 7.67 to 7.69 (m, 3H), 7.84 to 7.90 (m, 2H), 8.02 to 8.08 (m, 3H), 8.25 ( d, 1H)

MS/FAB : 726(M+)MS / FAB: 726 (M + )

[합성 예 99] 화합물 [99]의 합성Synthesis Example 99 Synthesis of Compound [99]

Figure 112010001724795-pat00114
Figure 112010001724795-pat00114

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-페닐-9H-3,9'-비카바졸-3'-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [99] 3.4g(34%)을 수득하였다. Synthesis Example 1 In the same manner, using 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9-phenyl-9H-3,9'-bicarbazole-3'-yl boronic acid, carbazole 3.4 g (34%) of the title compound (99 ) were obtained as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.23(m, 11H), 7.35~7.58(m, 13H), 7.67~7.69(m, 3H), 7.84~7.90(m, 3H), 8.02~8.08(m, 3H), 8.25(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 to 7.33 (m, 11H), 7.35 to 7.58 (m, 13H), 7.67 to 7.69 (m, 3H), 7.84 to 7.90 (m, 3H), 8.02 to 8.08 (m, 3H), 8.25 (m, 2H)

MS/FAB : 726(M+)MS / FAB: 726 (M + )

[합성 예 100] 화합물 [100]의 합성Synthesis Example 100 Synthesis of Compound [100]

Figure 112010001724795-pat00115
Figure 112010001724795-pat00115

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 3',6',9-트리페닐-9H-3,9'-비카바졸-6-일 보론산, 3',6'-디페닐-9H-3,9'-비카바졸을 사용하여 흰색 고체의 목적화합물 [100] 4.7g(28%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 3 ', 6', 9-triphenyl-9H-3,9'-bicarbazol-6-yl boronic acid 4.7 g (28%) of the desired compound [100] as a white solid was obtained using 3 ', 6'-diphenyl-9H-3,9'-bicarbazole.

1H NMR (300 MHz, CDCl3):δ 7.15~7.59(m, 41H), 7.67~7.69(m, 7H), 7.77~7.90(m, 6H), 8.08(m, 3H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 to 7.59 (m, 41H), 7.67 to 7.69 (m, 7H), 7.77 to 7.90 (m, 6H), 8.08 (m, 3H), 8.25 (d, 1H)

MS/FAB : 1196(M+)MS / FAB: 1196 (M + )

[합성 예 101] 화합물 [101]의 합성Synthesis Example 101 Synthesis of Compound

Figure 112010001724795-pat00116
Figure 112010001724795-pat00116

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 9-페닐-9H-3,9'-비카바졸-3'-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [101] 4.2g(34%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 9-phenyl-9H-3,9'-bicarbazol-3'-yl boronic acid, 3,6-di Phenyl-9H-carbazole was used to obtain 4.2 g (34%) of the title compound (101 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.19(m, 6H), 7.31~7.59(m, 24H), 7.67~7.69(m, 5H), 7.77~7.90(m, 4H), 8.02~8.08(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 to 7.19 (m, 6H), 7.31 to 7.59 (m, 24H), 7.67 to 7.69 (m, 5H), 7.77 to 7.90 (m, 4H), 8.02 to 8.08 (m, 4 H)

MS/FAB : 878(M+)MS / FAB: 878 (M &lt; + & gt ; ).

[합성 예 102] 화합물 [102]의 합성Synthesis Example 102 Synthesis of Compound [102]

Figure 112010001724795-pat00117
Figure 112010001724795-pat00117

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(9-(비페닐-4-일)-9H-카바졸-3-일)페닐 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [102] 3.9g(39%)을 수득하였다. Synthesis Example 1 5.0 g (13.93 mmol) of 4-bromo-4'-iodobiphenyl, 4- (9- (biphenyl-4-yl) -9H-carbazol-3-yl) phenyl boronic acid, Carbazole was used to obtain 3.9 g (39%) of the title compound (102 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.42(m, 19H), 7.53~7.58(m, 6H), 7.67~7.69(m, 5H), 7.84~7.90(m, 2H), 8.02~8.08(m, 3H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.42 (m, 19H), 7.53-7.58 (m, 6H), 7.67-7.69 (m, 5H), 7.84-7.90 (m, 2H), 8.02- 8.08 (m, 3H), 8.25 (d, 1H)

MS/FAB : 713(M+)MS / FAB: 713 (M &lt; + & gt ; ).

[합성 예 103] 화합물 [103]의 합성Synthesis Example 103 Synthesis of Compound [103]

Figure 112010001724795-pat00118
Figure 112010001724795-pat00118

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(9-(9,9-디메틸-9H-플로렌-2-일)-9H-카바졸-3-일)페닐 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [103] 4.4g(42%)을 수득하였다. Synthesis Example 1 In the same manner as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 4- (9- (9,9-dimethyl-9H-floren-2-yl) -9H-carbazole- 4.4 g (42%) of the title compound (103 ) as a white solid was obtained using 3-yl) phenyl boronic acid, carbazole.

1H NMR (300 MHz, CDCl3):δ 1.67(s, 6H), 7.15~7.30(m, 15H), 7.40~7.51(m, 4H), 7.53~7.58(m, 4H), 7.67~7.69(m, 3H), 7.84~7.90(m, 4H), 8.02~8.08(m, 3H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.67 (s, 6H), 7.15 ~ 7.30 (m, 15H), 7.40 ~ 7.51 (m, 4H), 7.53 ~ 7.58 (m, 4H), 7.67 ~ 7.69 ( m, 3H), 7.84-7.90 (m, 4H), 8.02-8.08 (m, 3H), 8.25 (d, 1H)

MS/FAB : 753(M+)MS / FAB: 753 (M + )

[합성 예 104] 화합물 [104]의 합성Synthesis Example 104 Synthesis of Compound

Figure 112010001724795-pat00119
Figure 112010001724795-pat00119

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(9-(비페닐-4-일)-6-페닐-9H-카바졸-3-일)페닐 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [104] 4.9g(45%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 4- (9- (biphenyl-4-yl) -6-phenyl-9H-carbazol-3-yl) using phenylboronic acid, carbazole, to give the desired compound as a white solid [104] 4.9g (45%) .

1H NMR (300 MHz, CDCl3):δ 7.15~7.42(m, 22H), 7.53~7.59(m, 6H), 7.67~7.69(m, 6H), 7.77~7.90(m, 3H), 8.02~8.08(m, 2H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.42 (m, 22H), 7.53-7.59 (m, 6H), 7.67-7.69 (m, 6H), 7.77-7.90 (m, 3H), 8.02- 8.08 (m, 2 H), 8.25 (d, 1 H)

MS/FAB : 789(M+)MS / FAB: 789 (M + )

[합성 예 105] 화합물 [105]의 합성Synthesis Example 105 Synthesis of Compound [105]

Figure 112010001724795-pat00120
Figure 112010001724795-pat00120

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(9-페닐-9H-카바졸-3-일)페닐 보론산, 3-페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [105] 4.1g(41%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 4- (9-phenyl-9H-carbazol-3-yl) phenyl boronic acid, 3-phenyl-9H-carba The sol was used to obtain 4.1 g (41%) of the title compound (105 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.58(m, 26H), 7.67~7.69(m, 4H), 7.77~7.90(m, 3H), 8.02~8.08(m, 2H), 8.25(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 to 7.58 (m, 26H), 7.67 to 7.69 (m, 4H), 7.77 to 7.90 (m, 3H), 8.02 to 8.08 (m, 2H), 8.25 ( d, 1H)

MS/FAB : 713(M+)MS / FAB: 713 (M &lt; + & gt ; ).

[합성 예 106] 화합물 [106]의 합성Synthesis Example 106 Synthesis of Compound [106]

Figure 112010001724795-pat00121
Figure 112010001724795-pat00121

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(9-페닐-9H-카바졸-3-일)페닐 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [106] 4.6g(42%)을 수득하였다. Synthesis Example 1 In the same manner as 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 4- (9-phenyl-9H-carbazol-3-yl) phenyl boronic acid, 3,6-diphenyl- 9H-carbazole was used to obtain 4.6 g (42%) of the title compound (106 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.19(m, 9H), 7.31~7.59(m, 20H), 7.67~7.69(m, 5H), 7.77(d, 1H), 7.90(d, 2H), 8.02~8.08(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.19 (m, 9H), 7.31-7.59 (m, 20H), 7.67-7.69 (m, 5H), 7.77 (d, 1H), 7.90 (d, 2H), 8.02-8.08 (m, 3H)

MS/FAB : 789(M+)MS / FAB: 789 (M + )

[합성 예 107] 화합물 [107]의 합성Synthesis Example 107 Synthesis of Compound [107]

Figure 112010001724795-pat00122
Figure 112010001724795-pat00122

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(9-(비페닐-4-일)-9H-카바졸-3-일)페닐 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [107] 5.2g(43%)을 수득하였다. Synthesis Example 1 5.0 g (13.93 mmol) of 4-bromo-4'-iodobiphenyl, 4- (9- (biphenyl-4-yl) -9H-carbazol-3-yl) phenyl boronic acid, 3,6-diphenyl-9H-carbazole was used to obtain 5.2 g (43%) of the title compound [107] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.19(m, 9H), 7.31~7.42(m, 16H), 7.53~7.59(m, 6H), 7.67~7.69(m, 7H), 7.77(d, 1H), 7.90(d, 2H), 8.02~8.08(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15-7.19 (m, 9H), 7.31-7.42 (m, 16H), 7.53-7.59 (m, 6H), 7.67-7.69 (m, 7H), 7.77 ( d, 1H), 7.90 (d, 2H), 8.02-8.08 (m, 3H)

MS/FAB : 865(M+)MS / FAB: 865 (M &lt; + & gt ; ).

[합성 예 108] 화합물 [108]의 합성Synthesis Example 108 Synthesis of Compound [108]

Figure 112010001724795-pat00123
Figure 112010001724795-pat00123

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(9-페닐-9H-카바졸-3-일)페닐 보론산, 3,6-디(비페닐-4-일)-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [108] 5.0g(38%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 4- (9-phenyl-9H-carbazol-3-yl) phenyl boronic acid, 3,6-di (r) 4-yl) -9H- carbazole using to give the desired compound [108] 5.0g (38%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15~7.19(m, 17H), 7.31~7.59(m, 20H), 7.67~7.69(m, 5H), 7.77(d, 1H), 7.90(d, 2H), 8.02~8.08(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 to 7.19 (m, 17H), 7.31 to 7.59 (m, 20H), 7.67 to 7.69 (m, 5H), 7.77 (d, 1H), 7.90 (d, 2H), 8.02-8.08 (m, 3H)

MS/FAB : 941(M+)MS / FAB: 941 (M + )

[합성 예 109] 화합물 [109]의 합성Synthesis Example 109 Synthesis of Compound [109]

Figure 112010001724795-pat00124
Figure 112010001724795-pat00124

합성예 1과동일한방법으로4-브로모-4'-요오도비페닐 5.0g (13.93mmol), 4-(6,9-디페닐-9H-카바졸-3-일)페닐 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [109] 5.5g(46%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodobiphenyl 5.0 g (13.93 mmol), 4- (6,9-diphenyl-9H-carbazol-3-yl) phenyl boronic acid, 3,6- Diphenyl-9H-carbazole was used to obtain 5.5 g (46%) of the title compound [109] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.15(m, 8H), 7.31~7.48(m, 20H), 7.58~7.59(m, 4H), 7.67~7.69(m, 6H), 7.77(d, 2H), 7.90(d, 2H), 8.08(d, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.15 (m, 8H), 7.31-7.48 (m, 20H), 7.58-7.59 (m, 4H), 7.67-7.69 (m, 6H), 7.77 (d, 2H), 7.90 (d, 2H), 8.08 (d, 2H)

MS/FAB : 865(M+)MS / FAB: 865 (M &lt; + & gt ; ).

[합성 예 110] 화합물 [110]의 합성Synthesis Example 110 Synthesis of Compound [110]

Figure 112010001724795-pat00125
Figure 112010001724795-pat00125

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 4-(9H-카바졸-9-일)페닐보론산, 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산을 사용하여 흰색 고체의 목적화합물 [110] 3.6g(42%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 4- (9H-carbazol-9-yl) phenylboronic acid, 9- (4- (diphenylamino) phenyl) 3.6 g (42%) of the target compound [110] as a white solid was obtained using -9H-carbazol-3-yl boronic acid.

1H NMR (300 MHz, CDCl3):δ 7.08~7.14(m, 8H), 7.20~7.29(m, 18H), 7.50(t, 2H), 7.63~ 1 H NMR (300 MHz, CDCl 3 ): δ 7.08 ~ 7.14 (m, 8H), 7.20 ~ 7.29 (m, 18H), 7.50 (t, 2H), 7.63 ~

7.68(m, 4H), 7.77~7.79(m, 3H), 7.94~8.00(m, 2H), 8.12~8.18(m, 3H), 8.45(d, 1H)7.68 (m, 4H), 7.77-7.79 (m, 3H), 7.94-8.00 (m, 2H), 8.12-8.18 (m, 3H), 8.45 (d, 1H)

MS/FAB : 803(M+)MS / FAB: 803 (M + )

[합성 예 111] 화합물 [111]의 합성Synthesis Example 111 Synthesis of Compound [111]

Figure 112010001724795-pat00126
Figure 112010001724795-pat00126

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 4-(9H-카바졸-9-일)페닐보론산, 9-(4-(9H-카바졸-9-일)페닐)-9H-카바졸-3-일 보론산을 사용하여 흰색 고체의 목적화합물 [111] 3.5g(41%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 4- (9H-carbazol-9-yl) phenylboronic acid, 9- (4- (9H-carbazole-9 -Yl) phenyl) -9H-carbazol-3-yl boronic acid was used to obtain 3.5 g (41%) of the target compound [111] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.25~7.33(m, 15H), 7.50~7.52(m, 3H), 7.62~7.68(m, 9H), 7.77~7.79(m, 3H), 7.94~8.00(m, 2H), 8.12~8.18(m, 2H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.73 (m, 15H), 7.50-7.52 (m, 3H), 7.62-7.68 (m, 9H), 7.77-7.79 (m, 3H), 7.94- 8.00 (m, 2H), 8.12-8.18 (m, 2H), 8.45 (d, 1H)

MS/FAB : 801(M+)MS / FAB: 801 (M + )

[합성 예 112] 화합물 [112]의 합성Synthesis Example 112 Synthesis of Compound [112]

Figure 112010001724795-pat00127
Figure 112010001724795-pat00127

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 4-(9H-카바졸-9-일)페닐보론산, 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일 보론산을 사용하여 흰색 고체의 목적화합물 [112] 3.6g(42%)을 수득하였다. Synthesis Example 1 In the same manner, 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 4- (9H-carbazol-9-yl) phenylboronic acid, 6- (diphenylamino) -9-phenyl- 9H-carbazol-3-yl boronic acid was used to obtain 3.6 g (42%) of the target compound [112] as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.08~7.15(m, 8H), 7.20~7.68(m, 25H), 7.77~7.79(m, 3H), 7.94~8.00(m, 2H), 8.12~8.18(m, 2H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.08 ~ 7.15 (m, 8H), 7.20 ~ 7.68 (m, 25H), 7.77 ~ 7.79 (m, 3H), 7.94 ~ 8.00 (m, 2H), 8.12 ~ 8.18 (m, 2H), 8.45 (d, 1H)

MS/FAB : 803(M+)MS / FAB: 803 (M + )

[합성 예 113] 화합물 [113]의 합성Synthesis Example 113 Synthesis of Compound [113]

Figure 112010001724795-pat00128
Figure 112010001724795-pat00128

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 4-(3-(디페닐아미노)-9H-카바졸-9-일)보론산을 사용하여 흰색 고체의 목적화합물 [113] 3.4g(40%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 4- (3- (diphenylamino) -9H- Carbazol-9-yl) boronic acid was used to obtain 3.4 g (40%) of the title compound (113 ) as a white solid.

1H NMR (300 MHz, CDCl3):δ 7.08~7.14(m, 8H), 7.20~7.68(m, 25H), 7.77~7.79(m, 3H), 7.94~8.00(m, 2H), 8.12~8.18(m, 2H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.08 ~ 7.14 (m, 8H), 7.20 ~ 7.68 (m, 25H), 7.77 ~ 7.79 (m, 3H), 7.94 ~ 8.00 (m, 2H), 8.12 ~ 8.18 (m, 2H), 8.45 (d, 1H)

MS/FAB : 803(M+)MS / FAB: 803 (M + )

[합성 예 114] 화합물 [114]의 합성Synthesis Example 114 Synthesis of Compound

Figure 112010001724795-pat00129
Figure 112010001724795-pat00129

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-페닐-9H-카바졸-3-일 보론산, 4-(3,6-비스(디페닐아미노)-9H-카바졸-9-일)페닐보론산을 사용하여 흰색 고체의 목적화합물 [114] 3.8g(38%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 4- (3,6-bis (diphenylamino) 3.8 g (38%) of the title compound [114] as a white solid was obtained using -9H-carbazol-9-yl) phenylboronic acid.

1H NMR (300 MHz, CDCl3):δ 6.95(d, 1H), 7.03~7.14(m, 14H), 7.20~7.29(m, 17H), 7.38~7.68(m, 12H), 7.77~7.79(m, 3H), 8.00(d, 1H), 8.12~8.18(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.95 (d, 1H), 7.03 to 7.14 (m, 14H), 7.20 to 7.29 (m, 17H), 7.38 to 7.68 (m, 12H), 7.77 to 7.79 ( m, 3H), 8.00 (d, 1H), 8.12-8.18 (m, 2H)

MS/FAB : 971(M+)MS / FAB: 971 (M + )

[합성 예 115] 화합물 [115]의 합성Synthesis Example 115 Synthesis of Compound [115]

Figure 112010001724795-pat00130
Figure 112010001724795-pat00130

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 4-(9H-카바졸-9-일)페닐보론산, 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산을 사용하여 흰색 고체의 목적화합물 [115] 3.9g(40%)을 수득하였다. Synthesis Example 1 In the same manner, 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 4- (9H-carbazol-9-yl) phenylboronic acid, 6- (diphenylamino) -9- (4 - a (di) phenyl) -9H- carbazol-3-yl target compound as a white solid using the boronic acid [115] 3.9g (40%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 7.03~7.14(m, 16H), 7.20~7.38(m, 22H), 7.50(t, 1H), 7.63~7.68(m, 3H), 7.77~7.79(m, 3H), 7.94~8.00(m, 2H), 8.10~8.12(m, 2H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.03 ~ 7.14 (m, 16H), 7.20 ~ 7.38 (m, 22H), 7.50 (t, 1H), 7.63 ~ 7.68 (m, 3H), 7.77 ~ 7.79 ( m, 3H), 7.94-8.00 (m, 2H), 8.10-8.12 (m, 2H), 8.45 (d, 1H)

MS/FAB : 971(M+)MS / FAB: 971 (M + )

[합성 예 116] 화합물 [116]의 합성Synthesis Example 116 Synthesis of Compound

Figure 112010001724795-pat00131
Figure 112010001724795-pat00131

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 4-(3,6-디페닐-9H-카바졸-9-일)페닐보론산, 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산을 사용하여 흰색 고체의 목적화합물 [116] 4.2g(35%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 4- (3,6-diphenyl-9H-carbazol-9-yl) phenylboronic acid, 6- (diphenyl amino) -9- (4- (diphenylamino) phenyl) -9H- carbazol-3-yl target compound as a white solid using the boronic acid [116] 4.2g (35%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 7.03~7.14(m, 16H), 7.20~7.25(m, 16H), 7.37~7.52(m, 13H), 7.68~7.69(m, 3H), 7.77~7.79(m, 5H), 7.87(d, 1H), 8.00~8.02(m, 2H), 8.18~8.19(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.03 ~ 7.14 (m, 16H), 7.20 ~ 7.25 (m, 16H), 7.37 ~ 7.52 (m, 13H), 7.68 ~ 7.69 (m, 3H), 7.77 ~ 7.79 (m, 5H), 7.87 (d, 1H), 8.00-8.02 (m, 2H), 8.18-8.19 (m, 2H)

MS/FAB : 1123(M+)MS / FAB: 1123 (M + )

[합성 예 117] 화합물 [117]의 합성Synthesis Example 117 Synthesis of Compound

Figure 112010001724795-pat00132
Figure 112010001724795-pat00132

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 4-(3-(디페닐아미노)-9H-카바졸-9-일)페닐보론산, 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산을 사용하여 흰색 고체의 목적화합물 [117] 3.7g(36%)을 수득하였다. Synthesis Example 1 In the same manner, 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 4- (3- (diphenylamino) -9H-carbazol-9-yl) phenylboronic acid, 9- (4 - a (di) phenyl) -9H- carbazol-3-yl target compound as a white solid using the boronic acid [117] 3.7g (36%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 7.04~7.14(m, 16H), 7.20~7.38(m, 22H), 7.61~7.68(m, 4H), 7.77~7.79(m, 3H), 7.94~8.00(m, 2H), 8.12~8.18(m, 2H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.04 ~ 7.14 (m, 16H), 7.20 ~ 7.38 (m, 22H), 7.61 ~ 7.68 (m, 4H), 7.77 ~ 7.79 (m, 3H), 7.94 ~ 8.00 (m, 2H), 8.12-8.18 (m, 2H), 8.45 (d, 1H)

MS/FAB : 971(M+)MS / FAB: 971 (M + )

[합성 예 118] 화합물 [118]의 합성Synthesis Example 118 Synthesis of Compound [118]

Figure 112010001724795-pat00133
Figure 112010001724795-pat00133

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 4-(3,6-비스(디페닐아미노)-9H-카바졸-9-일)페닐보론산을 사용하여 흰색 고체의 목적화합물 [118] 4.1g(34%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 9- (4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, 4- (3 , to give the 6-bis (diphenylamino) -9H- carbazol-9-yl) target compound as a white solid using the boronic acid [118] 4.1g (34%) .

1H NMR (300 MHz, CDCl3):δ 6.95(d, 1H), 7.03~7.14(m, 22H), 7.20~7.38(m, 24H), 7.61~7.68(m, 6H), 7.77~7.79(m, 3H), 8.00(d, 1H), 8.12~8.18(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.95 (d, 1H), 7.03 to 7.14 (m, 22H), 7.20 to 7.38 (m, 24H), 7.61 to 7.68 (m, 6H), 7.77 to 7.79 ( m, 3H), 8.00 (d, 1H), 8.12-8.18 (m, 2H)

MS/FAB : 1138(M+)MS / FAB: 1138 (M + )

[합성 예 119] 화합물 [119]의 합성Synthesis Example 119 Synthesis of Compound [119]

Figure 112010001724795-pat00134
Figure 112010001724795-pat00134

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일 보론산, 4-(3,6-비스(디페닐아미노)-9H-카바졸-9-일)페닐보론산을 사용하여 흰색 고체의 목적화합물 [119] 3.9g(32%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol 6- (diphenylamino) -9-phenyl-9H-carbazol-3-yl boronic acid, 4- (3,6- a bis (diphenylamino) -9H- carbazol-9-yl) phenylboronic target compound as a white solid using the acid [119] 3.9g (32%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 6.95(d, 1H), 7.03~7.14(m, 22H), 7.20~7.25(m, 20H), 7.38~7.69(m, 11H), 7.77~7.79(m, 3H), 8.00(d, 1H), 8.18(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.95 (d, 1H), 7.03 to 7.14 (m, 22H), 7.20 to 7.25 (m, 20H), 7.38 to 7.69 (m, 11H), 7.77 to 7.79 ( m, 3H), 8.00 (d, 1H), 8.18 (d, 1H)

MS/FAB : 1138(M+)MS / FAB: 1138 (M + )

[합성 예 120] 화합물 [120]의 합성Synthesis Example 120 Synthesis of Compound [120]

Figure 112010001724795-pat00135
Figure 112010001724795-pat00135

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 4-(3,6-비스(디페닐아미노)-9H-카바졸-9-일)페닐보론산을 사용하여 흰색 고체의 목적화합물 [120] 4.3g(31%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 6- (diphenylamino) -9- (4- (diphenylamino) phenyl) -9H-carbazole-3- One boronic acid, 4- (3,6-bis (diphenylamino) -9H-carbazol-9-yl) phenylboronic acid, gave 4.3 g (31%) of the title compound [120] as a white solid. .

1H NMR (300 MHz, CDCl3):δ 6.95(d, 1H), 7.01~7.15(m, 30H), 7.20~7.25(m, 24H), 7.37~7.38(m, 4H), 7.63~7.68(m, 4H), 7.77~7.79(m, 3H), 8.00(d, 1H), 8.18(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 6.95 (d, 1H), 7.01 to 7.15 (m, 30H), 7.20 to 7.25 (m, 24H), 7.37 to 7.38 (m, 4H), 7.63 to 7.58 ( m, 4H), 7.77-7.79 (m, 3H), 8.00 (d, 1H), 8.18 (d, 1H)

MS/FAB : 1305(M+)MS / FAB: 1305 (M + )

[합성 예 121] 화합물 [121]의 합성Synthesis Example 121 Synthesis of Compound [121]

Figure 112010001724795-pat00136
Figure 112010001724795-pat00136

합성예 1과동일한방법으로 1-브로모-4-요오도벤젠 5.0g (17.67mmol), 4-(11-페닐인돌로[3,2-b]카바졸-5(11H)-일)페닐보론산, 5,11-디페닐-5,11-디히드로인돌로[3,2-b]카바졸 -2-일 보론산을 사용하여 흰색 고체의 목적화합물 [121] 3.7g(36%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodobenzene 5.0 g (17.67 mmol), 4- (11-phenylindolo [3,2-b] carbazol-5 (11H) -yl) phenylboronic acid 3.7 g (36%) of the target compound [121] as a white solid was obtained using 5,11-diphenyl-5,11-dihydroindolo [3,2-b] carbazol-2-yl boronic acid. It was.

1H NMR (300 MHz, CDCl3):δ 7.25~7.68(m, 36H), 7.77~7.79(m, 3H), 7.94~8.00(m, 3H), 8.12~8.18(m, 2H), 8.45~8.46(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.68 (m, 36H), 7.77-7.79 (m, 3H), 7.94-8.00 (m, 3H), 8.12-8.18 (m, 2H), 8.45- 8.46 (m, 2 H)

MS/FAB : 967(M+)MS / FAB: 967 (M + )

[합성 예 122] 화합물 [122]의 합성Synthesis Example 122 Synthesis of Compound [122]

Figure 112010001724795-pat00137
Figure 112010001724795-pat00137

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-(바이페닐-4-일)-9H-카바졸-3-일 보론산, 9H-카바졸을 사용하여 흰색 고체의 목적화합물 [122] 2.0g(34%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 - to give a (biphenyl-4-yl) -9H- carbazol-3-yl boronic target compound as a white solid using the acid, 9H- carbazole [122] 2.0g (34%) .

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.25~7.52(m, 13H), 7.63~7.70(m, 6H), 7.77~7.87(m, 6H), 7.94~8.00(m, 2H), 8.12~8.18(m, 4H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.25 ~ 7.52 (m, 13H), 7.63 ~ 7.70 (m, 6H), 7.77 ~ 7.87 (m, 6H), 7.94 ~ 8.00 ( m, 2H), 8.12-8.18 (m, 4H), 8.45 (d, 1H)

MS/FAB : 793(M+)MS / FAB: 793 (M &lt; + & gt ; ) [

[합성 예 123] 화합물 [123]의 합성Synthesis Example 123 Synthesis of Compound [123]

Figure 112010001724795-pat00138
Figure 112010001724795-pat00138

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-페닐-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [123] 2.3g(36%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 2.3 g (36%) of the title compound [123] as a white solid was obtained using -phenyl-9H-carbazol-3-yl boronic acid, 3,6-diphenyl-9H-carbazole.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.29~7.70(m, 23H), 7.77~7.80(m, 4H), 7.83~7.87(m, 3H), 8.00~8.02(m, 2H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.29 to 7.70 (m, 23H), 7.77 to 7.80 (m, 4H), 7.83 to 7.87 (m, 3H), 8.00 to 8.02 ( m, 2H), 8.12-8.18 (m, 4H)

MS/FAB : 869(M+)MS / FAB: 869 (M + )

[합성 예 124] 화합물 [124]의 합성Synthesis Example 124 Synthesis of Compound [124]

Figure 112010001724795-pat00139
Figure 112010001724795-pat00139

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-(바이페닐-4-일)-9H-카바졸-3-일 보론산, 3,6-디(페닐-4-일)-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [124] 2.7g(34%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 Target compound of a white solid using-(biphenyl-4-yl) -9H-carbazol-3-yl boronic acid, 3,6-di (phenyl-4-yl) -9H-carbazole [124] 2.7 g (34%) was obtained.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.25~7.29(m, 9H), 7.40~7.52(m, 18H), 7.63~7.70(m, 6H), 7.77~7.87(m, 9H), 8.00~8.02(m, 2H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.25 to 7.29 (m, 9H), 7.40 to 7.52 (m, 18H), 7.63 to 7.70 (m, 6H), 7.77 to 7.87 ( m, 9H), 8.00-8.02 (m, 2H), 8.12-8.18 (m, 4H)

MS/FAB : 570(M+)MS / FAB: 570 (M + )

[합성 예 125] 화합물 [125]의 합성Synthesis Example 125 Synthesis of Compound

Figure 112010001724795-pat00140
Figure 112010001724795-pat00140

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 9H-카바졸을 사용하여 흰색 고체의 목적화합물 [125] 2.3g(35%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 - a (4- (diphenylamino) phenyl) -9H- carbazol-3-yl boronic acid, 9H- carbazol-white target compound [125] of the solid using 2.3g (35%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.03~7.10(m, 8H), 7.20~7.37(m, 11H), 7.50~7.52(m, 3H), 7.63~7.70(m, 4H), 7.77~7.80(m, 2H), 7.83~7.87(m, 2H), 7.94~8.00 (m, 2H), 8.12~8.18(m, 4H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.03-7.10 (m, 8H), 7.20-7.73 (m, 11H), 7.50-7.75 (m, 3H), 7.63-77.7 ( m, 4H), 7.77-7.80 (m, 2H), 7.83-7.87 (m, 2H), 7.94-8.00 (m, 2H), 8.12-8.18 (m, 4H), 8.45 (d, 1H)

MS/FAB : 884(M+)MS / FAB: 884 (M + )

[합성 예 126] 화합물 [126]의 합성Synthesis Example 126 Synthesis of Compound

Figure 112010001724795-pat00141
Figure 112010001724795-pat00141

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [126] 2.6g(34%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 2.6 g (34% ) of the title compound as a white solid using-(4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, 3,6-diphenyl-9H-carbazole. ) Was obtained.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.03~7.10(m, 8H), 7.20~7.29(m, 5H), 7.37~7.70(m, 4H), 7.77~7.80(m, 4H), 7.83~7.87(m, 3H), 8.00~8.02(m, 2H), 8.12~8.18 (m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.03-7.10 (m, 8H), 7.20-7.29 (m, 5H), 7.37-77.7 (m, 4H), 7.77-7.80 ( m, 4H), 7.83-7.87 (m, 3H), 8.00-8.02 (m, 2H), 8.12-8.18 (m, 4H)

MS/FAB : 1036(M+)MS / FAB: 1036 (M + )

[합성 예 127] 화합물 [127]의 합성Synthesis Example 127 Synthesis of Compound [127]

Figure 112010001724795-pat00142
Figure 112010001724795-pat00142

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N,N-디페닐-9H-카바졸-3-아민을 사용하여 흰색 고체의 목적화합물 [127] 2.5g(32%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 Target compound of a white solid using-(4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, N, N-diphenyl-9H-carbazol-3-amine [127] 2.5 g (32%) was obtained.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.03~7.14(m, 16H), 7.20~7.38(m, 15H), 7.50~7.52(m, 2H), 7.63~7.70(m, 3H), 7.77~7.80(m, 2H), 7.83~7.87(m, 2H), 7.94~8.00(m, 2H), 8.12~8.18(m, 3H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.03 ~ 7.14 (m, 16H), 7.20 ~ 7.38 (m, 15H), 7.50 ~ 7.52 (m, 2H), 7.63 ~ 7.70 ( m, 3H), 7.77-7.80 (m, 2H), 7.83-7.87 (m, 2H), 7.94-8.00 (m, 2H), 8.12-8.18 (m, 3H), 8.45 (d, 1H)

MS/FAB : 1051(M+)MS / FAB: 1051 (M + )

[합성 예 128] 화합물 [128]의 합성Synthesis Example 128 Synthesis of Compound [128]

Figure 112010001724795-pat00143
Figure 112010001724795-pat00143

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-페닐-9H-카바졸-3-일 보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-다이민을 사용하여 흰색 고체의 목적화합물 [128] 2.5g(33%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 Target compound of a white solid using -phenyl-9H-carbazol- 3- ylboronic acid, N 3 , N 3 , N 6 , N 6 -tetraphenyl-9H-carbazole-3,6-dimine [128 ] to give the 2.5g (33%).

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 6.95(d, 1H), 7.03~7.14(m, 14H), 7.20~7.29(m, 9H), 7.38~7.70(m, 14H), 7.77~7.80(m, 2H), 7.83~7.87(m, 2H), 8.00(d, 1H), 8.12~8.18(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 6.95 (d, 1H), 7.03 ~ 7.14 (m, 14H), 7.20 ~ 7.29 (m, 9H), 7.38 ~ 7.70 (m, 14H), 7.77-7.80 (m, 2H), 7.83-7.87 (m, 2H), 8.00 (d, 1H), 8.12-8.18 (m, 3H)

MS/FAB : 1051(M+)MS / FAB: 1051 (M + )

[합성 예 129] 화합물 [129]의 합성Synthesis Example 129 Synthesis of Compound [129]

Figure 112010001724795-pat00144
Figure 112010001724795-pat00144

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 9H-카바졸을 사용하여 흰색 고체의 목적화합물 [129] 2.4g(31%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 6 2.4 g (31 ) of the target compound as a white solid using-(diphenylamino) -9- (4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, 9H-carbazole. %) Was obtained.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.03~7.14(m, 16H), 7.20~7.40(m, 15H), 7.50~7.52(m, 2H), 7.63~7.70(m, 3H), 7.77~7.80(m, 2H), 7.83~7.87(m, 2H), 7.94~8.00 (m, 2H), 8.12~8.18(m, 3H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.03 ~ 7.14 (m, 16H), 7.20 ~ 7.40 (m, 15H), 7.50 ~ 7.52 (m, 2H), 7.63 ~ 7.70 ( m, 3H), 7.77-7.80 (m, 2H), 7.83-7.87 (m, 2H), 7.94-8.00 (m, 2H), 8.12-8.18 (m, 3H), 8.45 (d, 1H)

MS/FAB : 1051(M+)MS / FAB: 1051 (M + )

[합성 예 130] 화합물 [130]의 합성Synthesis Example 130 Synthesis of Compound [130]

Figure 112010001724795-pat00145
Figure 112010001724795-pat00145

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 6-(디페닐아미노)-9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-다이민을 사용하여 흰색 고체의 목적화합물 [130] 3.1g(30%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 6 -(Diphenylamino) -9- (4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, N 3 , N 3 , N 6 , N 6 -tetraphenyl-9H-carbazole 3.1 g (30%) of the desired compound [130] as a white solid was obtained using -3,6-dimine.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 6.95(d, 1H), 7.03~7.14(m, 30H), 7.20~7.25(m, 16H), 7.37~7.40(m, 5H), 7.50(s, 1H), 7.63(s, 1H), 7.68~7.70(m, 3H), 7.77~7.80 (m, 2H), 7.83~7.87(m, 2H), 8.18(d, 1H), 8.15~8.18(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 6.95 (d, 1H), 7.03 ~ 7.14 (m, 30H), 7.20 ~ 7.25 (m, 16H), 7.37 ~ 7.40 (m, 5H), 7.50 (s, 1H), 7.63 (s, 1H), 7.68-7.70 (m, 3H), 7.77-7.80 (m, 2H), 7.83-7.87 (m, 2H), 8.18 (d, 1H) , 8.15-8.18 (m, 2H)

MS/FAB : 1385(M+)MS / FAB: 1385 (M + )

[합성 예 131] 화합물 [131]의 합성Synthesis Example 131 Synthesis of Compound [131]

Figure 112010001724795-pat00146
Figure 112010001724795-pat00146

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-다이민을 사용하여 흰색 고체의 목적화합물 [131] 2.7g(30%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 -(4- (diphenylamino) phenyl) -9H-carbazol-3-yl boronic acid, N 3 , N 3 , N 6 , N 6 -tetraphenyl-9H-carbazole-3,6-dimine 2.7 g (30%) of the title compound [131] was obtained as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 6.95(d, 1H), 7.03~7.14(m, 22H), 7.20~7.40(m, 17H), 7.50~7.52(m, 2H), 7.63~7.70(m, 5H), 7.77~7.80(m, 2H), 7.83~7.87 (m, 2H), 8.00(d, 1H), 8.12~8.18(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 6.95 (d, 1H), 7.03 ~ 7.14 (m, 22H), 7.20 ~ 7.40 (m, 17H), 7.50 ~ 7.52 (m, 2H), 7.63-7.70 (m, 5H), 7.77-7.80 (m, 2H), 7.83-7.87 (m, 2H), 8.00 (d, 1H), 8.12-8.18 (m, 3H)

MS/FAB : 1218(M+)MS / FAB: 1218 (M + )

[합성 예 132] 화합물 [132]의 합성Synthesis Example 132 Synthesis of Compound

Figure 112010001724795-pat00147
Figure 112010001724795-pat00147

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 5,11-디페닐-5,11-디히드로인돌로[3,2-b]카바졸-2-일 보론산, 5-페닐-5,11-디히드로인돌로[3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [132] 2.2g(29%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] florene 5 g (9.70 mmol), 5 , 11-diphenyl-5,11-dihydroindolo [3,2-b] carbazol-2-yl boronic acid, 5-phenyl-5,11-dihydroindolo [3,2-b] carba The sol was used to obtain 2.2 g (29%) of the title compound [132] as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.25~7.70(m, 30H), 7.77~7.80(m, 2H), 7.94~8.00(m, 3H), 8.12~8.18(m, 3H), 8.45~8.46(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.25 to 7.70 (m, 30H), 7.77 to 7.80 (m, 2H), 7.94 to 8.00 (m, 3H), 8.12 to 8.18 ( m, 3H), 8.45-8.46 (m, 2H)

MS/FAB : 1047(M+)MS / FAB: 1047 (M + )

[합성 예 133] 화합물 [133]의 합성Synthesis Example 133 Synthesis of Compound [133]

Figure 112010001724795-pat00148
Figure 112010001724795-pat00148

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-페닐-9H-3,9'-바이카바졸-3'-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [133] 2.3g(30%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 - the phenyl -9H-3,9'- bi-carbazol-3'-yl-boronic acid, using 3,6-diphenyl--9H- carbazol-white solid the title compound [133] 2.3g (30%) Obtained.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.29~7.70(m, 28H), 7.77~7.80(m, 4H), 7.83~8.00(m, 6H), 8.12~8.18(m, 4H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.29 to 7.70 (m, 28H), 7.77 to 7.80 (m, 4H), 7.83 to 8.00 (m, 6H), 8.12 to 8.18 ( m, 4H), 8.45 (d, 1H)

MS/FAB : 1034(M+)MS / FAB: 1034 (M + )

[합성 예 134] 화합물 [134]의 합성Synthesis Example 134 Synthesis of Compound

Figure 112010001724795-pat00149
Figure 112010001724795-pat00149

합성예 1과동일한방법으로2-브로모-8-요오도-6,6,12,12-테트라메틸-6,12-디히드로인데노[1,2-b]플로렌 5g(9.70mmol), 9-페닐-9H-3,9'-바이카바졸-3'-일 보론산, 6-(9H-카바졸-9-일)-9H-3,9'-바이카바졸을 사용하여 흰색 고체의 목적화합물 [134] 2.5g(28%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-8-iodo-6,6,12,12-tetramethyl-6,12-dihydroindeno [1,2-b] fluorene 5 g (9.70 mmol), 9 Of a white solid using -phenyl-9H-3,9'-bicarbazol-3'-yl boronic acid, 6- (9H-carbazol-9-yl) -9H-3,9'-bicarbazole the target compound [134] 2.5g (28%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 1.72(s, 12H), 7.25~7.40(m, 12H), 7.50~7.70(m, 19H), 7.77~7.80(m, 2H), 7.83~8.00(m, 7H), 8.12~8.18(m, 6H), 8.45~8.47(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.72 (s, 12H), 7.25 ~ 7.40 (m, 12H), 7.50 ~ 7.70 (m, 19H), 7.77 ~ 7.80 (m, 2H), 7.83 ~ 8.00 ( m, 7H), 8.12-8.18 (m, 6H), 8.45-8.47 (m, 3H)

MS/FAB : 1212(M+)MS / FAB: 1212 (M + )

[합성 예 135] 화합물 [135]의 합성Synthesis Example 135 Synthesis of Compound [135]

Figure 112010001724795-pat00150
Figure 112010001724795-pat00150

합성예 1과동일한방법으로2-브로모-7-요오도-9,9-디메틸-9H-플로렌 5g(12.52 mmol), 4-(9-(바이페닐-4-일)-9H-카바졸-3-일)페닐보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [135] 3.3g(38%)을 수득하였다. Synthesis Example 1 In the same manner as 2-bromo-7-iodo-9,9-dimethyl-9H-florene 5 g (12.52 mmol), 4- (9- (biphenyl-4-yl) -9H-carbazole- 3-1) using a phenylboronic acid, 3,6-diphenyl--9H- carbazole, to give the desired compound [135] 3.3g (38%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 1.70(s, 6H), 7.25~7.29(m, 5H), 7.40~7.52(m, 18H), 7.63~7.69(m, 5H), 7.77~7.80(m, 6H), 7.87~7.93(m, 3H), 8.00~8.02(m, 2H), 8.12~8.18 (m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.70 (s, 6H), 7.25 to 7.29 (m, 5H), 7.40 to 7.52 (m, 18H), 7.63 to 7.69 (m, 5H), 7.77 to 7.80 ( m, 6H), 7.87-7.83 (m, 3H), 8.00-8.02 (m, 2H), 8.12-8.18 (m, 3H)

MS/FAB : 905(M+)MS / FAB: 905 (M + )

[합성 예 136] 화합물 [136]의 합성Synthesis Example 136 Synthesis of Compound [136]

Figure 112010001724795-pat00151
Figure 112010001724795-pat00151

합성예 1과동일한방법으로2-브로모-7-요오도-9,9-디메틸-9H-플로렌 5g(12.52 mmol), 4-(9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일)페닐보론산, 9H-카바졸을 사용하여 흰색 고체의 목적화합물 [136] 2.7g(34%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodo-9,9-dimethyl-9H-florene 5g (12.52 mmol), 4- (9- (4- (diphenylamino) phenyl) -9H-carba a-3-yl) phenylboronic acid target compound as a white solid using 9H- carbazole [136] 2.7g (34%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 1.70(s, 6H), 7.03~7.10(m, 8H), 7.20~7.37(m, 15H), 7.50~7.52(m, 3H), 7.63~7.65(m, 3H), 7.77~7.80(m, 2H), 7.87~8.00(m, 4H), 8.12~8.18 (m, 3H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.70 (s, 6H), 7.03-7.10 (m, 8H), 7.20-7.73 (m, 15H), 7.50-7.75 (m, 3H), 7.63-7.75 ( m, 3H), 7.77-7.80 (m, 2H), 7.87-8.00 (m, 4H), 8.12-8.18 (m, 3H), 8.45 (d, 1H)

MS/FAB : 844(M+)MS / FAB: 844 (M + )

[합성 예 137] 화합물 [137]의 합성Synthesis Example 137 Synthesis of Compound

Figure 112010001724795-pat00152
Figure 112010001724795-pat00152

합성예 1과동일한방법으로2-브로모-7-요오도-9,9-디메틸-9H-플로렌 5g(12.52 mmol), 4-(9-페닐-9H-카바졸-3-일)페닐보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6-다이민을 사용하여 흰색 고체의 목적화합물 [137] 3.1g(32%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodo-9,9-dimethyl-9H-florene 5g (12.52 mmol), 4- (9-phenyl-9H-carbazol-3-yl) phenylboronic acid , N 3, N 3, N 6, N 6 - tetraphenyl the -9H- carbazole-3,6 using the imine to give the desired compound [137] 3.1g (32%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 1.70(s, 6H), 6.95(d, 1H), 7.03~7.10(m, 14H), 7.20~7.29(m, 13H), 7.38~7.63(m, 13H), 7.77~7.80(m, 2H), 7.87~7.93(m, 2H), 8.00(d, 1H), 8.12~8.18 (m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.70 (s, 6H), 6.95 (d, 1H), 7.03-7.10 (m, 14H), 7.20-7.29 (m, 13H), 7.38-7.7.6 (m, 13H), 7.77-7.80 (m, 2H), 7.87-7.73 (m, 2H), 8.00 (d, 1H), 8.12-8.18 (m, 2H)

MS/FAB : 1011(M+)MS / FAB: 1011 (M + )

[합성 예 138] 화합물 [138]의 합성Synthesis Example 138 Synthesis of Compound [138]

Figure 112010001724795-pat00153
Figure 112010001724795-pat00153

합성예 1과동일한방법으로2-브로모-7-요오도-9,9-디메틸-9H-플로렌 5g(12.52 mmol), 9-(바이페닐-4-일)-9H-카바졸-3-일 보론산, 4-(3,6-디페닐-9H-카바졸-9-일)페닐보론산을 사용하여 흰색 고체의 목적화합물 [138] 2.8g(33%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodo-9,9-dimethyl-9H-florene 5g (12.52 mmol), 9- (biphenyl-4-yl) -9H-carbazol-3-yl to afford the boronic acid, 4- (3,6-diphenyl--9H- carbazol-9-yl) phenylboronic target compound as a white solid using the acid [138] 2.8g (33%) .

1H NMR (300 MHz, CDCl3):δ 1.70(s, 6H), 7.30~7.52(m, 17H), 7.63~7.69(m, 8H), 7.77~7.79(m, 9H), 7.87~7.93(m, 3H), 8.00~8.02(m, 2H), 8.12~8.18 (m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.70 (s, 6H), 7.30 ~ 7.52 (m, 17H), 7.63 ~ 7.69 (m, 8H), 7.77 ~ 7.79 (m, 9H), 7.87 ~ 7.93 ( m, 3H), 8.00-8.02 (m, 2H), 8.12-8.18 (m, 3H)

MS/FAB : 905(M+)MS / FAB: 905 (M + )

[합성 예 139] 화합물 [139]의 합성Synthesis Example 139 Synthesis of Compound

Figure 112010001724795-pat00154
Figure 112010001724795-pat00154

합성예 1과동일한방법으로2-브로모-7-요오도-9,9-디메틸-9H-플로렌 5g(12.52 mmol), 4-(9H-카바졸-9-일)페닐보론산, 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산을 사용하여 흰색 고체의 목적화합물 [139] 3.0g(37%)을 수득하였다. Synthesis Example 1 In the same manner, 5 g (12.52 mmol) of 2-bromo-7-iodo-9,9-dimethyl-9H-florene, 4- (9H-carbazol-9-yl) phenylboronic acid, 9- ( the 4- (diphenylamino) phenyl) -9H- carbazol-3-yl target compound as a white solid using the boronic acid [139] 3.0g (37%) of the title compound.

1H NMR (300 MHz, CDCl3):δ 1.70(s, 6H), 7.03~7.10(m, 8H), 7.20~7.37(m, 10H), 7.50~7.52(m, 2H), 7.63~7.68(m, 6H), 7.77~7.79(m ,5H), 7.93~8.00(m, 4H), 8.12~8.18 (m, 3H), 8.45(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.70 (s, 6H), 7.03-7.10 (m, 8H), 7.20-7.73 (m, 10H), 7.50-7.7.5 (m, 2H), 7.63-77.6 ( m, 6H), 7.77-7.79 (m, 5H), 7.93-8.00 (m, 4H), 8.12-8.18 (m, 3H), 8.45 (d, 1H)

MS/FAB : 844(M+)MS / FAB: 844 (M + )

[합성 예 140] 화합물 [140]의 합성Synthesis Example 140 Synthesis of Compound [140]

Figure 112010001724795-pat00155
Figure 112010001724795-pat00155

합성예 1과동일한방법으로2-브로모-7-요오도-9,9-디메틸-9H-플로렌 5g(12.52 mmol), 9-페닐-9H-카바졸-3-일 보론산, 4-(3,6-비스(디페닐아미노)-9H-카바졸-9-일)페닐보론산을 사용하여 흰색 고체의 목적화합물 [140] 3.3g(34%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodo-9,9-dimethyl-9H-florene 5g (12.52 mmol), 9-phenyl-9H-carbazol-3-yl boronic acid, 4- (3 3.3 g (34%) of the title compound [140] was obtained using, 6-bis (diphenylamino) -9H-carbazol-9-yl) phenylboronic acid.

1H NMR (300 MHz, CDCl3):δ 1.70(s, 6H), 6.95(d, 1H), 7.03~7.14(m, 14H), 7.20~7.29(m, 9H), 7.38~7.68(m, 14H), 7.77~7.79(m, 5H), 7.93~8.00(m ,3H), 8.12~8.18 (m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.70 (s, 6H), 6.95 (d, 1H), 7.03 ~ 7.14 (m, 14H), 7.20 ~ 7.29 (m, 9H), 7.38 ~ 7.68 (m, 14H), 7.77-7.79 (m, 5H), 7.93-8.00 (m, 3H), 8.12-8.18 (m, 2H)

MS/FAB : 1011(M+)MS / FAB: 1011 (M + )

[합성 예 141] 화합물 [141]의 합성Synthesis Example 141 Synthesis of Compound

Figure 112010001724795-pat00156
Figure 112010001724795-pat00156

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9-(비페닐-4-일)-카바졸-3-일 보론산, 카바졸을 사용하여 흰색 고체의 목적화합물 [141] 5.1g(60.1%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 9- (biphenyl-4-yl) -carbazol-3-yl boronic acid , by using the carbazole to give the target compound as a white solid [141] 5.1g (60.1%) .

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.3~7.52(m, 13H), 7.5~7.79(m, 9H), 7.9~8.18(m, 7H), 8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.3 to 7.52 (m, 13H), 7.5 to 7.79 (m, 9H), 7.9 to 8.18 (m, 7H), 8.55 (d, 1H)

MS/FAB : 676(M+) MS / FAB: 676 (M &lt; + & gt ; ) [

[합성 예 142] 화합물 [142]의 합성Synthesis Example 142 Synthesis of Compound

Figure 112010001724795-pat00157
Figure 112010001724795-pat00157

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9(비페닐-4-일)-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [142] 6.1g(58.7%)을 수득하였다. Synthesis Example 1 In the same manner as 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 9 (biphenyl-4-yl) -carbazol-3-yl boronic acid, 3,6-diphenyl-9H-carbazole was used to obtain 6.1 g (58.7%) of the title compound [142] as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.52(m, 19H), 7.58~7.69(m, 5H), 7.7~7.79(m, 6H), 7.87~8.01(m, 5H), 8.12~8.18(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25 to 7.52 (m, 19H), 7.58 to 7.69 (m, 5H), 7.7 to 7.79 (m, 6H), 7.87 to 8.01 ( m, 5H), 8.12-8.18 (m, 3H)

MS/FAB : 828(M+)MS / FAB: 828 (M + )

[합성 예 143] 화합물 [143]의 합성Synthesis Example 143 Synthesis of Compound [143]

Figure 112010001724795-pat00158
Figure 112010001724795-pat00158

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [143] 6.4g(55.5%)을 수득하였다. Synthesis Example 1 In the same manner as 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 9- (4- (diphenylamino) phenyl) -9H-carbazole-3 - using one acid, 3,6-diphenyl--9H- carbazole, to give the desired compound [143] 6.4g (55.5%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 6.63~6.81(m, 8H), 7.20~7.52(m, 20H), 7.63~7.69(m, 3H), 7.77~7.80(m, 4H), 7.87~8.21(m, 8H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 6.63 ~ 6.81 (m, 8H), 7.20 ~ 7.52 (m, 20H), 7.63 ~ 7.69 (m, 3H), 7.77 ~ 7.80 ( m, 4H), 7.87-8.21 (m, 8H)

MS/FAB : 919(M+)MS / FAB: 919 (M &lt; + & gt ; ).

[합성 예 144] 화합물 [144]의 합성Synthesis Example 144 Synthesis of Compound

Figure 112010001724795-pat00159
Figure 112010001724795-pat00159

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 6-(디페닐아미노)-9-페닐-9H-카바졸-3-일-보론산, N,N-디페닐-9H-카바졸 -3-아민 을 사용하여 흰색 고체의 목적화합물 [144] 6.0g(51.2%)을 수득하였다. Synthesis Example 1 In the same way as 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 6- (diphenylamino) -9-phenyl-9H-carbazole-3- 6.0 g (51.2%) of the title compound [144] as a white solid was obtained using mono-boronic acid, N, N-diphenyl-9H-carbazole-3-amine.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 6.63~6.81(m, 16H), 7.21~7.58(m, 20H), 7.77~8.02(m, 6H), 8.18~8.55(m, 2H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 6.63 ~ 6.81 (m, 16H), 7.21 ~ 7.58 (m, 20H), 7.77 ~ 8.02 (m, 6H), 8.18 ~ 8.55 ( m, 2H)

MS/FAB : 934(M+)MS / FAB: 934 (M + )

[합성 예 145] 화합물 [145]의 합성Synthesis Example 145 Synthesis of Compound

Figure 112010001724795-pat00160
Figure 112010001724795-pat00160

합성예 1과 동일한방법으로 2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9-(4-(디페닐아미노)페닐)-9H-카바졸-3-일 보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6디아민을 사용하여 흰색 고체의 목적화합물 [145] 7.1g(51.4%)을 수득하였다.2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol) and 9- (4- (diphenylamino) phenyl) -9H-carbazole in the same manner as in Synthesis example 1 3-yl boronic acid, N3, N3, N6, N6- using tetraphenyl -9H- carbazol -3,6-diamine to give the desired compound [145] 7.1g (51.4%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 5.93~6.63(m, 15H), 6.78~7.81(m, 8H), 7.20~7.41(m, 17H), 7.5~7.63(m, 6H), 7.7~8.18(m, 7H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 5.93-6.63 (m, 15H), 6.78-7.81 (m, 8H), 7.20-7.41 (m, 17H), 7.5-7.63 ( m, 6H), 7.7-8.18 (m, 7H)

MS/FAB : 1101(M+)MS / FAB: 1101 (M + )

[합성 예 146] 화합물 [146]의 합성Synthesis Example 146 Synthesis of Compound [146]

Figure 112010001724795-pat00161
Figure 112010001724795-pat00161

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9-페닐-9H-카바졸-3일-보론산, N3,N3,N6,N6-테트라페닐-9H-카바졸-3,6디아민을 사용하여 흰색 고체의 목적화합물 [146] 6.8g(58.0%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 9-phenyl-9H-carbazol-3yl-boronic acid, N3, N3, N6, N6- using tetraphenyl -9H- carbazol -3,6-diamine to give the desired compound [146] 6.8g (58.0%) of a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 5.93~6.81(m, 15H), 7.2~7.29(m, 9H), 7.38~7.69(m, 13H), 7.8~8.12(m, 7H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 5.93 ~ 6.81 (m, 15H), 7.2 ~ 7.29 (m, 9H), 7.38 ~ 7.69 (m, 13H), 7.8 ~ 8.12 ( m, 7H)

MS/FAB : 934 (M+)MS / FAB: 934 (M + )

[합성 예 147] 화합물 [147]의 합성Synthesis Example 147 Synthesis of Compound

Figure 112010001724795-pat00162
Figure 112010001724795-pat00162

합성예1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9-(4-(트리페닐실닐)페닐)-9H-카바졸-3-일-보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [147] 6.4g(50.5%)을 수득하였다. Synthesis Example 1 In the same manner as in 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 9- (4- (triphenylsilyl) phenyl) -9H-carbazole 6.4 g (50.5%) of the title compound [147] as a white solid was obtained using 3-yl-boronic acid, 3,6-diphenyl-9H-carbazole.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.45(m, 21H), 7.49~7.79(m, 19H), 7.87~8.00(m, 5H), 8.12~8.18(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25 to 7.45 (m, 21H), 7.49 to 7.79 (m, 19H), 7.87 to 8.00 (m, 5H), 8.12 to 8.18 ( m, 3H)

MS/FAB : 1010(M+)MS / FAB: 1010 (M + )

[합성 예 148] 화합물 [148]의 합성Synthesis Example 148 Synthesis of Compound

Figure 112010001724795-pat00163
Figure 112010001724795-pat00163

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 5,11-디페닐-5,11-디히드로인돌로 [3,2-b]카바졸-2-일-보론산, 5-페닐-5,11- 디히드로인돌로 [3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [148] 6.9g(59.1%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 5,11-diphenyl-5,11-dihydroindolo [3,2] 6.9 g (59.1% ) of the target compound as a white solid using carbazol-2-yl-boronic acid, 5-phenyl-5,11-dihydroindolo [3,2-b] carbazole. ) Was obtained.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.43(m, 14H), 7.48~7.6(m, 16H), 7.84~8.00(m, 6H), 8.12~8.18(m, 3H), 8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25-7.43 (m, 14H), 7.48-7.6 (m, 16H), 7.84-8.00 (m, 6H), 8.12-8.18 ( m, 3H), 8.55 (d, 1H)

MS/FAB : 930 (M+)MS / FAB: 930 (M + )

[합성 예 149] 화합물 [149]의 합성Synthesis Example 149 Synthesis of Compound [149]

Figure 112010001724795-pat00164
Figure 112010001724795-pat00164

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9-페닐-9H-카바졸-3일-보론산, 5-페닐-5,11- 디히드로인돌로 [3,2-b]카바졸을 사용하여 흰색 고체의 목적화합물 [149] 6.1g(63.6%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 9-phenyl-9H-carbazol-3yl-boronic acid, 5-phenyl- 6.1 g (63.6%) of the title compound [149] as a white solid was obtained using [3,2-b] carbazole with 5,11-dihydroindole.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.64(m, 23H), 7.78~7.99(m, 6H), 8.12~8.18(m, 3H), 8.55(d, 1H), 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25-7.7.6 (m, 23H), 7.78-7.99 (m, 6H), 8.12-8.18 (m, 3H), 8.55 (d, 1H),

MS/FAB : 765(M+)MS / FAB: 765 (M + )

[합성 예 150] 화합물 [150]의 합성Synthesis Example 150 Synthesis of Compound [150]

Figure 112010001724795-pat00165
Figure 112010001724795-pat00165

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 5,11-디페닐-5,11-디히드로인돌로[3,2-b]카바졸-2-일-보론산, 카바졸 을 사용하여 흰색 고체의 목적화합물 [150] 5.9g(61.5%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 5,11-diphenyl-5,11-dihydroindolo [3,2 -b] carbazol-2-yl-boronic acid, carbazole was used to obtain 5.9 g (61.5%) of the title compound [150] as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.64(m, 21H), 7.78~7.99(m, 7H), 8.12~8.18(m, 4H), 8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25-7.7.6 (m, 21H), 7.78-7.99 (m, 7H), 8.12-8.18 (m, 4H), 8.55 (d, 1H)

MS/FAB : 765(M+)MS / FAB: 765 (M + )

[합성 예 151] 화합물 [151]의 합성 Synthesis Example 151 Synthesis of Compound [151]

Figure 112010001724795-pat00166
Figure 112010001724795-pat00166

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 3',6',9-트리페닐-9H-3,9'-비카바졸-6-일-보론산, 3',6'-디페닐 -9H-3,9'-비카바졸 을 사용하여 흰색 고체의 목적화합물 [151] 6.5g(42.0%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 3 ', 6', 9-triphenyl-9H-3,9'-ratio 6.5 g (42.0%) of the title compound [151] as a white solid was obtained using carbazol-6-yl-boronic acid, 3 ', 6'-diphenyl-9H-3,9'-bicarbazole.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.41(m, 16H), 7.45~7.69(m, 22H), 7.77~8.00(m, 14H), 8.12~8.18(m, 3H), 8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25 to 7.41 (m, 16H), 7.45 to 7.69 (m, 22H), 7.77 to 8.00 (m, 14H), 8.12 to 8.18 ( m, 3H), 8.55 (d, 1H)

MS/FAB : 1234(M+)MS / FAB: 1234 (M + )

[합성 예 152] 화합물 [152]의 합성Synthesis Example 152 Synthesis of Compound [152]

Figure 112010001724795-pat00167
Figure 112010001724795-pat00167

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 5.0g (12.53mmol), 9-페닐-9H-3,9'-비카바졸-3'-일-보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [152] 6.6g(57.4%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-7-iodine-9,9-dimethyl-9H-florene 5.0 g (12.53 mmol), 9-phenyl-9H-3,9'-bicarbazol-3'-yl Boronic acid, 3,6-diphenyl-9H-carbazole, was used to obtain 6.6 g (57.4%) of the title compound [152] as a white solid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.64(m, 27H), 7.78~7.79(m, 10H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25 ~ 7.64 (m, 27H), 7.78 ~ 7.79 (m, 10H), 8.12 ~ 8.18 (m, 4H)

MS/FAB : 917(M+)MS / FAB: 917 (M + )

[합성 예 153] 화합물 [153]의 합성Synthesis Example 153 Synthesis of Compound [153]

Figure 112010001724795-pat00168
Figure 112010001724795-pat00168

합성예 1과동일한방법으로1-브로모-4-요오드나프탈렌 6.0g (18.0mmol), 9-페닐-9H-카바졸-3-일-보론산, 4-(9H-카바졸-9-일)페닐보론산을 사용하여 흰색 고체의 목적화합물 [153] 7.3g(66.3%)을 수득하였다. Synthesis Example 1 In the same manner 1-bromo-4-iodonaphthalene 6.0 g (18.0 mmol), 9-phenyl-9H-carbazol-3-yl-boronic acid, 4- (9H-carbazol-9-yl) phenyl using acid to yield the target compound as a white solid [153] 7.3g (66.3%) .

1H NMR (300 MHz, CDCl3):δ 7.25~7.33(m, 4H), 7.45~7.68(m, 13H), 7.77~7.79(m, 3H), 7.94~8.18(m, 7H), 8.45~8.55(m, 3H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25-7.73 (m, 4H), 7.45-7.68 (m, 13H), 7.77-7.79 (m, 3H), 7.94-8.18 (m, 7H), 8.45- 8.55 (m, 3H)

MS/FAB : 610(M+)MS / FAB: 610 (M + )

[합성 예 154] 화합물 [154]의 합성Synthesis Example 154 Synthesis of Compound [154]

Figure 112010001724795-pat00169
Figure 112010001724795-pat00169

합성예 1과동일한방법으로 2-브로모-6-요오드나프탈렌 6.0g (18.0mmol), 9-페닐-9H-카바졸-3-일-보론산, 4-(9H-카바졸-9-일)페닐보론산 을 사용하여 흰색 고체의 목적화합물 [154] 7.0g(63.6%)을 수득하였다. Synthesis Example 1 In the same manner, 2-bromo-6-iodinenaphthalene 6.0 g (18.0 mmol), 9-phenyl-9H-carbazol-3-yl-boronic acid, 4- (9H-carbazol-9-yl) phenyl using acid to yield the target compound as a white solid [154] 7.0g (63.6%) .

1H NMR (300 MHz, CDCl3):δ 7.25~7.33(m, 4H), 7.45~7.79(m, 18H), 7.92~8.1(m, 4H), 8.12~8.55(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 7.25 to 7.33 (m, 4H), 7.45 to 7.79 (m, 18H), 7.92 to 8.1 (m, 4H), 8.12 to 8.55 (m, 4H)

MS/FAB : 610(M+)MS / FAB: 610 (M + )

[합성 예 155] 화합물 [155]의 합성Synthesis Example 155 Synthesis of Compound [155]

Figure 112010001724795-pat00170
Figure 112010001724795-pat00170

합성예 1과동일한방법으로2-브로모-7-요오드-9,9-디메틸-9H-플로렌 6.0g (15.0mmol), 9-페닐-9H-카바졸-3-일-보론산, 4-(9H-카바졸-9-일)페닐보론산 을 사용하여 흰색 고체의 목적화합물 [155] 7.0g(63.6%)을 수득하였다. Synthesis Example 1 In the same way as 2-bromo-7-iodine-9,9-dimethyl-9H-florene 6.0 g (15.0 mmol), 9-phenyl-9H-carbazol-3-yl-boronic acid, 4- ( 7.0 g (63.6%) of the title compound [155] as a white solid was obtained using 9H-carbazol-9-yl) phenylboronic acid.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 6H), 7.25~7.33(m, 4H), 7.50~7.71(m, 13H), 7.87~8.00(m, 9H), 8.12~8.18(m, 4H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 6H), 7.25 to 7.33 (m, 4H), 7.50 to 7.71 (m, 13H), 7.87 to 8.00 (m, 9H), 8.12 to 8.18 ( m, 4H)

MS/FAB : 676(M+)MS / FAB: 676 (M &lt; + & gt ; ) [

[합성 예 156] 화합물 [156]의 합성Synthesis Example 156 Synthesis of Compound

Figure 112010001724795-pat00171
Figure 112010001724795-pat00171

합성예 1과동일한방법으로2,6-디브로모-9,9,10,10-테트라메틸-9,10-디하이드로안트라센 6.0g (15.2mmol), 9-페닐-9H-카바졸-3-일-보론산, 4-(9H-카바졸-9-일)페닐보론산 을 사용하여 흰색 고체의 목적화합물 [156] 6.1g(50.4%)을 수득하였다 Synthesis Example By the same method as one 2,6-dibromo--9,9,10,10- tetramethyl-9,10-dihydro-anthracene 6.0g (15.2mmol), 9- phenyl -9H- carbazol-3-yl -boronic acid, 4- (9H- carbazol-9-yl) phenylboronic target compound as a white solid using the acid [156] 6.1g (50.4%) was obtained

1H NMR (300 MHz, CDCl3):δ 1.73(s, 12H), 7.25~7.63(m, 25H), 7.77~7.87(m, 4H), 8.0~8.18(m, 5H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 12H), 7.25-7.63 (m, 25H), 7.77-7.87 (m, 4H), 8.0-8.18 (m, 5H)

MS/FAB : 794(M+)MS / FAB: 794 (M &lt; + & gt ; ) [

[합성 예157] 화합물 [157]의 합성Synthesis Example 157 Synthesis of Compound

Figure 112010001724795-pat00172
Figure 112010001724795-pat00172

합성예 1과동일한방법으로2,6-디브로모-9,9,10,10-테트라메틸-9,10-디하이드로안트라센6.0g (15.2mmol), 9-(비페닐-4-일)-카바졸-3-일 보론산, 3,6-디페닐-9H-카바졸을 사용하여 흰색 고체의 목적화합물 [157] 7.8g(58.8 %)을 수득하였다 Synthesis Example By the same method as one 2,6-dibromo--9,9,10,10- tetramethyl-9,10-dihydro-anthracene 6.0g (15.2mmol), 9- (biphenyl-4-yl) - carbazole -3-yl-boronic acid, using 3,6-diphenyl--9H- carbazole, to give the desired compound [157] 7.8g (58.8%) of a white solid

1H NMR (300 MHz, CDCl3):δ 1.73(s, 12H), 7.19~7.53(m, 23H), 7.63~7.79(m, 9H), 7.87~8.18(m, 6H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 12H), 7.19 ~ 7.53 (m, 23H), 7.63 ~ 7.79 (m, 9H), 7.87 ~ 8.18 (m, 6H)

MS/FAB : 870(M+)MS / FAB: 870 (M + )

[합성 예 158] 화합물 [158]의 합성Synthesis Example 158 Synthesis of Compound

Figure 112010001724795-pat00173
Figure 112010001724795-pat00173

합성예 1과동일한방법으로2,6-디브로모-9,9,10,10-테트라메틸-9,10-디하이드로안트라센 6.0g (15.2mmol), 9-페닐-9H-카바졸-3-일-보론산, 4-(9H-카바졸-9-일)페닐보론산 을 사용하여 흰색 고체의 목적화합물 [158] 7.1g(64.9%)을 수득하였다. Synthesis Example By the same method as one 2,6-dibromo--9,9,10,10- tetramethyl-9,10-di-hydro-anthracene 6.0g (15.2mmol), 9- phenyl -9H- carbazol-3-yl -boronic acid, 4- (9H- carbazol-9-yl) the preparation of the compound [158] 7.1g (64.9%) as a white solid using the boronic acid was obtained.

1H NMR (300 MHz, CDCl3):δ 1.73(s, 12H), 7.24~7.56(m, 21H), 7.77~7.79(m, 3H), 7.93~8.18(m, 5H), 8.55(d, 1H) 1 H NMR (300 MHz, CDCl 3 ): δ 1.73 (s, 12H), 7.24 to 7.56 (m, 21H), 7.77 to 7.79 (m, 3H), 7.93 to 8.18 (m, 5H), 8.55 (d, 1H)

MS/FAB : 718(M+)MS / FAB: 718 (M &lt; + & gt ; ).

[합성 예 159] 화합물 [159]의 합성Synthesis Example 159 Synthesis of Compound

Figure 112010001724795-pat00174
Figure 112010001724795-pat00174

합성예 1과동일한방법으로4-브로모-4'-요오드비페닐 6.0g (16.7mmol), 9-페닐-9H-카바졸-3-일-보론산, 10H-페노티아진을 사용하여 흰색 고체의 목적화합물 [159] 6.4g(64.6%)을 수득하였다. Synthesis Example 1 In the same manner, a white solid was prepared using 6.0 g (16.7 mmol) of 4-bromo-4'-iodine biphenyl, 9-phenyl-9H-carbazol-3-yl-boronic acid, 10H-phenothiazine. the target compound [159] 6.4g (64.6%) was obtained.

1H NMR (300 MHz, CDCl3):δ 6.69~6.97(m, 4H), 7.24~7.41(m, 11H), 7.48~7.69(m, 9H), 7.77~8.19(m, 4H), 1 H NMR (300 MHz, CDCl 3 ): δ 6.69-6.97 (m, 4H), 7.24-7.41 (m, 11H), 7.48-7.69 (m, 9H), 7.77-8.19 (m, 4H),

MS/FAB : 592(M+)MS / FAB: 592 (M &lt; + & gt ; ) [

[합성 예 160] 화합물 [160]의 합성Synthesis Example 160 Synthesis of Compound

Figure 112010001724795-pat00175
Figure 112010001724795-pat00175

합성예 1과동일한방법으로4-브로모-4'-요오드비페닐 6.0g (16.7mmol), 9-페닐-9H-카바졸-3-일-보론산, 10H-펜옥사진을 사용하여 흰색 고체의 목적화합물 [160] 6.4g(64.6%)을 수득하였다. Synthesis Example 1 In the same manner, the purpose of a white solid using 6.0 g (16.7 mmol) of 4-bromo-4'-iodine biphenyl, 9-phenyl-9H-carbazol-3-yl-boronic acid, 10H-phenoxazine 6.4 g (64.6%) of Compound [160] were obtained.

1H NMR (300 MHz, CDCl3):δ 6.55~6.77(m, 6H), 6.88~6.93(m, 4H), 7.24~7.29(m, 5H), 7.51~7.59(m, 9H), 7.77~8.19(m, 4H), 1 H NMR (300 MHz, CDCl 3 ): δ 6.55 ~ 6.77 (m, 6H), 6.88 ~ 6.93 (m, 4H), 7.24 ~ 7.29 (m, 5H), 7.51 ~ 7.59 (m, 9H), 7.77 ~ 8.19 (m, 4 H),

MS/FAB : 576(M+)MS / FAB: 576 (M &lt; + & gt ; ).

[합성 예 161] 화합물 [161]의 합성Synthesis Example 161 Synthesis of Compound

Figure 112010001724795-pat00176
Figure 112010001724795-pat00176

합성예 1과동일한방법으로4-브로모-4'-요오드비페닐 6.0g (16.7mmol), 9-페닐-9H-카바졸-3-일-보론산, 5-페닐-5,10-디하이드로페나진을 사용하여 흰색 고체의 목적화합물 [161] 6.5g(59.7%)을 수득하였다. Synthesis Example 1 In the same manner, 4-bromo-4'-iodine biphenyl 6.0 g (16.7 mmol), 9-phenyl-9H-carbazol-3-yl-boronic acid, 5-phenyl-5,10-dihydrofena Gins were used to obtain 6.5 g (59.7%) of the title compound [161] as a white solid.

1H NMR (300 MHz, CDCl3):δ 6.53~6.59(m, 4H), 6.61~6.82(m, 9H), 7.19~7.31(m, 7H), 7.41~7.59(m, 9H), 7.77~8.21(m, 4H), 1 H NMR (300 MHz, CDCl 3 ): δ 6.53 ~ 6.59 (m, 4H), 6.61 ~ 6.82 (m, 9H), 7.19 ~ 7.31 (m, 7H), 7.41 ~ 7.59 (m, 9H), 7.77 ~ 8.21 (m, 4 H),

MS/FAB : 651(M+)
MS / FAB: 651 (M &lt; + & gt ; ).

비교예Comparative Example 1 One

하기 화학식 α로 표시되는 화합물 a를 발광층 물질로 사용하고, 화학식 b로 표시되는 2-TNATA(4,4',4"tris(N-naphthalen-2-yl)-N-phenylamino)-triphenylamine)을 정공주입층 물질로 사용하고, 화학식 c로 표시되는 α-NPD(N,N'-di(naphthalene-1-yl)-N,N'-diphenylbenzidine)을 정공수송층 물질로 사용하여, 다음과 같은 구조를 갖는 유기발광소자를 제작하였다: ITO/2-TNATA(80nm)/α-NPD(30nm)/화합물a(30nm)/Alq3(30nm)/LiF(0.5nm) /Al(60nm).Using compound a represented by the formula α as a light emitting layer material, 2-TNATA (4,4 ', 4 "tris (N-naphthalen-2-yl) -N-phenylamino) -triphenylamine) represented by formula b Using as a hole injection layer material and using α-NPD (N, N'-di (naphthalene-1-yl) -N, N'-diphenylbenzidine) represented by the formula c as a hole transport layer material, An organic light emitting device was manufactured having: ITO / 2-TNATA (80 nm) / α-NPD (30 nm) / Compound a (30 nm) / Alq 3 (30 nm) / LiF (0.5 nm) / Al (60 nm).

애노드는 코닝(Corning)사의 15Ω/cm2(1000Å) ITO 유리 기판을 50mm x 50mm x 0.7mm크기로 잘라서 아세톤 이소프로필 알콜과 순수물 속에서 각 15분 동안 초음파 세정한 후, 30분 동안 UV 오존 세정하여 사용하였다. 상기 기판 상부에 2-TANATA를 진공 증착하여 80nm 두께의 정공주입층을 형성하였다. 상기 정공주입층 상부에, α-NPD를 진공 증착하여 30nm 두께의 정공수송층을 형성하였다. 상기 정공수송층 상부에 화학식 α로 표시되는 화합물 a를 진공 증착하여 25nm두께의 발광층을 형성하였다. 이후, 상기 발광층 상부에 Alq3 화합물을 30nm의 두께로 진공증착하여 전자수송층을 형성하였다. 상기 전자수송층 상부에 LiF 0.5nm(전자주입층)과 Al 600nm(캐소드)를 순차적으로 진공증착하여, 도 1b에 도시된 바와 같은 유기발광소자를 제조하였다. 이를 비교샘플 1이라고 한다.An anode was prepared by cutting Corning's 15 Ω / cm 2 (1000 Å) ITO glass substrate into 50 mm × 50 mm × 0.7 mm size, ultrasonically cleaning it in acetone isopropyl alcohol and pure water for 15 minutes each, Washed and used. 2-TANATA was vacuum-deposited on the substrate to form a hole injection layer having a thickness of 80 nm. On top of the hole injection layer,? -NPD was vacuum deposited to form a hole transport layer having a thickness of 30 nm. Compound a represented by Chemical Formula α was vacuum deposited on the hole transport layer to form a light emitting layer having a thickness of 25 nm. Then, an Alq3 compound was vacuum deposited on the light emitting layer to a thickness of 30 nm to form an electron transporting layer. LiF 0.5 nm (electron injection layer) and Al 600 nm (cathode) were sequentially vacuum deposited on the electron transport layer to prepare an organic light emitting device as shown in FIG. 1B. This is referred to as Comparative Sample 1.

본 실시예 및 이하의 실시예들에서는 디오브이사에서 제작한 EL 증착기를 사용하여 소자를 제작하였다.In this embodiment and the following examples, the device was fabricated using an EL deposition machine manufactured by DIOB Corporation.

<화학식 α> <화학식 b><Formula α> <Formula b>

Figure 112010001724795-pat00177
Figure 112010001724795-pat00178
Figure 112010001724795-pat00177
Figure 112010001724795-pat00178

<화학식 c> <Formula c>

Figure 112010001724795-pat00179
Figure 112010001724795-pat00179

실시예Example 1~161 1 to 161

상기 비교예 1 중, 발광층 화합물로서 화합물 a 대신 상기 합성예에 개시된 화합물 1~117을 EML층 화합물로 각각 이용한 것을 제외하고는 상기 비교예 1과 동일한 방법으로 ITO/2-TNATA(80nm)/α-NPD(30nm)/[EML 화합물 1~161](30nm)/Alq3(30nm)/LiF(0.5nm)/Al(60nm)의 구조를 갖는 유기발광소자를 제조하였다. 이를 각각 샘플 1 내지 161라고 한다.ITO / 2-TNATA (80nm) / α in the same manner as in Comparative Example 1, except that Compounds 1 to 117 disclosed in Synthesis Example were used as EML layer compounds instead of Compound a as Comparative Example 1, respectively. An organic light emitting diode having a structure of -NPD (30nm) / [EML Compound 1-161] (30nm) / Alq3 (30nm) / LiF (0.5nm) / Al (60nm) was prepared. These are referred to as samples 1 to 161, respectively.

평가예Evaluation example 1 : 비교샘플 1 및 샘플 1~161의 발광 특성 평가 1: Evaluation of Luminescence Characteristics of Comparative Sample 1 and Samples 1 to 161

비교샘플 1 및 샘플 1~161에 대하여, Keithley SMU 235, PR650를 이용하여 구동전압, 발광 휘도, 발광 효율, 발광피크를 각각 평가하여, 그 결과를 하기 표 1에 나타내었다. 상기 샘플들은 480~492nm 범위에서 청색 발광피크값을 보여주었다.
For Comparative Sample 1 and Samples 1 to 161, Keithley SMU 235 and PR650 were used to evaluate driving voltage, emission luminance, emission efficiency, and emission peak, respectively, and the results are shown in Table 1 below. The samples showed blue emission peak values in the range of 480 to 492 nm.

<표 1>TABLE 1

Figure 112010001724795-pat00180
Figure 112010001724795-pat00180

Figure 112010001724795-pat00181
Figure 112010001724795-pat00181

Figure 112010001724795-pat00182
Figure 112010001724795-pat00182

상기 표 1에 보여지는 바와 같이 샘플 1 내지 117은 비교샘플 1에 비하여 향상된 발광 특성을 나타내었다.As shown in Table 1, Samples 1 to 117 showed improved luminescence properties compared to Comparative Sample 1.

실시예Example 162~243 162-243

상기 비교예 1 중, 정공수송층 화합물로서 화학식 c 대신 상기 합성예에 개시된 화합물중 HTL용 화합물을 정공수송층 화합물로 각각 이용한 것을 제외하고는 상기 비교예 1과 동일한 방법으로 ITO/2-TNATA(80nm)/HTL용 화합물(30nm)/ 화학식 α(30nm)/ LiF(0.5nm)/Al(60nm)의 구조를 갖는 유기발광소자를 제조하였다. 이를 각각 샘플 162 내지 243라고 한다 ITO / 2-TNATA (80 nm) in the same manner as in Comparative Example 1, except that HTL compounds were used as the hole transport layer compounds among the compounds disclosed in Synthesis Example as the hole transport layer compounds in Comparative Example 1, respectively. An organic light emitting device was manufactured having a structure of a compound for HTL (30 nm) / general formula α (30 nm) / LiF (0.5 nm) / Al (60 nm). These are called samples 162 to 243, respectively.

평가예Evaluation example 2 : 비교샘플 1 및 샘플 162 ~ 243의 발광 특성 평가 2: Evaluation of Luminescence Characteristics of Comparative Sample 1 and Samples 162 to 243

비교샘플 1 및 샘플 162~243에 대하여, Keithley SMU 235, PR650를 이용하여 구동전압, 발광 휘도, 발광 효율, 발광피크를 각각 평가하여, 그 결과를 하기 표 2에 나타내었다. 상기 샘플들은 456~478nm 범위에서 청색 발광피크값을 보여주었다.For Comparative Sample 1 and Samples 162 to 243, Keithley SMU 235 and PR650 were used to evaluate driving voltage, emission luminance, emission efficiency, and emission peak, and the results are shown in Table 2 below. The samples showed blue emission peak values in the range of 456-478 nm.

<표 2><Table 2>

Figure 112010001724795-pat00183
Figure 112010001724795-pat00183

Figure 112010001724795-pat00184

Figure 112010001724795-pat00184

상기 표 2에 보여지는 바와 같이 샘플 162 내지 243은 비교샘플 1에 비하여 향상된 발광 특성을 나타내었다.As shown in Table 2, Samples 162 to 243 showed improved luminescence properties compared to Comparative Sample 1.

실시예Example 244~322 244-322

상기 비교예 1 중, 정공주입층 화합물로서 화학식 b 대신 상기 합성예에 개시된 화합물중 HIL용 화합물을 정공주입층 화합물로 각각 이용한 것을 제외하고는 상기 비교예 1과 동일한 방법으로 ITO/HIL용 화합물(80nm)/ α-NPD(30nm)/화학식 α(30nm)/ LiF(0.5nm)/Al(60nm)의 구조를 갖는 유기발광소자를 제조하였다. 이를 각각 샘플 244 내지 322라고 한다 Compounds for ITO / HIL were prepared in the same manner as in Comparative Example 1 except that HIL compounds were used as the hole injection layer compounds among the compounds disclosed in Synthesis Example instead of the formula b as the hole injection layer compounds. An organic light emitting device having a structure of 80 nm) / α-NPD (30 nm) / chemical formula α (30 nm) / LiF (0.5 nm) / Al (60 nm) was prepared. These are called samples 244 to 322, respectively.

평가예Evaluation example 3 : 비교샘플 1 및 샘플 244 ~ 322의 발광 특성 평가 3: Evaluation of Luminescence Characteristics of Comparative Sample 1 and Samples 244 to 322

비교샘플 1 및 샘플 244~322에 대하여, Keithley SMU 235, PR650를 이용하여 구동전압, 발광 휘도, 발광 효율, 발광피크를 각각 평가하여, 그 결과를 하기 표 3에 나타내었다. 상기 샘플들은 456~464nm 범위에서 청색 발광피크값을 보여주었다.
For Comparative Sample 1 and Samples 244 to 322, the driving voltage, emission luminance, emission efficiency, and emission peak were evaluated using Keithley SMU 235 and PR650, respectively, and the results are shown in Table 3 below. The samples showed blue emission peak values in the range of 456-464 nm.

<표 3>
<Table 3>

Figure 112010001724795-pat00185
Figure 112010001724795-pat00185

Figure 112010001724795-pat00186

Figure 112010001724795-pat00186

상기 표 3에 확인할 수 있는 바와 같이 샘플 244 내지 322은 비교샘플 1에 비하여 향상된 특성을 나타내었다.
As can be seen in Table 3, Samples 244 to 322 showed improved characteristics compared to Comparative Sample 1.

이상의 설명에서 통상의 공지된 기술을 생략되어 있으나, 당업자라면 용이하게 이를 추측 및 추론하고 재현할 수 있다.In the above description, the conventional well-known technique is omitted, but a person skilled in the art can easily guess, deduce and reproduce it.

Claims (10)

삭제delete 삭제delete 삭제delete 삭제delete 제1전극; 제2전극; 및 상기 제1전극과 상기 제2전극 사이에 적어도 한 층의 유기막을 포함하는 유기 광소자로서, 상기 유기막이 하기 화학식의 유기 광화합물들 중 어느 하나를 포함하는 것을 특징으로 하는 유기 광소자:

Figure 112012069262091-pat00223


Figure 112012069262091-pat00224


Figure 112012069262091-pat00216


Figure 112012069262091-pat00191


Figure 112012069262091-pat00217


Figure 112012069262091-pat00193


Figure 112012069262091-pat00194

Figure 112012069262091-pat00195


Figure 112012069262091-pat00196


Figure 112012069262091-pat00197


Figure 112012069262091-pat00198

Figure 112012069262091-pat00199


Figure 112012069262091-pat00218

A first electrode; A second electrode; And an organic optical device comprising at least one layer of an organic film between the first electrode and the second electrode, wherein the organic film comprises any one of organic photo compounds of the following formula:

Figure 112012069262091-pat00223


Figure 112012069262091-pat00224


Figure 112012069262091-pat00216


Figure 112012069262091-pat00191


Figure 112012069262091-pat00217


Figure 112012069262091-pat00193


Figure 112012069262091-pat00194

Figure 112012069262091-pat00195


Figure 112012069262091-pat00196


Figure 112012069262091-pat00197


Figure 112012069262091-pat00198

Figure 112012069262091-pat00199


Figure 112012069262091-pat00218

제 5 항에 있어서,
상기 유기막은 정공수송층, 정공주입층 또는 발광층인 것을 특징으로 하는 유기 광소자.
The method of claim 5, wherein
The organic film is an organic optical device, characterized in that the hole transport layer, hole injection layer or light emitting layer.
삭제delete 삭제delete 삭제delete 하기 화학식의 유기 광화합물들 중 어느 하나로 표시되는 유기 광화합물:

Figure 112012069262091-pat00225


Figure 112012069262091-pat00226


Figure 112012069262091-pat00219


Figure 112012069262091-pat00205


Figure 112012069262091-pat00220


Figure 112012069262091-pat00207


Figure 112012069262091-pat00208

Figure 112012069262091-pat00209


Figure 112012069262091-pat00210


Figure 112012069262091-pat00211


Figure 112012069262091-pat00212

Figure 112012069262091-pat00213


Figure 112012069262091-pat00221

An organic photo compound represented by any one of the organic photo compounds of the formula

Figure 112012069262091-pat00225


Figure 112012069262091-pat00226


Figure 112012069262091-pat00219


Figure 112012069262091-pat00205


Figure 112012069262091-pat00220


Figure 112012069262091-pat00207


Figure 112012069262091-pat00208

Figure 112012069262091-pat00209


Figure 112012069262091-pat00210


Figure 112012069262091-pat00211


Figure 112012069262091-pat00212

Figure 112012069262091-pat00213


Figure 112012069262091-pat00221

KR1020100002432A 2009-12-31 2010-01-11 Organic light device and organic light compound for the same KR101324788B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090135277 2009-12-31
KR20090135277 2009-12-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020110140986A Division KR20120013278A (en) 2009-12-31 2011-12-23 Organic light device and organic light compound for the same

Publications (2)

Publication Number Publication Date
KR20110079402A KR20110079402A (en) 2011-07-07
KR101324788B1 true KR101324788B1 (en) 2013-10-31

Family

ID=44918783

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020100002432A KR101324788B1 (en) 2009-12-31 2010-01-11 Organic light device and organic light compound for the same
KR1020110140986A KR20120013278A (en) 2009-12-31 2011-12-23 Organic light device and organic light compound for the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020110140986A KR20120013278A (en) 2009-12-31 2011-12-23 Organic light device and organic light compound for the same

Country Status (1)

Country Link
KR (2) KR101324788B1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10319921B2 (en) 2016-07-19 2019-06-11 Samsung Sdi Co., Ltd. Composition for organic optoelectronic device and organic optoelectronic device and display device
US10505126B2 (en) 2016-07-21 2019-12-10 Samsung Sdi Co., Ltd. Composition for organic optoelectric device and organic optoelectric device and display device
US10593894B2 (en) 2016-07-13 2020-03-17 Samsung Sdi Co., Ltd. Composition for organic optoelectronic device and organic optoelectronic device and display device
US10600971B2 (en) 2016-08-11 2020-03-24 Samsung Sdi Co., Ltd. Composition for organic optoelectric device and organic optoelectric device and display device
US10658594B2 (en) 2017-12-06 2020-05-19 Idemitsu Kosan Co., Ltd. Organic electroluminescence device and novel compound
US11038119B2 (en) 2016-02-03 2021-06-15 Samsung Sdi Co., Ltd. Organic compound, organic optoelectronic device and display apparatus
KR20230084115A (en) 2014-05-14 2023-06-12 롬엔드하스전자재료코리아유한회사 Multi-component host material and organic electroluminescent device comprising the same

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2556075B1 (en) * 2010-04-06 2019-02-27 UDC Ireland Limited Substituted carbazole derivatives and use thereof in organic electronics
EP2433929B1 (en) 2010-09-27 2013-10-23 Semiconductor Energy Laboratory Co, Ltd. Organic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device
KR20120052879A (en) * 2010-11-16 2012-05-24 롬엔드하스전자재료코리아유한회사 Novel compound for organic electronic material and organic electroluminescent device using the same
US9537107B2 (en) 2011-03-14 2017-01-03 Toray Industries, Inc. Light emitting device material and light emitting device
KR101486562B1 (en) * 2011-04-15 2015-01-28 제일모직 주식회사 Compound For Organic Optoelectronic Device, Organic Light Emitting Diode Including The Same and Display Including The Organic Light Emitting Diode
KR101879716B1 (en) * 2011-07-20 2018-07-18 엘지디스플레이 주식회사 Phosphorescent host transporting material and Organic electroluminescent device using the same
US9634255B2 (en) 2011-09-15 2017-04-25 Idemitsu Kosan Co., Ltd. Aromatic amine derivative and organic electroluminescence element using same
CN104011893B (en) * 2011-12-15 2016-06-22 新日铁住金化学株式会社 Organic electroluminescent device
KR20130127563A (en) * 2012-05-02 2013-11-25 롬엔드하스전자재료코리아유한회사 Novel organic electroluminescence compounds and organic electroluminescence device containing the same
KR101876777B1 (en) * 2012-05-24 2018-07-12 덕산네오룩스 주식회사 Compound for organic electronic element, organic electronic element using the same, and a electronic device thereof
KR20130134202A (en) * 2012-05-30 2013-12-10 롬엔드하스전자재료코리아유한회사 Novel organic electroluminescence compounds and organic electroluminescence device containing the same
KR101537005B1 (en) 2012-09-28 2015-07-20 제일모직 주식회사 Compound for organic optoelectronic device, organic light emitting diode including the same and display including the organic light emitting diode
TWI599570B (en) * 2012-09-28 2017-09-21 新日鐵住金化學股份有限公司 Compounds for organic electroluminescent devices and organic electroluminescent devices
JP2014108940A (en) * 2012-11-30 2014-06-12 Samsung Display Co Ltd Indolocarbazole derivative and organic electroluminescence device including the same
JP2014110315A (en) 2012-11-30 2014-06-12 Samsung Display Co Ltd Hole transport material for organic electroluminescent element and organic electroluminescent element using the same
JP2014227399A (en) 2013-05-24 2014-12-08 三星ディスプレイ株式會社Samsung Display Co.,Ltd. Aryl-amine derivative and organic electroluminescent device using the same as hole transport material
KR20140147498A (en) * 2013-06-20 2014-12-30 에스케이케미칼주식회사 Compound for organic electroluminescent device and organic electroluminescent device comprising the same
KR102066437B1 (en) * 2013-07-02 2020-01-15 덕산네오룩스 주식회사 An organic electronic element comprising a layer for improving light efficiency, and an electronic device comprising the same
KR101708090B1 (en) * 2013-12-11 2017-02-17 주식회사 두산 Organic lightingemitting compound and organic electroluminescent device using the same
CN103666459B (en) * 2013-12-16 2015-01-21 深圳市华星光电技术有限公司 Blue-fluorescence organic material and organic light emitting diode panel employing same
CN104650088B (en) * 2013-12-26 2017-08-01 固安鼎材科技有限公司 A kind of derivative of carbazolyl-containing and its application in organic electroluminescence device
CN104672229B (en) * 2013-12-26 2017-09-01 北京鼎材科技有限公司 A kind of fluorene kind derivative of base group containing carbazole 3 and its application
CN104650089B (en) * 2013-12-26 2017-10-03 固安鼎材科技有限公司 A kind of fluorene kind derivative of base group containing carbazole 9 and its application
CN104672230B (en) * 2013-12-26 2017-09-01 北京鼎材科技有限公司 Fluorene kind derivative containing aryl amine and its applied in electroluminescent device
CN104650090B (en) * 2013-12-26 2018-05-18 固安鼎材科技有限公司 A kind of fluorene kind derivative of the bases of -3- containing carbazole group and its application
CN104672228B (en) * 2013-12-26 2017-02-22 北京鼎材科技有限公司 Fluorene type compound containing carbazole-9-yl group and application thereof
US10208026B2 (en) 2014-03-18 2019-02-19 Universal Display Corporation Organic electroluminescent materials and devices
CN110713485A (en) * 2014-03-18 2020-01-21 环球展览公司 Organic electroluminescent material and device
KR101556241B1 (en) * 2014-04-02 2015-10-01 주식회사 엘엠에스 Novel compound and light-emitting diode containing the same
KR102502306B1 (en) * 2014-07-22 2023-02-23 롬엔드하스전자재료코리아유한회사 Organic Electroluminescence Device
JP6811548B2 (en) * 2015-08-21 2021-01-13 三星ディスプレイ株式會社Samsung Display Co.,Ltd. Torquesen derivatives and organic electroluminescent devices
US10777751B2 (en) 2015-08-21 2020-09-15 Samsung Display Co., Ltd. Truxene derivative and organic electroluminescence device including the same
KR102500012B1 (en) * 2017-06-16 2023-02-15 주식회사 동진쎄미켐 Novel compound and organic electroluminescent divice including the same
CN109928962A (en) * 2017-12-18 2019-06-25 江苏三月光电科技有限公司 It is a kind of using carbazole as the compound of core, preparation method and its application on organic electroluminescence device
KR20190090695A (en) * 2018-01-25 2019-08-02 롬엔드하스전자재료코리아유한회사 Organic electroluminescent compound and organic electroluminescent device comprising the same
WO2019147030A1 (en) * 2018-01-25 2019-08-01 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
US20200343457A1 (en) * 2019-04-29 2020-10-29 Universal Display Corporation Organic electroluminescent materials and devices
KR20210054902A (en) * 2019-11-06 2021-05-14 삼성전자주식회사 Photoelectric conversion device and sensor and electronic device
EP4372057A2 (en) 2020-07-24 2024-05-22 Noctiluca S.A. Tadf materials comprising 4-(3-(2-(10h-phenoxazin-10-yl)pyridin-5-yl)-9h-carbazol-9-yl)benzonitrile derivatives and related compounds for use in oleds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020026866A (en) * 2000-03-27 2002-04-12 도미나가 가즈토 Organic electroluminescence device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020026866A (en) * 2000-03-27 2002-04-12 도미나가 가즈토 Organic electroluminescence device

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230084115A (en) 2014-05-14 2023-06-12 롬엔드하스전자재료코리아유한회사 Multi-component host material and organic electroluminescent device comprising the same
US11038119B2 (en) 2016-02-03 2021-06-15 Samsung Sdi Co., Ltd. Organic compound, organic optoelectronic device and display apparatus
US10593894B2 (en) 2016-07-13 2020-03-17 Samsung Sdi Co., Ltd. Composition for organic optoelectronic device and organic optoelectronic device and display device
US10319921B2 (en) 2016-07-19 2019-06-11 Samsung Sdi Co., Ltd. Composition for organic optoelectronic device and organic optoelectronic device and display device
US10505126B2 (en) 2016-07-21 2019-12-10 Samsung Sdi Co., Ltd. Composition for organic optoelectric device and organic optoelectric device and display device
US10600971B2 (en) 2016-08-11 2020-03-24 Samsung Sdi Co., Ltd. Composition for organic optoelectric device and organic optoelectric device and display device
US10658594B2 (en) 2017-12-06 2020-05-19 Idemitsu Kosan Co., Ltd. Organic electroluminescence device and novel compound
US10672989B2 (en) 2017-12-06 2020-06-02 Idemitsu Kosan Co., Ltd. Organic electroluminescence device and novel compound

Also Published As

Publication number Publication date
KR20110079402A (en) 2011-07-07
KR20120013278A (en) 2012-02-14

Similar Documents

Publication Publication Date Title
KR101324788B1 (en) Organic light device and organic light compound for the same
KR101324782B1 (en) Organic light device and organic light compound for the same
KR101536167B1 (en) Organic light compound and organic light device using the same
KR101512019B1 (en) Organic light compound and organic light device using the same
KR101399636B1 (en) Organic light compound and organic light device using the same
KR101536165B1 (en) Organic light compound and organic light device using the same
KR101375359B1 (en) Organic light compound and organic light device using the same
KR101247956B1 (en) Organic light emitting device and organic light emitting compound for the same
KR101324784B1 (en) Organic light compound and organic light device using the same
KR101375361B1 (en) Organic light compound and organic light device using the same
KR101395607B1 (en) Organic light compound and organic light device using the same
KR101324785B1 (en) Organic light compound and organic light device using the same
KR101324786B1 (en) Organic light compound and organic light device using the same
KR20130029131A (en) Organic light compound and organic light device using the same
KR101501239B1 (en) Organic light device and organic light compound for the same
KR20130084952A (en) Organic light emiiting compound and organic light emitting device comprising the same
KR20150051201A (en) Organic light compound and organic light device using the same
KR101375358B1 (en) Organic light compound and organic light device using the same
KR20120120885A (en) Organic light compound and organic light device using the same
KR20130067283A (en) Organic light compound and organic light device using the same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20161007

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20171012

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20181004

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20191002

Year of fee payment: 7